Factors governing gastrointestinal motility by Ullah, Sana
 1
 
 
 
Factors governing gastrointestinal motility 
 
 
 
 
Submitted for Degree of Doctor of Medicine 2012 
 
By 
Mr Sana Ullah 
MBBS, MRCS 
 
 2
Abstract  
Introduction: The reasons for the rapid resolution of diabetes (DM) following bariatric 
surgery in a significant proportion of patients with morbid obesity remain unclear. This 
thesis investigates the putative role of changes in gastrointestinal (GI) motility and GI 
hormones as well as the possible significance of alterations in energy expenditure that 
occur as a consequence of weight loss.  
 
Methodology: My preliminary studies involved a systematic review of GI motility in 
obesity, and retrospective studies measuring GI motility with alternative methods 
including capsule endoscopy and hydrogen breath test. Subsequent to this I measured 
changes in GI motility in two very different patient cohorts; one following bariatric 
surgery for morbid obesity and the other a group of patients with proven gastroparesis 
treated with gastric neuromodulation (GNM). Parallel to the above I conducted studies 
of indirect calorimetry in these patients in an attempt to determine if changes in energy 
expenditure which occur as a consequence of weight loss were significant. 
 
Results: In our prospective study temporary GNM significantly improved gastric 
emptying and nutritional intake. 
There was conclusive evidence to causally relate alterations in GI motility and 
Glucagon like peptide -1 (GLP-1) with weight loss and resolution of DM following 
bariatric surgery. 
An interesting "spin off" result of my studies was validation of capsule endoscopy (CE) 
as a means of assessing GI motility.  
My results obtained from measure if indirect calorimetrty clearly show that standard 
equations tend to over estimate the energy requirements of this group. The implications 
of this are discussed.   
 
Conclusions:  
1. Fast pouch emptying; an early and exaggerated GLP-1 response contributes in 
resolution of type 2 diabetes following RYGB. 
2. GNM is an effective treatment for gastroparesis. 
3. Capsule endoscopy may be used to assess GI motility. 
4. Prediction equations over estimate energy requirements in morbidly obese patients. 
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1 Introduction and literature review 
 
 
 
 
 
 
“That Quantity that is sufficient, the Stomach can perfectly 
concoct and digest, and it sufficeth the due Nourishment of the 
Body.” 
 
Benjamin Franklin  1706–1790 
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1.1 Introduction to GI motility  
1.1.1 Gastric emptying (GE) 
 
Definition: The fraction of food delivered into the intestine in unit time is called the 
gastric emptying time (GE time). 
 
Basic physiology of the GI tract: The basic structure of the alimentary canal shows that 
its wall follows a constant pattern from the oesophagus onwards. The wall of the 
alimentary canal consists of the following layers (Figure 1-1): 
1. Adventitia or serosa (outer layer) 
2. Muscle layer 
3. Submucosa 
4. Mucosa (inner layer)  
 
Adventitia is a loose fibrous tissue and in the abdomen it is covered by a serous 
membrane called the peritoneum. The muscle layer consists of two layers of involuntary 
muscle including an outer longitudinal layer and an inner circular layer. Blood vessels, 
lymphatics and nerves (including the plexus) run between these two layers. This plexus 
(network) consists of nerve fibres from sympathetic and parasympathetic tracts and is 
called the myenteric/Auerbach’s plexus. Contraction and relaxation of these muscles 
cause peristalsis. Peristalsis of the oesophagus delivers the food into the stomach. This 
involves symmetrical contraction and relaxation of the muscles which propagates in a 
wave down the muscular tube. Intestinal and gastric hormones also play a vital role in 
this process. Some of them are briefly described in Table 1-1. Muscle contraction is also 
used to mix food with the digestive juices. At various points the sphincters control this 
movement. These sphincters consist of a thick layer of circular muscle and are 
innervated by the parasympathetic and sympathetic nervous systems. Contraction of 
sphincters regulates food movement. They also act as a one-way valve and prevent the 
backward flow of GI contents. This control helps the food to be digested and absorbed 
in various parts of the GI tract.  
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The submucosal layer consists of loose connective tissue (containing collagen and 
elastic fibres) which binds the muscle layer with mucosa. Another plexus of blood 
vessels, lymphatics, and nerves lie within this layer. The nerve plexus in this layer is 
called Meissner’s plexus and also consists of parasympathetic and sympathetic 
connections. Meissner’s plexus and the myenteric plexus are explained in detail below. 
 
Mucosa (the inner most layer) consists of 3 layers:  
 
A. Mucosal membrane: This is formed by stratified squamous epithelium in the 
oesophagus and columnar epithelium in the stomach, and the small and large intestine. 
Its main functions include secretion and absorption. Below the surface of the mucous 
membrane in specific areas, collections of specialised cells (glands) are present which 
release their secretions in various parts of the GI tract. This includes gastric, intestinal, 
pancreatic, and bile secretions. 
B. Lamina propria: Loose connective tissue containing blood vessels and lymphatics. 
C. Muscular mucosa: A thin layer of smooth muscles.  
 
Figure 1-1: Layers of the GI tract 
Serosa (outer layer), longitudinal muscle, Myenteric plexus, circular muscle, 
submucosal plexus, muscular mucosae, mucosa (inner most). 
 
 
 18
 
Anatomy and physiology of stomach:  
The average capacity of an adult stomach is 1.5 litres. The basic anatomy includes a J-
shaped dilated abdominal part of the GI tract. Different parts of the stomach are briefly 
described below in Figure 1-2: 
1. Cardia: the upper part is connected to oesophagus. 
2. Fundus: under the diaphragm and which is usually filled with gas. 
3. The body extends from the cardia and fundus to continue to the antrum. The 
body of the stomach contains 2 surfaces and 2 curvatures (lesser and greater 
curvature). 
4. Antrum: starts at the level of the lower part/notch of the lesser curvature 
(incisura) and continues down as the pylorus. 
5. Pylorus/pyloric canal: the last part of the stomach, it is controlled by the pyloric 
sphincter. This continues as the first part of the duodenum.  
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Figure 1-2: Anatomy of the stomach 
Anatomical location, parts of the stomach, musccle layers of the stomach. 
The stomach serves three main functions which are: 
1. Food storage: an adult stomach can accommodate 1.5 litres of food. However, 
this may vary depens ding on eating habits and increases in obesity. 
2. Mixing the food with gastric secretion and formation of chyme. There are 2 
types of waves in the stomach which serve this function: the peristalsis waves 
and mixing waves. Mixing waves originate mid-stomach (body) at a rate of 8–10 
per minute. In the stomach these waves are strong and they rise above the 
threshold even without action potential. Rhythmic gastric peristalsis without 
food in the stomach is called hunger pangs/hunger contractions. They usually 
begin 12–24 hours after the last meal. The constrictive peristalsis and mixing 
waves together convert the food particles into chyme in the presence of gastric 
juice. 
 
3. Controlled delivery of food into the intestine (GE). 
 20
 
 
Electrical activity in the GI’s smooth muscles 
Smooth muscles in the GI tract contain a continuous electrical activity. This consists of 
two types of waves: 
1. Slow waves 
2. Spikes 
Slow waves: slow waves are the main determinants of rhythmic contraction throughout 
the GI tract. Their occurrence is secondary to change in the underlying resting 
membrane potential in the smooth muscles of the GI tract. Their typical intensity varies 
between 5–15 millivolts. The frequency of slow waves varies in different parts of the GI 
tract. In the stomach the typical frequency is 3 per minute, in the duodenum it is 12 per 
minute and in the rest of the small intestine it is 8–9 per minute. The exact mechanisms 
of slow-wave production are not known; however, it is believed that they may result 
from the activity of a sodium-potassium pump in the GI’s smooth muscle. The gastric 
slow waves result in muscle contractions in the stomach; however, they control the 
spike waves in other parts of the GI tract which potentiates the muscle contraction.  
 
Spike waves: spike waves are true action potential. They are generated in the interstitial 
cells of Cajal.1, 2 These cells are satellite pacemaker cells with multiple branches that 
send to the GI smooth muscles. In the stomach and small intestine they are located in 
the outer circular layer of smooth muscles. Upon activation of these pacemaker cells, 
the resting membrane potential in the GI’s smooth muscles becomes more +ve. The 
usual resting membrane potential in GI smooth muscles is between 50 and -60. A large 
influx of calcium ion (Ca) along with a small amount of sodium (Na) results in an 
increased +ve charge inside the muscle fibre. This process is conducted through Ca-Na 
channels. This results in decreased -ve charge (influx of +ve ions) and the membrane 
potential drops from -60 to -40. The typical frequency of these waves ranges between 1 
to 10 spikes per second. The action potential generated by the GI smooth muscles is 
different compared to the nerve fibre, as in nerve fibres the action potential is generated 
by Na-K (potassium) channels and the entry of ions in smooth muscles is significantly 
slow compared to nerve fibres. The influx of Ca ions in gastric smooth muscle is the 
key factor in the generation of contraction of the intestinal smooth muscle. 
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In a fasting state, the electrical and motor activity of the GI tract is slightly modified, 
and the cycles of this activity propagate from the stomach to the ileum and this is 
known as the Migratory Motor Complex.1 The pattern runs in three phases. Phase 1: no 
spike potentials/contractions; Phase 2: irregular spike potentials resulting in irregular 
contractions; Phase 3: regular spike potentials and contractions. This pattern is inhibited 
by the meal and reoccurs after 90–120 minutes following a meal. 
 
Tonic contraction: Some smooth muscles of the GI tract display tonic contraction. This 
may be in conjunction with GI contraction waves or isolated and not combined with 
these contractions. Tonic contractions usually last for several minutes or even hours. 
The intensity may increase or decrease; however, sometimes they may be caused by 
continuous spike potentials. The other possible causes of tonic contractions include 
depolarisation of smooth muscles caused by hormones and Ca influx in the GI smooth 
muscles3, 4 
 
Nerve supply of GI tract 
The nervous system in the GI tract and associated organs are supplied by both divisions 
of the autonomic nervous system, i.e. sympathetic and parasympathetic nervous system. 
In addition, the network of two plexus (myenteric and Meissner’s) in the GI tracts 
remains the mainstay of GI control. They have briefly been described above. 
Collectively this system is called the enteric nervous system. It extends from the 
oesophagus to the anus. The main function of the enteric nervous system is to control 
GI motility and secretions.  
 
1. Enteric nervous system 
   
The myenteric plexus (between the longitudinal and circular muscle layer) and 
Meissner’s (submucosal) plexus are shown in Figure 1-3. The main function of 
Myenteric plexus is to control GI motility and the main control of Meissner’s plexus is 
to control GI secretions and blood flow. Although the enteric nervous system may work 
on its own, its function is potentiated and controlled (increased or decreased) by the 
autonomic nervous system. Sensory control of GI epithelium is conducted to the enteric 
nervous system as well, and afferent fibres to prevertebral ganglia of the sympathetic 
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chain. Therefore, some of these signals travel to the spinal cord (through paravertebral 
ganglia) and the rest of them travel to the brain through the vagus nerve. 
 
There is a structural difference between the two plexus. The myenteric plexus tends to 
run in a linear and chained pattern. These chains are located a few millimetres from 
each other. This pattern helps to control GI motility. The myenteric nervous system on 
activation results in increased intensity of rhythmic contraction by increased intensity, 
increased frequency and basal tone of the gut wall. It is, however, important to note that 
not all the fibres in the mesenteric plexus are excitatory. Some of these fibres secrete 
inhibitory peptides and signals to inhibit the food movement at sphincter levels. 
Amongst them, two sphincters are of great importance:  
a. Pyloric sphincter ( to control GE) 
b. Iliocaecal sphincter (to control intestinal transit) 
 
In contrast, the Meissner’s plexus is mainly associated with GI secretions and 
absorption of food. It acts  in response to the signals originating from the epithelium and 
produces secretions and/or absorb the food and other particles. 
 
The important neurotransmitters at the nerve endings of the enteric nervous system 
include (1) acetylcholine and (2) noradrenaline. There are certain other 
neurotransmitters being discovered; however, their function and existence is still in the 
experimental stages. The main function of acetylcholine release at these nerve endings 
of the enteric nervous system is excitatory (i.e. it increases GI activity), and 
noradrenaline is inhibitory (i.e. decreases GI activity).  
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Figure 1-3: Description of the enteric nervous system 
Mesentry of GI tract elaborating enteric submucosal plexus, myenteric plexus. 
 
 
2. Autonomic Nervous system  
 
a. Sympathetic nervous system (Figure 1-3) 
 
The sympathetic fibres innervating the GI tract originate from segment T5 (thoracic 5) 
to segment L2 (lumbar 2) of the spinal cord. Preganglionic fibres enter the sympathetic 
chains after leaving the spinal cords and end at their corresponding ganglia including 
the celiac and mesenteric ganglia. Postganglionic fibres originate from the ganglion and 
end at the neurons of the enteric nervous system. The sympathetic innervations 
comprise all parts of the GI tract, and the nerve endings of the sympathetic neurons 
secrete noradrenaline. The sympathetic stimulation of the GI tract results in the 
inhibition of GI activity. A strong stimulation of the sympathetic nervous system may 
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result in the blockage of food and motility through the GI tract. This is caused mainly 
by the direct effect of noradrenaline (secreted at the sympathetic nerve endings) on the 
gastric smooth muscles. 
 
b. Parasympathetic nervous system (Figure 1-3, Figure 1-4). 
 
The parasympathetic nerve supply to the GI tract is derived from cranial and sacral 
parts. Cranial parasympathetic nerve fibres are transmitted through the vagus nerve. 
These fibres innervate oesophagus, stomach, intestine, pancreas, gall bladder, proximal 
part of large intestine. 
  
The sacral parasympathetic nerve fibres originate from segments 2, 3 and 4 of the sacral 
part of the spinal cord. These fibres run through the pelvic nerves and innervate the 
large intestine, sigmoid colon, rectum and anal canal. These fibres also control 
defecation reflux as internal anal sphincter is relaxed and a forceful pelvic muscle 
contraction and peristalsis of colon push the faeces when there is an urge. External anal 
sphincter is under voluntary control. Parasympathetic ganglia lie in the effector organs 
as a part of the enteric nervous system (enteric plexus) and the postganglionic fibres 
innervate the oesophagus, stomach, intestine, pancreas, gall bladder, liver, colon, rectum 
and anal canal. The main function of parasympathetic activity is excitatory (increased 
activity). 
 
The vagus nerve (Xth cranial nerve) 
 
This nerve originates from the medulla oblongata and leaves the skull through jugular 
foramen. These nerve comprise sensory and secreto-motor fibres. It passes through the 
carotid sheath and supplies meninges, auricle, pharynx, larynx and then enters the 
thorax. The left vagus nerve supplies the heart, lungs, great vessels, trachea, bronchi and 
oesophageal plexus before entering the abdomen anterior to the oesophagus. The right 
vagus passes behind the right lung and supplies the pulmonary plexus, oesophageal 
plexus (posteriorly) and reaches the anterior part of the stomach with the left vagus 
nerve. The oesophageal sphincter is also innervated by the fibres of both vagus nerves. 
In the abdomen, vagus nerves innervate most of the abdominal viscera including the GI 
tract, liver, gall bladder and pancreas. 80% of the vagus nerve fibres are afferent 
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(sensory) whereas the remainder act as efferent (secreto-motor) to all the organs below 
the neck (the organs in the thorax and abdomen). There is an exception, however, as the 
suprarenal gland and part of the large intestine is not innervated by vagus (as explained 
above). 
 
 
Figure 1-4: The sympathetic and parasympathetic nervous system 
Cranio-sacral part of parasympathetic (left side) and thoraco-lumber (right side) part of 
autonomic nervous system. 
 
c. GI reflexes 
 
The enteric and autonomic nervous systems support three types of GI reflexes which are 
important for GI function. 
 
1. Reflexes within the enteric nervous system. They facilitate GI secretions, contractions 
and maxing of food. 
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2. Reflexes between the GI tract and the sympathetic chain. They include gastrocolic 
reflex (to cause evacuation/defecation of faeces after intake of a meal), enterogastric 
(from intestine to stomach – to reduce/inhibit gastric motility and GE) and colonoileal 
reflex (to reduce GI transit of contents from small intestine to colon). 
3. Reflexes between the GI tract and the spinal cord and/or brain. These include: 
GE reflex (via the vagus nerve) to control gastric secretary and motor activity.  
Pain reflex resulting in inhibition of GI motility and decreased GI function.  
Defecation reflex involving the spinal cord. This involves the colon, rectum, anal 
sphincters and abdominal muscles for defecation. 
 
Physiological GI motility 
There are two types of movements in the GI tract to facilitate its function. 
 
1. Propulsive/peristalsis 
  
This is the basic and most important GI movement. A contractile ring appears at a 
particular part of the GI tract which propagates and is followed by a similar contraction 
ring. This is a result of synchronised smooth muscle activity of the GI wall. The same 
principle applies to the GI ducts, and  hormone ducts. The food in the GI tract is 
detected by the stretch on its wall, which stimulates the enteric nervous system which, 
in turn, results in the formation of a ring above the bolus/food to propel it to the next 
part of the GI tract. In addition to food and dissention, they can also be activated by 
stimulation of parasympathetic activity by the vagus nerve. Therefore, peristalsis can be 
reduced or stopped if the cholinergic nerve endings of the myenteric plexus are 
paralysed or treated with atropine. Each peristalsis is considered to push the bolus or 
food for 5–10 cm before they finish and are preceded by another wave/movement. The 
peristaltic waves start in the pharynx and continue in the oesophagus after the 
pharyngeal stage of swallowing. A wave takes about 8–10 seconds to reach the stomach 
and if the subject is sitting upright the food may reach the stomach quicker than the 
peristalsis. Distension of the oesophagus results in a secondary peristalsis wave due to 
the presence of food. As the upper third of oesophageal muscles are stratified, this part 
of peristalsis is controlled by skeletal nerve impulse generated by the glossophareangeal 
nerve and the vagus nerve. However, from the second part of the oesophagus onwards 
the vagus nerve takes over the control. As the food passes through the oesophagus, the 
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inhibitory neurons in the enteric nervous system of the stomach and duodenum are 
activated, resulting in relaxation of the gastric and duodenal smooth muscles for the 
accommodation of food. In addition, the distal oesophagus acts as a one-way valve and 
prevents reflux of proteolytic gastric contents. Peristalsis in the oesophagus is 
elaborated in Figure 1-4 and Figure 1-5. 
 
 
 
 
 
 
Figure 1-5: Mechanism of peristalsis 
Upper oesophageal sphincter, swallowing reflex, mechanism of peristalsis elaborated in 
the figure above. 
 
2. Mixing 
  
Peristalsis acts as a mixing wave at certain parts in the GI tract. However, there are 
different forms of movements acting as mixing waves/movements in other parts of the 
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GI tract, especially in the stomach. A strong peristaltic wave throughout the stomach 
along with the mixing wave pushes the food down into the pylorus. However, the 
pylorus remains closed or opens only a few millimetres, permitting only a small amount 
of food into the duodenum. The remainder is pushed back into the body of the stomach 
for further mixing. 
 
Gastric motility and emptying 
 
GE is mediated by strong peristaltic contractions in the antrum of the stomach. When 
the food enters the stomach, the fundus and body of the stomach relax to accommodate 
the food with minimal increase in pressure. This phenomenon is called receptive 
relaxation. Most of the gastric contractions (80%) do not exceed the threshold; 
however, 20% become very powerful and do not act as mixing waves/contraction, but 
rather act as strong emptying waves. They become more intense in the lower body of 
the stomach and move further up and up in the stomach as the stomach empties. These 
strong antral contractions at this stage are called antral systole.1 The pressure generated 
by these contractions is quite high and often reaches 50–70 cm of water pressure. Each 
peristalsis forces several millilitres of chyme into the duodenum through the pyloric 
pump. Normally the intestinal contents do not regurgitate as pylorus acts as a pump; 
however, it may be overridden by certain factors like atony of the distal part of the GI 
tract or mechanical obstruction. 
 
The role of the pylorus in GE 
 
The distal part of the stomach is called the pylorus, as shown in Figure 1-2. The circular 
smooth muscle increases up to 100% at this level and remains in a state of tonic 
contraction. Therefore, these muscles are called pyloric sphincter. The pylorus regulates 
food delivery by enterogastric reflux, as explained above. This is mediated by 
hormones, local signals by the enteric nervous system and the vagus nerve.  
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The suggested factors to contribute in GE are described as follows: 
 
1. Gastric influence 
  
A. Food volume: Increased food volume in the stomach is thought to promote GE. It is, 
however, considered that it is not the pressure of the food itself which generates the GE, 
but rather the stretch on the gastric mucosa resulting in myenteric reflexes promoting 
the activities like gastric contractility and increased pyloric pump activity. 
 
B. Gastric hormones: Food in the stomach stretches the walls resulting in the release of 
gastrin hormone. Gastrin has a strong effect on the stimulation of gastric acid secretion; 
however, it is also considered to enhance the motor function of the stomach by the 
pylorus pump. It is, however, important to note that a new hormone, ghrelin, is also 
considered to enhance GE and its peak is considered to be much earlier than the food 
actually reaching the stomach. There is, however, very little objective evidence in terms 
of the release of this hormone in response to food and its impact on gastric empting in 
humans. 
 
2. Duodenal/small intestine influence 
 
A. Enterogastric reflex: the presence of food in the duodenum causes the reflex 
inhibition of gastric acid production and reduces GE by the activation of the enteric 
nervous system, and is also helped by certain hormones including cholecystokinin 
(CCK), gastric inhibitory peptide (GIP) and polypeptide Y (PYY). This also results in 
the inhibition of the gastric G cells to produce gastrin. Duodenal hypertonicity, 
duodenal acidic pH, and sympathetic stimulation also result in the inhibition of GE. 
 
B. Hormonal control: Hormones such as CCK, GIP, PYY, motilin and secretin have 
extensively been studied in the past in relation to their role on GI motility. In addition, 
glucocorticoids and catecholamines (adrenaline and noradrenaline) also have an effect 
on GI motility. Some of them are released in the circulation and effect remote target 
organs/cells, and are called endocrine hormones. This includes gastrin and secretin. The 
peptides/hormones which act on nearby target organs/cells by diffusion through 
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interstitial apace are called paracrine peptides/hormones. This includes histamine and 
5HT. Neurocrines release from the nerve endings and act through nerves and 
neurotransmitters. This difference of enteroendocrine cells is described in Figure 1-6. 
 
Figure 1-6: Enteroendocrine cells 
Overview of signalling mechanism of neurocrine, paracrine, endocrine hormones in GI 
tract. 
 
A brief description of these hormones along with their gastric metabolic role and 
their role in GI motility are described in table below (Table 1-1).1, 3, 4 
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Table 1-1: Hormones influencing GE and intestinal transit (IT) 
 
 
Name Organ 
 
Physiology and mechanism of action 
 
 
Gastrin 
 
Secreted 
mainly from  
the stomach. 
 
Fractions 
secreted by 
the 
hypothalamus
, vagus nerve. 
 
Polypeptide with multiple forms. 
Types: There are different forms of gastrin, 
however, G17 is the commonest form secreted 
from the stomach. 
Secreted by:  G-cells in the stomach in response 
to distension of the stomach.  
Also released in response to vagal stimulation, 
hypercalcaemia.  
↑ Gastrin secretion by: gastric distension, vagal 
stimulation, Ca and epinephrine. 
↓ Gastrin secretion by: acidic contents in bowel 
lumon, somatostatin, other hormones secretin, 
GIP, VIP (vasoactive peptide), glucagon and 
calcitonin these are considered to reduce the 
secretion of gastrin. 
Functions include:  
1. Stimulating parietal cell maturation and fundal 
growth. 
2. Causing chief cells to secrete pepsinogen. 
3. Secretion of HCL from parietal cells. 
4. Release of insulin after carbohydrate (CHO) 
meal. 
5. Increasing antral muscle motility and 
promoting stomach contractions.5 
A small amount of this hormone is released from 
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the duodenum and the pancreas as well. 
It also causes increased motility in the stomach. 
The role of gastrin is established in diseases like 
Zollinger-Ellison Syndrome and autoimmune 
gastritis.5 
Inhibition of gastrin: is caused by direct negative 
feedback to G cells. Other mechanisms include 
the release of somatostatin. 
Gastrin levels are high in conditions with 
pernicious anaemia because of damaged parietal 
cells. 
 
Ghrelin 
 
Stomach 
 
28-amino acid peptide/hormone. 
Ssecreted by P cells in the stomach. It is also 
secreted from the intestines, kidneys, pituitary, 
hypothalamus and placenta.6 
 
Based upon previous studies, it is considered to 
be an appetite stimulatory hormone as levels were 
recorded high before meal intake.6, 7 
It also: 
- Is considered to alter GE.7 
- Stimulates growth hormone from the 
pituitary gland. 
Ghrelin is described in detail below.  
 
 
GIP 
 
Small 
intestine 
 
Secreted by the K cells in small intestine. 
Mainly from the duodenum and jejunum. 
It is also called incretin hormone (a hormone that 
enhances insulin secretion and/or sensitivity) 
along with GLP (a glucagon-like peptide). 
Functions:  
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1. Inhibits gastric acid production by the direct 
inhibition of parietal cells or  indirectly by G cell 
inhibition via somatostain. 
2. Insulinotropic (insulin release) from pancreas 
in response to glucose and fat in duodenum and 
jejunum. 
3. No strong evidence that it affects GI motility. 
GIP is inactivated by dipeptidyl-peptidase IV 
(DPP-IV). 
 
GLP 
 
Mainly by the 
small 
intestine. 
 
A small 
fraction is 
secreted by 
the pancreas 
and neurons 
in 
hypothalamus 
and pituitary 
gland. 
 
Secreted: mainly by distal ilium (L cells). 
Functions:  
1. It is also called incretin hormone, i.e. it is 
secreted in response to glucose in the GI tract and 
it potentiates the release of insulin from the 
pancreatic beta cells along with GIP. 
2. It is considered to reduce food intake by 
decreasing GE.8 
3. Reduces the release of Glucagon from alpha 
cells of pancreas. 
GLP is discussed in detail below. 
 
 
Secretin 
 
Small 
intestine 
 
A polypeptide secreted from S cells of the 
duodenum and jejunum. 
Its target cells are located mainly in the pancreas. 
Function:  
1. ↑ pancreatic enzyme secretion. 
2. ↓ gastric acid secretion. 
3. Pyloric sphincter contraction. 
4. Produces watery bile rich in HCO3. 
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Cholecystokinin 
(CCK) 
 
Mainly from 
the small 
intestine. 
 
Also secreted 
from the 
distal ileum, 
colon and 
fractions in 
the 
hypothalamus
. 
 
Secreted by: mainly from the duodenum and 
jejunum I cells. 
Forms: there are multiple forms of CCK in 
circulation secreted in response to fatty and/or 
protein rich meals. The common forms of CCK 
include CCK8, CCK22 and CCK33. 
However, in the brain CCK8 and CCK58 are 
found, whereas the pancreatic cells secrete small 
amounts of CCK 4. 
Functions: CCK is considered to initiate gall 
bladder contraction and relaxation of the 
sphincter of Oddi to facilitate fat digestion and 
absorption. 
Increases pancreatic secretions. 
Enhances the effect of secretin in the release of 
pancreatic secretions. 
Adds to the contraction of the pyloric sphincter. 
Has a possible role in satiety induction through its 
effect on the hypothalamus. 
Reduces the meal intake, delaying GE.9 
Control of CCK: Most potent lapids. 
Proteins and amino acids also increase its release. 
 
 
 
Amongst these hormones, ghrelin and GLP were considered to be most important in 
terms of their effect on GE and intestinal transit (IT). These hormones were also 
deemed important because of their proposed role in glucose homeostasis. Here follows a 
detailed description of these hormones along with their proposed role in GI motility and 
glucose metabolism:  
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Ghrelin: Its name is based on ghre, a Proto-Indo-European word  meaning grow, in 
reference to its ability to stimulate growth hormone (GH) release.6 It is a 28-amino acid 
peptide, as shown below. In the stomach the ghrelin-producing cells are present in the 
fundus and pylorus. The G cells (producing ghrelin) are present in the mucosal layer.  
 
Figure 1-7: Structure of ghrelin 
 
Many forms of ghrelin have been described in literature; however, two common forms 
include active (acylated) and inactive (non-acylated) ghrelin.6 Inactive ghrelin is found 
in larger quantities in the blood as its clearance rate is low and therefore its half-life is 
higher compared to active ghrelin. Inactive ghrelin is considered not to possess 
endocrine activities. The normal plasma levels in humans is 10–20 fmol/ml for active 
(acylated) ghrelin and 100–150 fmol/ml for total ghrelin, including both active and non-
active ghrelin. 
 
Ghrelin receptors are mainly present in the hypothalamus and pituitary gland. Ghrelin 
has mainly been found in the arcuate nucleus of the hypothalamus, which is an 
important region to control appetite.6, 10 In addition, ghrelin is also found in the third 
ventricle and the paraventricular areas of the brain adjacent to the hypothalamus. These 
areas are related to food and appetite control. It is considered that by the activation of 
neuropeptite Y (NYP) and agouti-related protein (ARP), ghrelin helps to control 
appetite in the hypothalamus. Similarly, in the pituitary gland GH-releasing 
somatotrophs are the target cells for ghrelin. In addition, ghrelin is found in the pituitary 
gland and acts as an autocrine and paracrine hormone.  
 36
 
it is well accepted that feeding is mainly controlled by the hypothalamus. Feeding is 
controlled by a balance between excitatory and inhibitory signals in the hypothalamus. 
Previous studies have suggested that intravenous and subcutaneous injections of ghrelin 
increase food intake.11 The same response has also been observed when ghrelin was 
injected into the third ventricles of the rat brain.12 These studies along with some other 
studies elaborate the role of this hormone as an appetite stimulant.  
 
The proposed mechanism of appetite stimulation by ghrelin is mediated by the release 
of NYP and ARP in the hypothalamus. This is mediated by ghrelin secreted by the 
stomach and signals conducted by the vagus nerve and through blood circulation.6 
  
Ghrelin is considered as a satiety hormone as levels are considered to be higher in the 
fasting state and decrease after food intake.13 The findings of this paper support the 
theory that ghrelin is a satiety hormone which does influence food intake. The findings 
of this paper are elaborated in Figure 1-8 below. 
 
 
 
 
Figure 1-8: Change in ghrelin levels over 24 hours.  
Higher Ghrelin levels observed before the meal intake. 
Higher levels of ghrelin observed before meal intake (before breakfast, lunch, dinner).  
 37
 
The role of ghrelin in GI motility has been studied in very few studies. In a similar 
study, intravenous ghrelin resulted in an increase in gastric acid production and 
increased GE in rats.14 There is, however, a lack of data in terms of the effects of ghrelin 
on GI motility in humans. 
 
Ghrelin is also considered to be closely related to glucose homeostasis by its effects on 
insulin secretion. It is, however, yet to be proven whether a small amount of ghrelin 
may be released from the pancreas. A study by Date et al15 reported that ghrelin 
increased insulin from the pancreatic cells in rats, suggesting its role in insulin and 
glucose homeostasis. 
 
High plasma ghrelin levels have been reported in lean subjects and low levels observed 
in obesity.7, 16, 17 Gastric bypass reduces the weight and ghrelin-producing cells are also 
bypassed. It is therefore believed that ghrelin levels may remain low after gastric bypass 
surgery. 
 
Because of its impact on GH secretion, it is proposed that this hormone may be used in 
conditions associated with GH deficiency. In obesity, the blockage of appetite and an 
induced satiety may result in low food intake and treatment of obesity. However, further 
research is required on this hypothesis. In addition, there is limited data on its role to 
increase GI motility and GE.14, 18 If proved, this may have a role in the treatment of 
paralytic ilius. 
On the basis of these facts and hypothesis, ghrelin was considered to be an important 
hormone to be studied. 
 
Glucagon-like peptide 1 (GLP-1):  
Glucagon was discovered in 1923 as a hyperglycaemic agent in pancreatic juice.19 The 
cells resembling pancreatic alpha (A) cells in gastrointestinal mucosa were subsequently 
discovered. These cells were further studied and found to be different in morphology 
compared to pancreatic A cells and were called L cells.19 It was later established that the 
secretion/hormone secreted by these cells differs from glucagon in terms of 
morphology, physiology and biology. 
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GLP is derived from the proglucagon gene. In mammals, two different sequences of this 
gene result in two forms of GLP: GLP-1 and GLP-2. GLP-1 sequence remains 
preserved whereas GLP-2 changes into four different forms. L cells are mainly located 
in the distal small intestine and only a few cells are present proximal to ligament of 
Treitz.20 The highest level of GLP-1 therefore is observed in iliel secretions.21  
 
GLP-1 is very susceptible to degradation and catalytic activity of enzyme dipeptidyl 
peptidase IV (DDP-IV) results in a large amount of it becoming inactive immediately 
after release from the GI tract. It is estimated that 20–25% of newly secreted GLP-1 is 
inactive form, with further degradation of 50–60% in the liver, and therefore only 10–
15% of active GLP-1 reaches systemic circulation.19 The half-time of GLP-1 is very 
short (1–2 minutes). Release of the incretins (GLP-1 and GIP) along with insulin is 
described in the figure below (adopted from Wren et al). 
 
Figure 1-9: Release of incretins and insulin in healthy subjects  
 This figure suggests that a higher concentration of GIP is released; however, GLP was 
more related to the release of insulin. 
 
GLP is a meal-related peptide. This has been demonstrated in previous studies.19, 22 
There is, however, a basal level of GLP secretion; therefore, in fasting state it is 
considered to be low but not zero. Furthermore, it is believed that the presence of food 
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in intestinal lumen results in the activation of L cells of the intestinal villi, causing GLP 
release.23 Rapid release of GLP was seen when food was introduced into the ileum in 
normal subjects in an experimental setting.24 In animal studies, GIP release may 
enhance GLP secretion; however, there was no evidence of this finding in human 
studies.19 It was also observed that in a glucose meal response, atropine resulted in 
decreased GI motility and reduced GLP secretion.19 The effect of vagal and sympathetic 
stimulation was observed in a recent study. This study demonstrated that sympathetic 
stimulation had an inhibitory effect on GLP secretion; however, it was concluded that 
vagal stimulation did not result in increased GLP secretion.25 
 
GLP receptors are located in the pancreas, brain, kidney, heart and GI tract, including 
the stomach.19 Their presence and the mechanism of action of GLP on these organs are 
not fully understood; however, the effects set out below have been studied in the past. 
 
Incretin effect: This implies enhancement of the secretion of insulin after GLP is 
secreted from the GI tract. In previous studies it has been demonstrated that post-meal 
enhanced insulin release may be secondary to GLP-induced insulin release along with 
GIP.19, 26, 27 Both of these hormones powerfully enhance the release of insulin and 
therefore collectively are called incretins. It is important to note that GIP secretions 
(including basal levels) are much higher (10-fold) compared to GLP. GLP predominates 
in meal-related response in terms of its incretin effect compared to GIP. In addition, 
GLP results in the inhibition of glucagon and this effect is not seen with GIP.27-29 A 
detailed description of difference between GLP and GIP is described in the table below 
(Table 1-2). 
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Table 1-2: A detailed description of GlP-1 and GIP 
 
  GIP  GLP-1  
Peptide 42-amino acid  30/31-amino acid  
Secreted by K cells, primarily in the 
duodenum and proximal 
jejunum  
L cells, primarily in the 
ileum and colon  
Stimulated by  Oral ingestion of nutrients  Oral ingestion of nutrients  
Effects on insulin secretion Stimulates  Stimulates  
Effects on GE Slows?  Slows  
Effects on beta-cell 
proliferation  
Stimulates*  Stimulates*  
Effects on glucagon 
secretion  
None significant  Suppresses  
Effects on food intake  
Effects on insulin 
sensitivity  
? Improves?  
Secretion in type 2 
diabetes  
Preserved  Impaired  
Adipose tissue  
Receptors 
 
G-protein coupled 
receptors 
G-protein coupled 
receptors 
 
 
Effects on GI tract (gastric secretion and GI motility): GLP-1 is considered to decrease 
gastric secretions and GI motility.30, 31 It was noted that GLP not only reduces gastric 
acid secretion but also results in the inhibition of GE and decreased pancreatic 
secretions.31 This has further been demonstrated by a recent study by Schirra et al,32 
which demonstrated that GLP analogue Exenatide can enhance antroduodenal motility 
and pancreatic insulin secretion (Figure 1-10). This figure demonstrates that in healthy 
individuals GLP infusion along with glucose resulted in enhanced motor response. The 
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ileal brake activity of GLP has been demonstrated as the presence of unabsorbed food in 
ileum which results in decreased GE.19, 24 
 
Figure 1-10: Enteroduodenal activity after GLP-1 infusion.  
 
Schirra et al32 demonstrated the enhanced enteroduodenal motility after GLP analogue 
infusion in healthy volunteers.  
 
The proposed role of GLP-1 in obesity and type 2 diabetes: The role of GLP on the 
induction of obesity and type 2 diabetes mellitus (DM) was proposed because of its 
relation with food intake and satiety.33 It was also noted that there was no measurable 
increase in GLP-1 secretion in obese subjects after meal intake34 and it improved 
significantly after gastrojejunal bypass.35, 36 Meal-related low GLP-1 secretion in 
obesity was also noted by others and it was reported that glucose levels significantly 
decrease after GLP-1 infusion; however, they may not reach a level of 
normoglycaemia.37, 38 This review of literature suggests a very important role of GLP-1 
in insulin secretion (incretin), obesity, GE and ileal brake activity. It is interesting to 
note that bariatric operations (particularly Roux-en-Y gastric bypass (RYGB)) result in 
weight loss; however, the normoglycaemia and improved insulin resistance is noted 
much earlier than a significant weight loss. Could this be related to a change in GI 
motility and a change in these GI hormones (ghrelin and GLP-1)? We conducted a 
prospective observational study (see Chapters 2 and 4). 
 
Measurement of GE: Here follows brief descriptions of methods of GE measurement. 
They are covered in detail in Chapter 2 (section 2.2) and Chapter 4. These methods 
assess different aspects of gastric motility including:  
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1. GE 
2. Gastric motor function  
3. Gastric myoelectric activity 
 
Gastric scintigraphy (GS): Solid phase GS is considered as a gold standard for 
assessment of GE. This is based upon the fact that a physiological meal is used; it 
quantifies the GE, and the rate of GE at any given point during the test can be 
calculated. Some clinicians have proposed to perform solid and liquid phase 
scintigraphy. In most of the centres 99m Tc (radioactive material) mixed in egg 
sandwich is used as a test meal.39 In the past, different meals have been used for 
assessment of GE, including beef liver (radioactive labelled), chicken liver (radioactive 
labelled) and low-fat meal (radioactive labelled).40-42 However, egg sandwich is readily 
available, easy to cook and more physiological compared to other meals. 100–120-
minute GS should be for the evaluation of GE and the test can be extended for 4–6 
hours for the assessment of IT. It is considered that solid GE shows a lag phase (no/little 
GE) followed by GE. Certain drugs may affect GE including opiates (to slow GE) and 
prokinetic and macrolides (to enhance GE). In addition, Ca channel blockers, K channel 
blockers, laxatives and other medication may affect GI motility. It is therefore 
recommended that such medicines should ideally be stopped 2–3 days before the test. 
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The table below sets out a list of medications affecting GI motility. 
 
Table 1-3: Medicines affecting GI motility 
 
 
 
Adapted from Parkman et al43   
 
GS results vary in each patient and they may differ in one patient if GS is performed at 
a different time. It is therefore recommended that centres should conduct their own 
studies and conclude the reference value. In addition, other factors such as gender, 
smoking and phase of menstrual cycle may also influence the GS results.40, 44, 45 The 
basic equipment required to assess GS is a gamma camera (Figure 1-11). 
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Figure 1-11: Gamma camera 
This is the picture of the camera used in our studies at the Department of Radiology and 
Nuclear Medicine, Castle Hill Hospital, Cottingham. 
 
Assessment of GE by GS: After a meal intake, an area of interest is drawn around the 
stomach. Data points are corrected for decay, movements and skin marker (if used). 
Anterior and posterior acquisitions are calculated within the area of interest and a 
geometric mean is calculated for each data point. It is, however, one disadvantage of GS 
that there is radiation exposure even though the dose used in GS is very small. GE time 
can be described in terms of gastric half-emptying time (T50 ) and total emptying can 
also be calculated (Figure 1-12, Figure 1-13). 
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Figure 1-12: Assessment of GE by GS 
An area of interest around the stomach is drawn in both anterior and posterior pictures 
(top two pictures). The geometric mean at each data point is shown in the lower left 
graph. T50 is then calculated as shown in the lower right graph. 
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Figure 1-13: Calculation of T50 by GS 
 
Showing radioactivity and time relation (data in the lower right corner). 
% GE is calculated as shown. 
T50 on a linear fit in this patient marked at 70 minutes (graph + reading). 
 
Radiographic contrast studies: This is not a recommended method of assessment of GE; 
however, in certain cases poor emptying of barium from the stomach or gastric 
dilatation may be suggestive of gastroparesis. No emptying of contrast after half an hour 
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and retention even after six hours is suggestive of gastroparesis.46 This is, however, 
non-physiological and not comparable to a test meal. 
 
Lactulose breath test/hydrogen breath test (described in detail in Chapter 3): Non-
radioactive isotope of C bound with substrate (usually a polysaccharide). The technique 
requires substrate to reach the caecum and get fermented, releasing H2. H2 is then 
detected in expired air. This, however, requires normal absorption, metabolism and 
pulmonary function to provide the appropriate results. Its utility in clinical services is 
still under review; however, it is used in experimental services.  
 
EGG (electrogastrography): EGG measures the myoelectric activity of the stomach. 
Gastric slow waves are detected by skin electrodes on the abdominal wall and the 
frequency, pattern and intensity of myoelectric activity is recorded47(see Figure 1-14). 
 
Figure 1-14: Electrogastrography (EEG) 
Adapted from Parkman et al47 
 
 
The EGG results are described in terms of bradygastria, tachygastria or normal. 
Normally, gastric myoelectric activity is recorded as 2–4 cycles/min. An increase 
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>4/min is called tachygastria and a decrease <2/min is classified as bradygastria 
(Figure 1-15). 
 
 
Figure 1-15: Gastric electrical activity on EEG 
Adapted from Parkman et al47. Tachegastria > 4/minute, bradygastria < than 2 / minute.  
 
This procedure is also not a part of routine clinical care and more research and 
movement may result in artefact and invalidate the results. 
 
Antroduodenal monometry: This procedure is used to assess the duodenal and lower 
gastric motor function and is described in terms of the origin and propagation of 
migratory motor complex (MMC). These complexes occur in three phases: Phase 1 (no 
or little activity); Phase 2 (MMC irregular activity/spike potentials); and Phase 3 (MMC 
strong expulsive movement produced to push the food from the distal stomach to the 
ileum). This is a useful test to assess small IT problems and to evaluate the problems 
relating to the small intestine secondary to amyliodosis and myopathies. An abnormal 
Phase 3 MMC is considered an important finding to conclude motility-related problems. 
The test should ideally be performed in fasting and postprandial states. This test has not 
been validated and needs more research for routine clinical use. In addition, the 
intolerance of electrodes in the GI tract and wire migration/displacement may also 
invalidate the results.43, 48  
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Ultrasonography (USG): GE can be assessed by transabdominal USG. This is done by 
serial changes noted by USG in the antral part of the stomach. It can also assess the 
gastric and anteral wall movement. The antral blood flow can also be assessed by 
duplex. This is not a widely accepted method as it is highly operative dependent, 
difficult to perform in obese subjects and examination may be difficult due to the 
presence of air in the stomach and transverse colon. This is not a validated method for 
this purpose.48 
 
Single photon emission computed tomography (CT): CT scan after radioisotope 99m Tc 
may be used for the assessment of gastric accommodation and GE. There is, however, a 
large amount of radiation exposure in this technique, and therefore it is not often used 
for this purpose.43, 48 
 
Magnetic resonance imaging (MRI): Transaxial scans after every 15 minutes using MRI 
can be used to detect gastric accommodation and GE. The advantages of this method 
include no exposure to radiation; however, it requires special equipment and is still 
quite expensive, and therefore not widely used except in experimental studies.43, 48 
 
Water/nutrient test for gastric accommodation: In this simple test, subjects are asked to 
drink mineral water at a specific rate (such as 15 ml/hr). 30 minutes later a visual 
analogue score is used to assess the gastric distension, and the amount of fluid intake is 
also recorded. This is not a standardised method and therefore is not valid and accepted 
across most of the centres.48 
 
Paracetamol absorption test: This method has been used extensively in the past. 
Paracetamol is completely absorbed in the small intestine and levels can be calculated 
by serial plasma/serum levels. This is an easy test and most of the labs perform 
paracetamol levels; therefore, the measurement of the samples is not difficult. The test 
is valid for liquid GE only and is not valid for solid emptying. In addition, a normal 
intestinal absorption/function, metabolism and liver function are required. Certain drugs 
also interact with paracetamol, invalidating the results.48 
 
A brief description of the above methods is provided in Table 1-4 below. 
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Table 1-4: Methods of assessment of GE 
 
1.1.2 Intestinal transit (IT) 
Definition: The transit of food through the small bowel (duodenum to caecum) is called 
small intestinal transit. The time taken by food to transit through the intestine is called 
intestinal transit time. 
Mechanism of intestinal motility: The mechanism of GI motility has been explained in 
detail in section 1.1.1 above. Small IT is an important factor that determines the 
absorption of food. Variation in intestinal motility and transit is also mediated by a 
feedback mechanism though the enteric nervous system and GI tract hormones.49 
Following a meal intake, the following types of intestinal motility are observed: 
1. Segmental contraction to roll and mix the chyme. 
2. Peristalsis to propagate the food to the large intestine. 
 
Segmental contraction: When the chyme enters the small intestine, this exerts 
pressure/stretch on the wall of the small intestine which triggers the slow-wave action 
potentials at that area. These slow waves are a continuation of gastric slow waves; 
however, their rate is different in the small intestine. This varies from the duodenum 
(12/min) to the terminal ileum (9/min).3 These slow waves cause localised segmental 
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contraction (a few cm) followed by relaxation which propagates in the entire small 
intestine. They are controlled locally by the enteric nervous system (excitatory effect); 
however, application of an external stimuli like atropine may cause blockade of these 
contractions.3 During inter-digestive periods, the housekeeping of the intestine is 
observed by contractions of the stomach which propagate through the small intestine to 
clear the debris and digested food. This may cause growling. These contractions are 
called migratory motor complex (MMC).1, 3 
 
Peristalsis/propulsive movements: Peristaltic contractions are weak intestinal 
contractions which propagate the food into the next part of the GI tract. They usually die 
after 5–10 cm and push a small amount of food after every 1–2 minutes. Therefore, it 
requires 3–5 hrs for them to take the chyme from the pylorus to the ileocecal valve.3 
The control of these movements by the enteric nervous system, the effect of the vagus 
nerve and the hormonal influence has been discussed in detail in section 1.1.1. 
Iliocecal Valve: The main functions of the ileocecal valve are to prevent the backflow of 
colonic contents to reach the small intestine. In addition, the periodic opening of this 
valve allows the maximum time for chyme to stay in the small intestine to get absorbed 
and approximately 1500 ml/day to reach into the caecum. This valve is supported by the 
thick muscles of the small intestine which act as ileocecal sphincter. Peristalsis in the 
terminal ileum and the frequency of the ileocecal valve opening and closure is 
determined by local reflexes (colonoileal reflex). If the caecum is full/distended, this 
local myenteric reflux inhibits the peristalsis in the terminal ileum and intensifies the 
ileocecal valve/sphincter not to permit chyme from the small intestine into the caecum.1, 
3 
Measurement of IT:  
GI Scintigraphy: Small intestine scintigraphy is considered as a gold slandard for 
assessment of intestine transit (IT).50 The methodology of IT remains the same; 
however, the interpretation of results differs in different centres. It can be measured as 
colonic filling (% filling at certain time points), or in mayo method <10% colonic filling 
after six hours is considered as slow IT and >70% filling at six hours is considered as 
rapid IT.50 In the Tample method 70% radioactivity is reached in the ileocecal region 
after 205 minutes.50 In another study on health volunteers, radioisotope tablets were 
used and the results revealed similar fasting and postprandial IT (204 minutes and 210 
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minutes respectively).51 There are, however, difficulties related to the test as this 
requires multiple scans and radiation exposure and it is an expensive method.  
 
Lactulose breath test: This is a minimally invasive test. Subjects are required to take a 
labelled lactulose. This is fermented in caecum and the exhaled gases are expired and 
measured reflecting the IT time. In previous studies, methane, CO2 and hydrogen have 
been used to measure the results in this test. The problem with the interpretation of 
these results is that this can only be representative of the transit of lactulose, which 
cannot serve as a substitute to a transit of a physiological meal. In addition, the timing 
of the food may affect the small IT time.51 In literature, the normal orocaecal transit 
time (OCTT) varies between 192–234 minutes.50 
Wireless capsule endoscopy: Capsule endoscopy is mainly used for the assessment of 
occult GI bleeding. However, its utility as a tool to assess GI motility is not widely 
explored. Figure 1-16 below briefly describes the procedure.  
 
Figure 1-16: Capsule endoscopy (CE) 
Copied from Birmingham GI association website  
 
The utility of these methods (lactulose breath test and CE) as an alternative to small 
intestine scintigraphy is described in detail in Chapters 2 and 3.  
 
 53
 
1.2 Delayed GE/gastroparesis 
 
Definition: Gastroparesis is a chronic motility disorder of the stomach, defined as 
delayed GE of the solid meal in the absence of mechanical obstruction. The most 
frequent symptoms of gastroparesis include nausea, vomiting, early satiety and 
postprandial fullness. Abdominal discomfort and pain are also reported. Weight loss, 
malnutrition and dehydration may be prominent in chronic cases. 
 
Aetiology 
 
The three most common aetiologies include: 
 
1. Diabetes mellitus (DM)  
2. Gastric surgery involving vagotomy  
3. Idiopathic (no identifiable cause) 
 
Other causes of gastroparesis have also been described in literature. They include intra-
abdominal malignancy, eating disorders, chronic renal failure, muscular  dystrophy and 
certain medications including atropine, opiates, tricyclic antidepressants, 
phenothiazines, calcium channel blockers and lithium.8 
 
The true prevalence of gastroparesis is not known; however, it has been estimated that 
up to 4% of the population experiences symptomatic manifestations of this condition.3 
  
Prevalence of gastroparesis is increased in diabetic patients and may occur in 30–50% 
of patients with DM.4,5 
 
Gastroparesis in these patients interferes with oral drug absorption and impairs blood 
glucose levels, leading to further complications as a result of problems with ineffective 
blood sugar control. 
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Gastroparesis is a debilitating condition, which can reduce a functional individual into 
an existence tied to hospitals and emergency rooms. Gastroparetic patients have no 
good long-term solutions and death can result from interventions and life-threatening 
complications, such as electrolyte imbalances, dehydration and malnutrition. Soykan et 
al in their analysis of 146 patients seen over six years in two centers2 indicate that 10% 
of patients died during the follow-up period. They describe gastroparesis as “far from 
being a benign disorder”. A detailed description of this condition and treatment options 
are described in Chapter 5. 
 
1.3 GI motility in obesity 
 
Obesity is known to be attributed to an imbalance between food intake and energy 
expenditure. Food intake and its absorption is carried out by a complex mechanism of 
GI motility regulated by signals (hormones, neuropeptides and the autonomic nervous 
system), metabolic cues from hormones, peptides and absorbed nutrients, and 
hypothalamic brain centres. Rapid GE is thought to deliver more nutrients and also 
reduces negative feedback of satiety signals, resulting in more feelings of hunger and an 
increased demand for food.52 
 
GE and accommodation plays an important role in the delivery of nutrients to the 
intestine. High-energy-density meals reduce GE, which levels the rate of energy 
delivery to the intestine.53,54 There are also apposite reports suggesting that high-
calorific food may lead to rapid GE in obese subjects.55 It is suggested that GE is altered 
in obesity. Small intestinal motility and absorptive capacity also play an important role 
in the absorption of nutrients. It has been speculated that intestinal absorption of 
nutrients is rapid, more efficient and not related to IT rate but there is not much 
evidence to support this hypothesis.52 On the other hand, it is stated that obesity is 
related to increased IT and contractile activity, resulting in excessive nutrient 
absorption.52, 56 GI transit studies provide an assessment of overall GI motor activity. 
Slow GE may result in retention and early satiety, which may result in weight 
reduction57 
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GE is slow in 30–50% of long-standing diabetics. The relation of GE with symptoms is 
poor. GE is slow in hyperglycaemia, and fast in hypoglycaemia. A number of therapies 
are being developed to modulate the delivery of nutrients to the intestine.8 
A trend for bariatric surgery has increased significantly and, according to the National 
Institute for Clinical Excellence (NICE) guidelines, subjects with a body mass index 
(BMI) of 40 or over without comorbidities and a BMI of 35 or more with comorbidities 
should be considered for bariatric surgery. 
 
GE in obesity: 
There is conflicting data regarding the GI transit (GE and IT) in obesity (see Table 
below).  
 
Table 1-5: GE in obesity 
A total of 16 studies; including 7 in favour of increased GE, 4 decreased GE and 5 
demonstrated normal GE in obesity. 
 
Evidence of increased GE in obesity 
 
Study ref 
 
Type Number of subjects Outcome 
Cardoso-Júnior A58 Controlled 14 obese + 24 control Increased GE in obese
Valera Mora ME59 Controlled 20 obese + 16 control Increased GE in obese
Bertin E60 Controlled 13 obese + 7 control Increased GE in obese
Wright RA53 Controlled 46 obese + 31 control Increased GE in obese
Tosetti C61 Controlled 20 obese + 20 control Increased GE in obese
Grybäck P54 Controlled 9 obese + 21 control Increased GE in obese
Verdich C62 Controlled 19 obese + 12 control Increased GE in obese 
during initial 30 
minutes 
 
Evidence of decreased GE in obesity 
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Glasbrenner B63 Controlled 24 obese + 8 control Normal solid emptying 
Decreased liquid 
emptying in obese 
Maddox A64 Controlled 31 obese + 31 control Decreased GE In 
obese 
Horowitz M57 Controlled 15 obese + 11 control Decreased solid GE 
Normal liquid 
emptying 
Jackson SJ65 Controlled 16 obese + 16 control Delayed GE in obese 
 
Normal GE in obesity 
 
Mathus-Vliegen 
EM66 
Uncontrolled 45 obese Increased liquid 
emptying 
Normal solid emptying
Verdich C62 Controlled 19 obese + 12 control Normal solid emptying
Hutson WR67 Controlled 30 obese + 23 control Normal GE 
Zurakowski A68 Controlled 10 obese +10 control Normal GE 
Glasbrenner B63 Controlled 24 obese + 8 control Normal solid emptying 
Decreased liquid 
emptying in obese 
 
This systematic review of literature demonstrated that 7 studies showed an increase in 
GE in obesity, 4 in favour of decreased GE in obesity and 5 in favour of normal GE in 
obesity. It is, however, important to know that there was great diversity in their 
methodology, interpretation of GE results and meal composition. In addition, there was 
a wide range in BMI and gender differences in these studies. This may have an 
implication for their results. 
 
 
 
Change in GI motility after bariatric procedures 
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A systematic literature review was conducted regarding the impact of bariactric 
procedures on GI motility.  
 
Search criteria 
Medline, Embase, PubMed databases and the Cochrane Library were searched 
independently by two authors. The search was limited from January 1980 to July 2009 
and to the English literature. 
 
The following keywords were searched: (“Gastric Emptying” OR “Gastric Motility”) 
AND (“Bariatric Surgery” OR “surgery” OR “Gastric bypass” OR “gastric banding”) 
AND (“obesity”).  
 
Further searches were made from the references of the original articles. A separate 
search was performed in non-indexed citations and relevant scientific meeting abstracts. 
The search result of each author was combined with removal of duplicate references. 
 
Inclusion criteria 
All human studies looking into any aspect of GE or motility before and after any form 
of bariatric surgery were included in the review. All forms of study designs, including 
case-control studies, case series and case reports, were included. Animal studies were 
excluded. 
 
Results 
Gastroplasty: 
Gastroplasty is a restrictive operation for weight control and it has been in practice since 
1970. The original horizontal gastroplasty operation (stapling the stomach horizontally 
and leaving a small stoma) has been replaced by vertical band gastroplasty, which 
involves creating a small (15–25 ml) pouch by stapling line and the outlet is controlled 
by a silicon band. The size of the created stoma is approximately 1 cm.69 The lap 
adjustable gastric band was introduced in 1990. It is the least invasive procedure and it 
involves creating a small pouch on the upper part of the stomach. Patients require 
outpatient follow-ups for adjustment of the band through the access port.69 Previous 
studies have demonstrated that the weight loss in such procedures is caused by food 
restriction, change in pouch and GE following the procedure.57, 70-82 
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A total of 13 case series, including 3 case control studies were identified in the 
literature. Studies only using scintigraphy as a method of GE were considered 
appropriate for inclusion (see Table 1-6). The time of gastric and pouch emptying 
assessment varied between two weeks to over two and half years after surgery in these 
studies. Five studies72, 73, 76, 78, 82 noticed slow GE, two noticed rapid GE73, 74 and two79, 
80 reported normal GE after gastroplasty. Pouch emptying is considered as an important 
determinant for food delivery and inducing early satiety following bariatric surgery. 
Most of the studies reported rapid pouch emptying70, 73-75, 77, 81, 82; however, only one 
study71 reported slow pouch emptying. Most of the papers also concluded that there is 
no correlation between GE and weight loss.70, 73, 74, 76, 78, 80, 81 The total number of 
patients studied in each study were low (11–50) and only four studies compared the GE 
results with a control group. Similarly, there is large heterogeneity in method to conduct 
scintigraphy, meal composition and duration of scintigraphy. Different types of 
gastroplasty procedures were conducted including vertical, horizontal, Gomez, Mason, 
Magenstrasse and Mill gastroplasty. Despite the fact that there were different 
procedures, the principle of the procedure was the same – to create a small pouch 
(approximated size 5 ml) and a stoma (1–1.5 cm) in the proximal stomach. The 
mechanism of pouch function is mainly restrictive and all studies reported weight loss 
following the procedures. This published data regarding gastroplasty suggests that 
post-operatively a slow total GE and  rapid pouch emptying was observed; however, 
the changes may not be fully accountable for the weight loss in these patients (Table 
1-6). 
 
Gastroplasty was common from 1970 to the 1990s. However, because of poor long-term 
weight loss83, 84 and a high rate of late complications, it has been replaced by alternative 
procedures.85 
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Table 1-6: Pouch emptying and change in GE following gastroplasty 
 
Study 
 
Design 
 
Intervention 
 
Method of 
GE 
 
Time of 
measurement 
 
N 
 
Control 
 
Conclusion 
 
 
Horowitz M82 
1982 
Case 
control 
Gastroplasty 
(vertical) 
Scintigraphy Post-op at 6–8 
months. 
11   22 Slow GE after 
surgery. 
Rapid pouch 
emptying. 
Drane W E71 
1983 
Case 
series 
Gastroplasty 
(horizontal) 
Scintigraphy  Post-op.  14   Slow pouch 
emptying results in 
weight loss. 
Andersen T81 
1985 
Case 
series 
Gastroplasty Scintigraphy  Post-op pouch 
emptying at 0, 
6, 12, 18, 24 
months. 
27  Rapid pouch 
emptying. 
No correlation with 
weight loss. 
Gannon MX72 
1985 
Case 
series 
Gastroplasty Scintigraphy  Pre-op, 7 
months post-op. 
13  Slow GE after 
surgery.  
This may result in 
early satiety and 
weight loss. 
Miskowiak J73 
1985 
Case 
series 
Gastroplasty Scintigraphy 
(liquid) 
Pre-op, 3, 12 
months post-op. 
16   Slow GE at 3 
months.  
Rapid GE at 12 
months. 
Rapid pouch 
emptying. 
No correlation with 
weight loss. 
Arnstein N B74 
1985 
Case 
series 
Gastroplasty  
(Gomez 
n=30,Mason n= 
20) 
Scintigraphy  Pre-op,1–4 
weeks, 2–24 
months post-op. 
50   Rapid pouch 
emptying after 
surgery 
Rapid GE after 
surgery 
No correlation with 
weight loss. 
Christian P E75 
1986 
Case 
control 
Gastroplasty Scintigraphy Pre-op in obese, 
normal weight 
subjects.  
Post-op 3 ,12 
months.  
16  17 Normal GE in 
obesity. 
Rapid pouch 
emptying.  
Efficacy of surgery 
lies in food 
limitation, not GE.  
Vezina W C76 
1986 
Case 
series 
Gastroplasty Scintigraphy  Pre-op,3,12 
months post-op. 
23  Slow GE at early 
post-op period. 
Normal GE after 1 
year. 
No correlation with 
weight loss. 
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Andersen T77 
1988 
Case 
series 
Gastroplasty Scintigraphy  Post-op pouch 
emptying at 6, 
12 months. 
27    Rapid pouch 
emptying. 
Anderson T70 
1989 
Case 
series 
(rando
mised) 
Gastroplasty  
(vertical, 
horizontal) 
Scintigraphy  Post-op pouch 
emptying at 2 
weeks and 6 
months. 
45   Rapid vertical pouch 
emptying. 
No relation of GE 
with weight  loss. 
Bendet N 78 
1996 
Case 
series 
Gastroplasty Scintigraphy  Pre-op, 1, 3, 6 
month post-op. 
24  Slow GE after 
surgery. 
No relation with 
weight loss. 
Mistiaen W79 
2000 
Case 
series 
Gastroplasty Scintigraphy  Pre-op, 2 week 
post-op pouch 
emptying. 
13  11 Normal GE after 
surgery. 
Rapid pouch 
emptying. 
Carmichael A 
R80 
2001 
Case 
control 
Gastroplasty  
(Magenstrasse 
& Mill) 
Scintigraphy  Post-op 2.8 
year. Matched 
pre-op obese. 
Age matched 
non-obese. 
13  10 
(obese), 
7 (normal 
weight) 
Normal GE in 
obesity. 
No significant 
change after surgery. 
Majority of the studies (5) noticed slow GE, 2 noticed rapid GE and 2 reported normal 
GE after gastroplasty 
 
Jejunoileal bypass (JIB): 
The jejunoileal bypass (JIB) was designed solely for weight loss and this procedure has 
been in practice since the late 1960s and 1970s. JIB induces malabsorption by 
bypassing most of the intestines while the stomach is kept intact. This procedure 
induces good weight loss, but many patients, post-operatively, have developed severe 
complications like liver diseases, night blindness secondary to vitamin A deficiency, 
vitamin D deficiency, bacterial overgrowth and kidney stones.86 Consequently, many of 
these patients have required reversal of the procedure, resulting in further operations.86, 
87 
 
Only four studies (Table 1-7), including three by one author, were identified in literature 
looking into GE following JIB.34-36, 88, 89 Short- and long-term GE did not change after 
JIB.35, 88 However, other studies published by Naslund et al revealed slightly slower GE 
after JIB. All the studies were conducted on a small number of patients with possible 
duplication of data in papers by Naslund et al.34, 36 They also looked into the hormonal 
changes following JIB and noticed elevated fasting PYY, elevated postprandial NT, 
PYY, and GLP-1 and delayed GE. These studies suggested a possible association 
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between impaired postprandial GLP-1 response in obesity, and after JIB, PYY seems 
to regulate GI motility whereas GLP-1 may regulate GE.  
 
Table 1-7: Change in GI transit following JIB 
Study Design Intervention Method of 
GE 
Time of 
Measurement 
N Control Conclusion 
Moberg S88 
1976 
Case control JIB Scintigraphy  Post-op (months) 9 7 No change in GE 
after JIB (short 
term). 
Naslund E35  
1998 
Case control JIB Scintigraphy Post-op 20 years, 
pre-op obese 
(control group) 
7 7 No change in GE 
after JIB (long 
term). 
Naslund E36 
34  
1997,1998 
Case control JIB Scintigraphy  Pre-op, 9 months 
post-op. Pre-op 
non-obese (control 
group). 
9 9 Rapid GE in 
obesity. Slow GE 
after surgery. 
No change in GE following JIB in 2 papers, slow GE after JIB in 1 published study. 
Small number of patients included. 
 
Laparoscopic adjustable gastric band (LAGB): 
Laparoscopic adjustable gastric band has been in practice since 1993. The procedure 
involves placement of an inflatable balloon on the gastric cardia 1 cm below the 
gastroesophageal junction. It is connected with a tube to a subcutaneous port attached to 
the rectus sheet. The size of the balloon is adjusted by injecting normal saline, resulting 
in narrowing of the stomach. The advantage of LAGB over other procedures is that it 
does not require an anastomosis and stapling, therefore the morbidity and mortality of 
LAGB is lower than RYGB. Unlike other operations, LAGB needs band adjustments 
necessitating multiple appointments, delayed or unsatisfactory weight loss, band 
slippage, band erosion and port site complications.90 
 
Five studies, including one case control study, were identified in published literature 
(Table 1-8). One of them was included in this review despite the fact that they used 
electrogastrography60 for the assessment of gastric motility. Two to four myoelectric 
waves/min are considered normal, whereas >4 are classed as tachygastria and <2 as 
bradygastria, as described in the section on EEG above.47 Two studies reported normal 
GE in obesity,91, 92 two reported no change in GE after LAGB91, 93 and one noticed slow 
pouch emptying.92 One study compared different sizes of pouch and noticed that the 
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small pouch fills and empties quickly.94 However, none of the studies established any 
firm relation of change in gastric and pouch emptying with weight loss. 
 
Table 1-8: Change in gastric emptying following LAGB 
 
Study 
 
 
Design 
 
Intervention 
 
Method of GE 
 
Time of 
Measurement 
 
N 
 
Control 
 
Conclusion 
Hladik P95 
2008 
Case series LAGB Scintigraphy  Pre- and post-
op.  
6  Slow GE after 
LAGB. 
Gao F94 
2008 
Case series LAGB Scintigraphy Post-op pouch 
emptying. 
17  Small pouch 
fills and 
empties 
quickly. 
Jong J R93 
2009 
Case series LAGB Scintigraphy Pre-op, 6 
months post-
op.  
16  Normal GE 
after LAGB.  
No correlation 
with weight 
loss. 
Tiktinsky 
E92  
2009 
Case 
control 
LAGB Scintigraphy  Pre-op, 6–12 
months post-
op. 
11 (pre-
op), 
16 (post-
op). 
10 Normal GE in 
obesity. 
Slow pouch 
emptying. 
Van Dielen 
F M H91  
2003 
Case series Lap band 
(N=21) 
Gastroplasty 
(N=19) 
*EGG (before & 
after  test meal) 
Pre-op, 3 
months post-
op. 
40 
 
 Normal GE in 
obesity.  
No change 
after LAGB. 
Two studies reported normal GE in obesity, 2 reported no change in GE after LAGB 
and one noticed slow pouch emptying.  
 
Change in GI motility following Roux-en-Y gastric bypass (RYGB): 
Gastric bypass has been in practice since 1960, and it was developed to combine 
malabsorptive and restrictive components. In addition to weight loss, other changes like 
neuroendocrine and dumping may also seem to play a role in weight loss following this 
procedure. This procedure involves formation of a small lesser curvature pouch, 
transaction of the stomach and Roux-en-Y reconstruction. The jejunum is typically 
divided at the level of the ligament of Treitz and anastomosed with a gastric pouch, 
creating an alimentary limb. The biliopancreatic limb is typically connected at 75–150 
cm distal to the gastrojajunostomy. Patients undergoing RYGB lose 60–70% of 
excessive body weight, with a 75% resolution of comorbidities. In general, the outcome 
is considered better than LAGB and less than biliopancreatic diversion and duodenal 
switch.90, 96 
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Five case series, including one case control study, were identified (Table 1-9). Rapid 
post-op GE was reported in two studies,97, 98 whereas one study reported slow GE.57 
Only one study looked into IT (using the lactulose breath test) and they reported rapid 
IT following surgery.98 Another study looked into the contrast held up as a 
representative of delayed GE. This was mainly performed to assess the anastomosis leak 
using gastrograffin in this study.99 They reported 188 patients with normal GE, and 116 
patients with very slow or no emptying of contrast from the gastric pouch. Patients with 
normal initial pouch emptying lost more weight.99 Although this is not a preferred 
method of GE assessment, further data on gastrograffin pouch emptying may help to 
understand pouch dynamics in the future.  
 
Table 1-9: Change in GI transit following RYGB 
Study Design Intervention Method of GE Time of 
Measurement 
N Control Conclusion 
Villar H 
V97 
1981 
Case series Gastric bypass 
(N=19) 
Partitioning 
(N=12) 
Scintigraphy Post-op 4 
months 
19, 
12 
 Rapid GE after 
gastric bypass. 
Slow GE after 
gastric 
partitioning. 
Naslund 
I89 
1987 
Case series 
(randomised) 
Gastric bypass 
(N=29) 
Gastroplasty 
(N=28) 
Scintigraphy  Pre-op, post-op 
2,12 months. 
29, 
28 
 Equal pre- and 
post-op GE.  
Slow GE (pouch) 
after RYGB. 
No relation of GE 
with weight loss. 
Morinigo 
R98 
2006 
Case series Lap RYGB Paracetamol 
(GE). 
Lactulose 
breath test (for 
orocaecal 
transit). 
Pre-op,6 weeks 
post-op. 
6  Rapid GE and IT 
following RYGB. 
Akkary 
E99 
2009 
Case series Lap RYGB Gastrograffin 
(liquid) 
Post-op day 1 
(retrospective 
review) 
304  More weight loss 
in patients with 
normal GE. 
Post-op oedema 
may decrease GE. 
 
Horowitz 
M57 
1982 
Case control Gastric bypass Scintigraphy  Post-op 12 
months 
12 11 Slow GE after 
RYGB for solid 
meal. 
Fast GE after 
RYGB for liquid 
meal. 
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Rapid post-op GE was reported in two studies whereas one study reported slow GE. 
Intestinal Transit (IT) was studied in only one study (using the lactulose breath test) and 
they reported rapid IT following surgery. 
 
GE following sleeve gastrectomy:  
Sleeve gastrectomy is a fairly new procedure. The procedure involves removing 80% of 
the stomach, leaving behind only a sleeve of stomach along the lesser curvature. Sleeve 
gastrectomy was initially described as a first-line procedure to be followed by BPD-DS 
or RYGB in super-obese groups (BMI>60 kg/m2).100 However, it is also used as a 
primary treatment in morbidly obese patients.101 The gastric tube created by this method 
is considered to restrict the food intake. It is believed that in addition to food 
restriction, slow GE and a possible role of a gastric satiety hormone (ghrelin) may 
play an important role in weight reduction following this procedure.102 
 
Only two studies on a small number of patients have looked into GE following sleeve 
gastrectomy (Table 1-10). The results remain inconclusive as one reported slow GE and 
other recorded no change in GE following sleeve gastrectomy.101, 102 Bernstine et al 
emphasised the fact that this may be because of preservation of anteroduodenal control 
and the difference in their finding with Melissas et al may be because of different 
operative techniques.102 
 
Table 1-10: Change in GE following sleeve gastrectomy 
Study Design Intervention Method of GE Time of 
Measurement 
N Conclusion 
Melissas J101 
2008 
Case series Sleeve 
gastrectomy 
Scintigraphy Pre-op,6, 24 
months post-
op 
14  Rapid GE after surgery. 
Bernstine H102 
2009 
Case series Sleeve 
gastrectomy 
Scintigraphy Pre-op,  
3 months 
post-op 
19  No significant change in 
GE following surgery. 
No relation of GE with 
weight loss. 
One study demonstrated slow GE and other no change in GE after sleeve gastrectomy. 
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Role of gastric electric stimulation (GES) as bariatric procedures and change in 
GE following GES: 
Electric stimulation of the GI tract has been in practice for the last two decades. GES is 
applied to control the muscle contractility, similar to the concepts in practice for cardiac 
stimulation. Two types of GES devices have been used in the past including 
MEDTRONIC and TANTALUS gastric electric stimulators. TANTALUS is considered 
as a non-excitatory mechanism of GES since the signals do not entrain the muscle, but 
maintain the basic rhythm by synchronising their delivery to gastric slow waves. This 
results in increased force of gastric contractions during stomach distension, contributed 
by increased vagal afferents resulting in satiety.103, 104 
The treatment of heart failure stimulation parameters approved in clinical practice do 
not regulate gastric slow-wave activity and have an inconsistent effect on GE.105 
Improved glucose and weight reduction have been noticed in studies using 
TANTALUS.106, 107 
It is, however, interesting to know that antergrade103, 104, 107-109 as well as retrograde110 
GES was used in these studies. One study was conducted in a normal weight 
population.110 In most of the TANTALUS-based studies, improved weight loss was 
reported.103, 107, 108 MEDTRONIC antegrade109 GES was used in one study after failed 
gastric bands, and there was no weight improvement seen. MEDTRONIC retrograde 
GES in one study was used on normal weight volunteers which showed decreased food 
intake110 GE was recorded to be normal in obesity,104 increased after antegrade GES 
using TANTALUS104 and decreased after retrograde GES using MEDTRONIC device 
in normal weight subjects.110 
This data of mixed results still remain inconclusive in terms of the results and 
mechanism how GES may work in obesity treatment. 
This is based upon the facts that two out of three studies showing improvement in 
weight after TANTALUS were reported from one centre with possible duplication of 
results,106, 108 whereas the only study with relatively long-term results (5 years) used 
antegrade GES (Medtronic device) and reported no weight reduction in obese 
patients.109 
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Table 1-11: Gastric motility following gastric neuromodulation (GNM) 
 
Study 
 
 
Design 
 
Intervention 
 
Method of 
GE 
 
N 
 
Results 
 
Conclusion 
Policker S103 
2009 
Review  Gastric electric 
stimulation 
(TANTALUS) 
NA 132 24 weeks follow-up. 5.5 kg 
weight reduction,  
↓(1.1) HbA1c, improved 
DM. 
Weight improved,  
DM improved, 
GES is an 
effective 
treatment. 
Bohdjalian 
A107  
2009 
Case 
series 
Gastric electric 
stimulation 
(TANTALUS) 
NA 24 1 year follow-up. 4.5 kg 
weight reduction in 21 
ptatients  
No improvement in pts on 
insulin. 
Weight improved, 
GES effective. 
Bohdjalian 
A108 
2006 
Case 
series 
Gastric electric 
stimulation 
(TANTALUS) 
NA 12 52 weeks follow-up, 
improved weight in 8 pts.  
No improvement in 3 pts. 
Two quit the study. 
Weight improved 
(possible 
replication of 
data). 
Hoeller E109 
2006 
Case 
series 
Antigrade 
Gastric Electric 
Stimulation 
(Using 
MEDTRONIC 
device) 
NA 8 Post-failed gastric band 
patients. IGS device 
(Medtronic). 
No weight reduction 5 
years following GES. 
Further surgical 
intervention required. 
Weight not 
improved, GES 
ineffective. 
Yao S110 
2005 
Case 
series 
Retrograde 
Gastric Electric 
Stimulation 
(Using 
MEDTRONIC 
device). 
NA 12 Normal weight subjects 
13% fluid reduction, 16% 
food reduction. Sham 
pacing GE T50(177m), 
pacing GE T50(235). 
↓ GE following 
retrograde GES.  
↓ Food intake. 
Sanmiguel C 
P104 
2007 
Case 
series 
Gastric electric 
stimulation 
(TANTALUS) 
Scintigraphy 
Without 
stimulation, 
6 weeks after 
stimulation. 
12  % GE at 2 hrs (slow if 
>60%, fast if <16% left in 
stomach). Normal GE 
before GES. ↑ GE  after 
GES (gastric retention 
decreased from 31.9±16.4 
to 18.7±12.2%) after 2 
hours). 
Normal GE in 
obesity. 
↑ GE after GES. 
 
Two types of GES systems have been used (Medtronic, TENTALUS). Decreased 
weight reported in most of TENTALUS based studies. Antegrade and retrograde GES 
has been experimented using Medtronic device. 
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Summery of literature review and aims of this thesis: 
 
1. GI motility may closely be related to GLP, Ghrelin and these hormones may 
have a therapeutic role in obesity, weight reduction and resolution of DM. Rest 
of the hormones were not significally relavent and therefore excluded for further 
discussion and research in our studies.  
 
2. Methods of assessment of GI motility were studied and concluded that GI 
Scintigraphy is gold standered method; however further research is required to 
improve the interpretation and alternative method should also be explored. We 
focused on Capsule endoscopy and lactulose breath test in addition to GS in our 
studies.  
 
3. Data regarding GE in obesity and change in GE following bariatric procedures 
remain inconclusive because of hetrogeniety of the studies, methods implied; 
non standerdised interpretation of results. There is a change in practice as RYGB 
is now considered as an intervention of choice in morbid obesity. Diabetes 
resolved very quickly following this procedure and is considered to be a result of 
change in GI motility and change in GI hormones. We conducted a prospective 
study to lood into resolution of DM following RYGB with special focus on GI 
motility and hormones effecting GI motility, DM and insulin resistance (ie 
Ghrelin and GLP). 
 
4. Slow GE (gastroparesis) is a major problem in a small number of patients and it 
is a clinical and nutritional challenge to manage these patients. There is limited 
data in support of the use of GES in such patients. We conducted a prospective 
study on such patient and treated them with GES and closely monitored their 
clinical, nutritional, QOL outcomes. 
 
5. Accorate assessment of nutritional intake in obesity and in critically ill patients 
were also the focus of our research as they are closely related to GI motility, 
metabolism, GUT function, weight loss/weight gain. 
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2 Alternative methods of assessment of GI motility 
 
Excerpts of this chapter were presented as a poster in the Association of Surgeons of 
Great Britain and Ireland (ASGBI). 
Ullah S, Sadia M, Dakkak M, Babu S, MacFie J. Role of Capsule endoscopy in GI 
transit. ASGBI 2011. 
Ullah S, Khan S, Tayyab M, Babu S, MacFie J. Measurement of gastrointestinal 
transit using capsule endoscopy. ASGBI April 2010. 
 
 
2.1 Role of capsule endoscopy in GI motility 
2.1.1 Introduction 
 
The small intestine has been considered to be a difficult area to assess because of the 
distance from the mouth to the ileum. The mainstay of investigations for the small 
bowel has been radiological investigations (contrast studies and CT scan), nuclear scan 
(scintigraphy) and MRI. Although there are certain advantages of CT scan and MRI, 
such as diagnosing a relatively large lesion in the small intestine, small and flat lesions 
and small intestinal wall pathologies may be missed with these modalities. 
 
Traditional endoscopy has its advantages but comes with discomfort and requires 
significant skills to perform. It is still not possible to completely visualise the small 
bowel, especially the distal jejunum and ileum. Capsule endoscopy (CE) emerged as an 
option to diagnose small intestinal problems in 2001.111 Technology has improved since 
then and now high-resolution video of the small intestine is possible with capsule 
endoscopy without the need for sedation and/or radiation.  
 
Indications of capsule endoscopy: 
Obscure GI bleeding is the main indication for CE. 70–80% patients undergo CE for 
this indication,112 and two recent meta-analyses have shown that CE is better in 
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diagnosing obscure GI bleeding compared to radiological investigations and that it is 
safer than push endoscopy.113, 114 Furthermore, it eliminates the need for further tests 
and lengthy hospital stays.115, 116 On the basis of a large amount of published data, it is 
now considered a valuable tool to diagnose obscure GI bleeding. 
 
Incidence of small intestinal Crohn’s disease is about 45% of the total number of 
patients with Crohn’s and in 25% it is confined to the terminal ileum.117 The diagnostic 
yield of CE in Crohn’s disease is between 30–70%.113, 114 There is a theoretical risk of 
capsule retention in patients with Crohn’s disease; however, this risk was not more than 
in patients with obscure GI bleeding.118 The risk of capsule retention in patients with 
diagnosed Crohn’s stricture is high (5–13%).112, 119 CE is therefore considered an 
important tool in diagnostic work-up in patients suspected of Crohn’s disease. 
 
Other indications for utility of CE include non steroidal anti inflammatory drugs 
(NSAID-induced small ulcerations, and erosions in the stomach and the intestine. 
Although traditional endoscopy and biopsy remains the gold standard for the diagnosis 
of celiac disease, some authors have noticed significant positive and negative predictive 
values of CE in these patients.120, 121 Small intestinal tumours account for 1–2% of 
primary GI tumours. The rate of capsule retention in larger-size tumours will be 
relatively high; however, these patients will subsequently require surgical resection 
decreasing the risk of the capsule being left in the small intestine. CE is also used in a 
small number of patients with abdominal pain. Two studies used CE in such patients 
after extensive diagnostic work-ups and did not find any significant pathology in 85% 
of cases.122, 123 
 
Current British Society of Gastroenterology (BSG) guidelines on the role of CE:124 
 
1. Second look upper GI endoscopy before CE in patients with high suspicion of 
upper GI bleeding.  
2. An upper and lower GI endoscopy should be performed for obscure GI bleed 
before CE.  
3. Patients should be counselled and the risk of capsule retention should be 
explained.  
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4. The role of intra-operative CE should be kept for patients with undiagnosed 
obscure GI bleeding.  
5. Patients with high suspicion of small bowel Crohn’s should be considered for 
CE.  
6. There is a role of CE in refractory celiac disease and its associated 
complications. 
 
AIM: The review of the published literature and the BSG guidelines elaborate the role 
of CE in obscure GI bleeding, Crohn’s disease and small intestinal tumours. This is, 
however, dependent upon its transit through the GI tract, and subsequently dependent 
upon GI motility. The role of CE in GI transit is not very well established and we 
therefore conducted a retrospective study to elaborate its role in the assessment of GI 
motility.  
 
2.1.2 Methodology 
 
A total of 113 patients underwent CE in two regional (East Yorkshire) centres from 
2006 to 2010. The centres included: 
1. Hull and East Yorkshire Hospital NHS Trust 
2. Scarborough Hospital NHS Trust. 
 
The number of capsule endoscopy/centres were:  
Scarborough (Aug 2007–Dec 2009) = 43  
Hull (June 2006–June 2010) = 70  
 
Patient preparation and procedure: 
Patients were instructed to continue a normal diet up to one day before CE. They were 
advised to continue tea, coffee, juice and clear fluids in the evening before CE and not 
to eat and drink anything after midnight. Bowel preparation was not used routinely in 
these patients. Patients were also suggested to continue their medications on the 
morning of the test. They were advised to wear loose clothes and attend the CE suite in 
these centres. They were seen by the CE specialist nurse and an informed consent was 
taken. Small adhesive pads were applied at the abdomen and data recorders were 
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attached (Figure 2-1). Patients were then advised to swallow a capsule with sips of 
water. They were advised not to eat and drink anything for two hours, with only clear 
fluid after two hours, and were allowed to have a light snack after four hours. They were 
free to walk around or stay in the CE unit and they were also allowed to go home and 
come back after eight hours. Waist belts and data recorders were retrieved and video 
data later was reviewed by clinicians. 
 
Figure 2-1: Components and methodology of CE 
Leads, data recorder, equipment and CE 
 
Data collection:   
Clinical reports of CE were generated by consultant physicians. Data (video, letters, 
notes) was revisited by the researcher for the assessment of GI motility. The following 
additional information along with the demographic data was recorded.  
1. Time of capsule ingestion 
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2. First image of stomach and time of this image 
3. First image of D1 (first part of the duodenum) and time of this image 
4. Identification of caecum and time  
 
GE time was calculated by the time taken from the first image of the stomach to the first 
image of the duodenum. This was also confirmed by the data of the capsule journey in 
the GI tract. (See Figure 2-2  – the capsule journey in the stomach is marked with a blue 
line.) 
 
 
 
 
 
Figure 2-2: Capsule journey and GE 
Blue line indicates the capsule journey in stomach, brown line indicates the capsule 
journey in the small intestine.  
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The journey of the capsule in the stomach marked in blue and pictures taken during its 
journey in the stomach. 
 
Intestinal Transit Time: Calculated by the time taken by the capsule from D1 to the 
caecum (Figure 2-3, Figure 2-4, Figure 2-5, Figure 2-6).  
 
 
 
Figure 2-3: Capsule journey in the duodenum 
Figure 2-3: Capsule journey marked with brown colour in the duodenum. And the 
figure below showing the images of the distal stomach and first duodenal image when 
the capsule enters the duodenum.  
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Figure 2-4: Capsule transit through the small intestine 
 
Figure 2-4: Capsule journey marked in brown in the small intestine. The second image 
demonstrates pictures taken in different parts of the ileum, until the capsule is seen in 
the terminal ileum at 02:22:41 after ingestion. Time of entry in the duodenum is 
subtracted from the total time to calculate IT. 
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Figure 2-5: Capsule transit through the terminal ileum and into the caecum 
 
Figure 2-5: These figures demonstrate the journey of the capsule in the terminal ileum 
and caecum. Images taken at 02:24:38 demonstrate the ileocaecal valve. The capsule 
entered the caecum at 02:27:15 as shown in the images above. The capsule continued to 
move in the caecum thereafter, as shown in the capsule journey (colour green) in both 
images. 
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Identification of the caecum can sometimes be difficult in CE. However, the change in 
villous pattern and identification of the ileocaecal valve along with identification of 
caecal landmarks help to identify the caecum. Figure 2-6 demonstrates the presence of 
submucosal blood vessels, semisolid faecal matter and loss of the villous pattern of the 
ileum.  
 
 
 
Figure 2-6: Identification of the caecum 
 
Figure 2-6: Identification of the caecum:  
1. Submucosal blood vessels  
2. Semisolid faecal matter 
3. Loss of villous pattern of the ileum 
 
2.1.3 Study approval 
 
Study approval by the hospital clinical governance department was obtained. Video, 
electronic and paper records were reviewed in this study.  
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2.1.4 Statistics 
 
Data was entered into an Excel datasheet and statistical analysis was performed using 
SPSS 17. Values are expressed as mean +/- standard deviation (SD) unless otherwise 
stated. Significance of difference was calculated using two-tailed paired or unpaired 
student t tests. 
2.1.5 Results  
 
A total of 113 patients underwent CE during this period. The male to female ratio was 
male 61 (54%): female 52 (46%). The mean age of the patients was 56+/-17 years 
(range 17–84 years). ASA grade included 1 = 15 (13%), 2 = 68 (61%), 3 = 29 (25.5%), 
4 = 01 (0.5%).  
  
Indications of capsule endoscopy are explained in  
Table 2-1. The majority (84%) of these patients underwent CE as a part of diagnostic 
process for anaemia of unknown origin/occult GI bleeding. 6 patients (5%) had a known 
source of GI bleeding and were further assessed by CE. Other causes included suspected 
or part of a work-up for inflammatory bowel disease in seven patients (6.1%) and rare 
indications included abdominal pain in three patients, and weight loss investigations in 
one patient. 
 
Findings of CE are explained in Table 2-2. CE was reported normal in 23 cases (20%). 
Areas of redness or red spots of unknown origin were found in 14 patients (12%). Small 
bowel erosions were seen in 10 patients (8%), ulcers in the small intestine in 9 patients 
(7.5%) and polyps in the small intestine in 8 patients (7%). Bleeding sites were 
identified in the small intestine in 3 patients and in stomach in 2 patients. Crohn’s work-
up/evaluation was carried out in 2 patients. Angiodysplasia and telangactasia were seen 
in 12 patients (10%). Collectively, the findings were picked up in 68 cases (60%). In 
one patient, threadworms were identified as a cause of anaemia. Some of these findings 
are presented in the tables below. 
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Table 2-1: Indications of CE 
Indications  N % 
Anaemia 96/113 84 
Bleeding 6/113 5.3 
Weight loss 1/113 0.88 
Inflammatory bowel disease 7/113 6.1 
Abdominal pain 3/113 2.6 
Indications of CE included anaemia in 84%, inflammatory bowel disease in 6.1%. 
 
Table 2-2: Findings of CE 
Findings  N 
Angiodysplasia  6 
Ulcers (stomach) +/- bleeding 2 
Ulcers (small bowel) 9 
Erosions (stomach) 5 
Erosions (small bowel) 10 
Polyps in small bowel 8 
Crohn’s disease 2 
Red spots/area of redness 14 
Bleeding site (small bowel) 3 
Threadworm (small bowel) 1 
Telangiectasia  6 
Bowel narrowing 2 
Total 68 (60%) 
23/113 (20%) normal  
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Threadworm 
 
Angiodysplasia of the jejunum 
 
Angiodysplasia of the jejunum 
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Aphthous ulcers in the jejunum and ileum 
Duodenal and early jejunal polyps  
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Diverticuli in the jejunum and ileum 
 
 
Ulcers in the distal ileum; thick oedematous mucosa – suspected Crohn’s disease 
 
Figure 2-7: Pathologies identified with CE 
Mean capsule passage time in the stomach was 00:31 (SD 39) minutes (median 00:17, 
range 01:00-05:00). Similarly, mean capsule transit time in the small intestine was 04:40 
(SD 01:20) hours (median 04:22, range 01:02-07:44) (for details see Table 2-3). The 
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capsule failed to reach the caecum in 8 patients (7%). This included 2 post-surgical 
(Crohn’s disease) patients, 1 with DM, whereas no obvious cause was seen in 5 patients. 
The capsule reached the caecum after > 6 hrs in 22 pts, > 7 hr in 3 pts. Capsule retention 
in the stomach was observed in 3 patients, including 1 post-procto-colectomy and 2 
unknown causes. 
A subgroup analysis of 12 patients with long-standing DM revealed gastric passage time 
of 00:31 (SD 39) minutes and intestinal passage time of 05:31 (SD 02:03) hours. These 
patients matched for age and American Society of Anesthesiologists (ASA) with non-
DM group. Comparison of the DM group with the rest of the patients did not show any 
significant difference in gastric passage time; however, intestinal passage time was 
significantly prolonged in the DM group (p value 0.07, 0.004 respectively) (Mean 
capsule transit time through stomach was 31 minutes; intestinal transit time was 4 hours 
40 minutes. 
 
Table 2-4Table 2-4). 
Opiates or opiates derivative use was observed in 4 patients. The mean age of this group 
was 52 years. Gastric passage time was 00:50 (SD 00:55) and intestinal passage time 
was 04:14 (SD 01:38) hours. This difference was not statistically significant compared 
to patients not on opiate analgesia (p 0.36, p 0.29 respectively).  
3 out of the 113 patients required repeat CE (1 could not swallow, 1 had poor bowel 
preparation). 1 patient experienced nausea 14 days after CE and an X-ray of the 
abdomen revealed a capsule in the small intestine. Symptoms however settled 
spontaneously and the patient did not require surgery. No other complications were 
observed in this group of patients.  
 
Table 2-3: GE and IT passage time of CE 
 Minimum Maximum Mean & SD 
(Hr: Min) 
Median 
Gastric passage 
time (N=110) 
00:01 05:00 00:31 (39) 17 
Intestinal 
passage/transit 
01:02 07:44 04:40(01:20) 04:22 
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time (N=95) 
Mean capsule transit time through stomach was 31 minutes; intestinal transit time was 4 
hours 40 minutes. 
 
Table 2-4: Capsule passage time in diabetic patients 
 Minimum Maximum Mean & SD 
(Hr: Min) 
P 
Gastric passage time 00:02 05:00 00:45 (1:22) 0.07 
Intestinal 
passage/transit time 
02:59 08:18 05:31(02:03) 0.004* 
*Significantly short intestinal transit time in DM compared to the non DM patients.  
2.1.6 Discussion 
The British Society of Gastroenterology (BSG) has issued guidelines elaborating the 
role of CE and these were published in 2008.124 CE uses a 26x11 mm disposable 
capsule containing a battery, camera, image transmitter, antenna and a light source 
(Figure 2-2). The capsule travels with GI motility. There are three major companies 
manufacturing CE: Pillcam SB by Given Imaging Ltd, Endocapsule by Olympus and 
OMOM capsule by Jinshan Science and Technology Group.124 One of our centres used 
Pillcam and the other used Endocapsule. The equipment and techniques are similar for 
both companies. The approximate battery life is 8 hours and previous literature has 
demonstrated that in 85% of cases the capsule can reach the caecum by this time. In this 
time period, CE records approximately 50,000 images. The main limitations of CE 
include poor bowel preparation and incomplete examination because of limited (8 
hours) battery time, and/or slow transit of the capsule through the GI tract. Based upon 
these limitations, CE completion rate is published between at 75–90% in different 
pathologies.112, 121, 124 In a recent meta-analysis, the diagnostic yield of CE in diagnosing 
occult GI bleeding was reported to be better than other modalities.124 When comparing 
CE with other forms of endoscopy (enteroscopy), the diagnostic yield was similar.114, 124 
Diagnosis of small intestinal Crohn’s disease is difficult and previous studies have 
compared the other modalities with CE. 45% detection of Crohn’s disease has been 
reported in a recent meta-analysis.114 In another study, the yield for CE versus ileoscopy 
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was 61% and 46% respectively, showing CE as a better tool for investigation of small 
intestinal Crohn’s.113 The main complication of CE is capsule retention. It is therefore 
important that patients should be fully informed about the procedure. Variable results of 
capsule retention have been reported from 0% (health subjects) to 21% (intestinal 
obstruction).112 This problem may be more common in patients with Crohn’s disease as 
there is a high risk of ulceration and stricture formation in Crohn’s disease. False 
negative results are reported to be around 11% (range 5–18%) because CE may miss 
some information.125 Other limitations include inability to control the movement, transit 
through the GI tract and biopsies cannot be taken. The findings were in line with the 
published data, indicating total finding pick-up rate of 60% and normal CE in 20% of 
cases. In the rest of the patients, findings were considered not suggestive of any firm 
conclusions. The capsule failed to reach the caecum (incomplete CE) in 7% of cases.  
 
GI motility depends on multiple factors, including the food composition, medications 
and body fluids. The results of gastric passage time and IT time in this study were 
comparable with a large published study to assess GE and IT using CE.126 This study 
published the GI motility data of 790 patients using CE and reported GE time of 0:41 ± 
0:49 and IT time of 4:22 ± 1:30 hours in subjects over 40 years of age. There was no 
significant difference in GE time; however, IT time was prolonged in the >40 years age 
group. A subgroup analysis of health volunteers revealed GE time of 0:39 ± 0:43 and IT 
time of 3:56 ± 1:22 in 87 subjects. GI motility results are comparable between healthy 
subjects and patients with celiac disease, obscure GI bleeding, PAF (familial 
adenomatous polyposis), intestinal lymphoma and ulcerative colitis. In this study, 
gastric passage time was 00:31+/-00:39 minutes which demonstrates fast GE 
comparable with this published data.126 In addition, we noticed a wide range in our 
gastric passage time data (range 01:00-05:00) and in 3 patients the capsule failed to 
leave the stomach without any obvious reason. In patients with very short gastric 
passage time, the capsule fell into the pylorus and passed quickly through the 
duodenum. This cannot be representative of true GE in these patients.  
 
However, mean capsule transit time in the small intestine (04:40+/-01:20 hours) was 
comparable with the largest published study,126 suggesting that the assessment of IT 
may be more reliable using CE. In our experience, the gastric passage time in patients 
with DM was unaffected; however, IT time was significantly prolonged in those patients 
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(Mean capsule transit time through stomach was 31 minutes; intestinal transit time was 
4 hours 40 minutes. 
 
Table 2-4 . There is no published available data to compare this finding. In addition, we 
noticed that gastric passage time was prolonged in patients with opiate use but their 
results should be cited with caution as the number was very low (n=4). 
 
In 1 of our patients there was severe oesophageal spasm and the capsule failed to 
progress three hours after ingestion Figure 2-8 (pictures taken after every 30 minutes). 
In another patient, the capsule was retained in the stomach (Figure 2-9). This patient 
was suspected with Crohn’s disease and subacute bowel obstruction. Food and bile were 
visible in the stomach and the capsule remained in the stomach during the study time. 
The patient later underwent small bowel resection for a terminal ileum stricture. The 
capsule passed spontaneously through the small intestine after the operation. Some 
unusual findings like diverticuli of the small intestine and ringworm were also 
identified. 
 
Limitations of CE. 
Battery life is approximately 8 hours. In some cases, the capsule may not reach the 
caecum during this time, and therefore the test will be classified as incomplete. In our 
study, the capsule failed to reach the caecum in 8 cases (7%). This represents slow GI 
transit as no other cause of obstruction was identified. 
 
Another limitation of CE is inability to take biopsy of lesions found in small intestine. 
This may necessitate enteroscopy in such patients; however, this may also fail to obtain 
biopsy or resection subject to the distance and length of scope, technical inability and 
patient factors. 
 
Inability to manoeuvre the capsule may result in missing some part of the mucosa. 
Based upon the previous studies, 10–15% missed mucosa was reported. This may result 
in missing some important information which may lead to false negative results.  
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Bowel preparation can hamper the image quality and therefore result in incomplete tests 
or inaccurate results. This can be rectified by bowel preparation and a repeat 
examination. In our study, 2 patients required a repeat test on these grounds. 
 
 
Conclusion:  
The role of CE is well established in obscure GI bleeding. It is also a valuable tool in 
assessment of Crohn’s disease, celiac disease and other small bowel pathologies. We 
propose that it can be used as a tool to assess IT. It may not be a true representative of 
GE.   
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Figure 2-8: Oesophageal sphincter spasm 
Oesophageal sphincter spasm. Capsule failed to progress until 3 hours after ingestion. 6 
pictures taken at 30-minute intervals. 
 
 
 
 
Figure 2-9: Crohn's stricture on CE 
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A patient with Crohn’s stricture and subacute small bowel obstruction. Food and bile is 
visible in the stomach. The capsule failed to progress in the small intestine and was 
retained in the stomach. 
2.2 Role of lactulose breath test in assessment of GI 
motility 
2.2.1 Introduction 
 
Hydrogen breath test is a non-invasive and safe investigation. In a hydrogen breath test, 
patients are asked to take a test solution to drink after they have fasted overnight. The 
concentration of hydrogen (measured in parts per million (ppm)) in the breath is then 
measured using a breath test machine. If the breath contains a large amount of hydrogen 
(more than 20 ppm above the baseline) it is classified as a positive test. The baseline 
amount of hydrogen present in the breath before drinking the test solution is also 
measured. Hydrogen breath tests have been in practice for a long time; however, their 
utility is not fully explored. They are used for the assessment of GI metabolic 
disturbance (lactose and fructose intolerance) and assessment of bacterial 
overgrowth.127-130  
 
The time between ingestion and first rise of hydrogen in the breath is considered as a 
positive test.131, 132 Further interpretation of the results is controversial. Although 
generally accepted, interpretation of a positive test is >20 ppm rise in hydrogen in the 
breath; however, some studies have used more flexible definitions such as simply a rise 
of hydrogen within 90 minutes as positive test.133-135 In a recent review article about 
methods of GI motility assessment, a rise of above 10 ppm was considered as a positive 
test.136 
 
Castle Hill Hospital is a tertiary referral hospital and breath tests are regularly 
performed for suspected metabolic disorders, bacterial overgrowth and impaired GI 
transit. The aim of this study was to evaluate our practice and interpretation of the 
hydrogen breath test and evaluate the results of consecutive patients. In addition, we 
wanted to critically review the use of the hydrogen breath test in OCTT. 
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Figure 2-10: Breath test analyser  
Gastro+ Gastrolyzer® analyser for lactulose breath test as used in our department 
 
2.2.2 Methodology 
 
Apparatus:  
 
The breath test machine used in our centre was Bedfont Gastro+ Gastrolyzer made by 
Bedfont Scientific Ltd, Maidstone, Kent, UK (Figure 2-10). It is a user-friendly 
apparatus which measures the end expiratory breath using single-use disposable 
cardboard Flatpak™ mouthpieces or disposable face masks. The instrument is 
calibrated regularly. The calibration gas settings were kept at 100 ppm. 
 
Hydrogen Breath Tests Protocol 
Patient preparation: 
1. Patients were asked to fast from 6pm the night prior to the study (water 
allowed up to 4 hours prior to the study). They were asked not to take any 
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antibiotics 6 weeks before the test. In addition, motility agents or laxatives 
were also stopped 5 days prior to the study. They were suggested to take a 
restricted diet 24 hours prior to the test (no roughage or complex 
carbohydrates) with a suggested menu sent to the patient with their 
appointment letter. Furthermore, they were requested not to smoke on the 
morning of the test. 
2. The patients were asked to inhale as deeply as possible and hold their breath 
throughout the on-screen countdown. After the audio beep, they exhaled 
slowly but gently into the mouthpiece, aiming to empty the lungs as much as 
possible.  
 
Test description:  
 
1. Glucose test for small bowel bacterial overgrowth  
Procedure: Patients were fasted overnight (from 6pm). Prior to the procedure, patients 
had 3 measurements of hydrogen breath. (If the baseline average exceeded 5 ppm, the 
test was abandoned.) The patients were given the 200 ml test solution to drink (50 
grams of glucose dissolved in 200 ml of lemon spirit, sorbic acid and citric acid). 
Breath hydrogen was then measured at x – 15, 30, 60, 90, 120, 150, 180, 210 and 240 
minutes. The hydrogen breath data were plotted in a software programme (Microsoft 
Access) or written on a results sheet. 
Interpretation: Under normal circumstances, the amount of hydrogen in a breath 
sample will remain unchanged as the glucose is absorbed in the small intestine. 
However, in patients with bacterial overgrowth the glucose will be digested by the 
bacteria, producing hydrogen, which is released in the breath. In general, a rise of 20 
ppm above the baseline is taken as a positive hydrogen breath test; this must be seen on 
two consecutive hydrogen breath measurements before the test can be stopped or at the 
240-minute point, whichever comes first. 
 
2. Lactulose breath test for the measurement of oral-caecal transit time 
Patients were fasted overnight (from 6pm). Prior to the procedure, patients had 3 
measurements of hydrogen breath. (If the baseline average exceeded 5 ppm, the test was 
abandoned.) The patients were given 30 ml of lactulose solution taken orally. Breath 
hydrogen was then measured at x – 15, 30, 60, 90, 120, 150, 180, 210 and 240 minutes. 
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The hydrogen breath data was plotted in a software programme (Microsoft Access) or 
written on a results sheet. 
Interpretation: The rise in breath hydrogen, which reflects delivery of lactulose to the 
caecum was noted. This is taken as the oral-caecal transit time. In general, a rise of 20 
ppm above the baseline is taken as a positive test in our centre. 
 
3. Lactose test for diagnosis of intestinal lactose deficiency  
Patients were fasted overnight (from 6pm). Prior to the procedure, patients had 3 
measurements of hydrogen breath. (If the baseline average exceeded 5 ppm, the test was 
stopped.) The patient was given the 200 ml test solution to drink (50 grams of lactose 
dissolved in 200 ml of lemon spirit and sorbic acid). Breath hydrogen was then 
measured at x – 15, 30, 60, 90, 120, 150, 180, 210 and 240 minutes. The hydrogen 
breath data was plotted in a software programme (Microsoft Access) or written on a 
results sheet. Interpretation: Under normal circumstances, the amount of hydrogen in a 
breath sample will remain unaltered as the lactose is absorbed in the small intestine. 
However, if a patient has lactose intolerance, the lactose will not be absorbed and 
hydrogen will be produced, which is released in the breath sample. In general, a rise of 
20 ppm above the baseline is taken as a positive test. 
 
2.2.3 Statistics 
 
Data was entered in an Excel sheet and analysed using SPSS 19. Mean +/- standard 
deviation was used.  
2.2.4 Results  
 
A total of 495 patients underwent hydrogen breath tests from march1998 to August 
2010. 217 patients (43%) had a glucose test for suspected bacterial overgrowth, 114 
(23%) had lactose test for suspected lactose intolerance. The remaining 164 patients 
(33%) had a lactulose test for suspected impaired OCTT.  
 
Presenting complaints included constipation (90%) and diarrhoea (4%), and rare 
indications included scleroderma in 1 patient, cystic fibrosis in 1 patient, high output 
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from iliostomy in 1 patient, and 2 diabetic patients presented with constipation (Table 
2-5: Indications of breath test). 
 
Normal OCTT was observed in 67 patients (40%) (20 ppm rise within 0–90 
minutes), blunted in 10 patients (0.6%) (0–19 ppm rise within 0–90 minutes). In 
another 20 patients (12%) the OCTT increased by >20 ppm; however, this was 
demonstrated after 90 minutes (Figure 2-11). A rise 100 ppm was observed in 2 
patients (Figure 2-11). A mean increase was 2 +/- 5 to 19 +/- 20 from baseline to 
120 minutes (Figure 2-11,  
 
 
 
 
 
 
Table 2-6, Figure 2-12, Figure 2-13). Patients with scleroderma and cystic fibrosis 
demonstrated slow OCTT; however, it was blunted in diabetes. 
 
Table 2-5: Indications of breath test 
 
 
Indications of lactulose breath test 
 
N (%)  
Constipation/decreased bowel frequency 148 (90%) 
Diarrhoea/increased bowel frequency 7 (4%) 
DM, suspected decreased OCTT* 2 (1%) 
Scleroderma** 1 (0.6%) 
Cystic fibrosis*** 1 (0.6%) 
High output from iliostomy (post Crohn’s surgery)**** 1 (0.6%) 
Indication not documented 4 (2%) 
 
In patients with scleroderma,** and cystic fibrosis*** the OCTT was 150 minutes. Fast 
OCTT was noticed in patients with high-output iliostomy**** (< than 60 minutes). It 
was inconclusive in DM.* 
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Figure 2-11: Categorical results of breath test 
This figure demonstrates the categorical data of patients with normal OCTT. 
Labels 
X axis: (1=O MINUTES, 2=15 MINUTES, 3=30 MINUTES, 4=60 MINUTES, 5=90 
MINUTES, 6=120 MINUTES, 7=150 MINUTES, 8=180 MINUTES, 9=210 
MINUTES, 10=240 MINUTES) 
Y axis: ppm 
Number of patients demonstrating >20 ppm rise from baseline=119 (72%) 
Number of patients demonstrating >20 ppm rise within 0–60 minutes=32 
Number of patients demonstrating >20 ppm rise within 0–90 minutes=67(40%) 
Number of patients demonstrating >20 ppm rise after 90 minutes=20 (including 4 @ 
240 minutes and 5 @ 210 minutes). 
Blunted response ppm rise of 10–19 from baseline=10 
Early rise within 30 minutes noted in only 1 patient. 
 
 
 
 
 
 
 
Normal OCTT= n 67 
-------- --------
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Table 2-6: Cumulative OCTT data 
Baseline mean breath test = 2+/-5(range 0–30) ppm, maximum at 90 minutes 16+/-18 
(range 0–83) ppm.  
Time (minutes) 0 15 30 60 90 120 150 180 210 240 
N Valid 164 158 158 158 151 125 91 68 46 13
Missing 0 6 6 6 13 39 73 96 118 151
Mean 2 2 3 9 16 19 18 18 10 14
Median 0 0 1 2 8 13 14 12 8 12
Std. Deviation 5 5 6 13 18 21 18 21 11 14
Range 30 30 31 63 83 136 97 114 54 50
Minimum 0 0 0 0 0 0 0 0 0 0
Maximum 30 30 31 63 83 136 97 114 54 50
Percentiles 25 0 0 0 0 1 2 4 3 0 2
50 0 0 1 2 8 13 14 12 8 12
75 1 2 3 12 26 29 25 27 16 22
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Figure 2-12: OCTT (mean) 
This figure demonstrates the mean (blue) + Standard deviation of OCTT in all patients. 
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Figure 2-13: Minimum and peak value of OCTT 
Graphic representation of OCTT in all patients. Highest levels observed from 90 
minutes to 180 minutes. 
 
2.2.5 Discussion 
 
This study addressed the issue of OCTT in altered GI motility. If we imply the 
definition of a rise of hydrogen in breath at 90 minutes to a normal test, our results 
demonstrate that 40% of patients had normal OCTT. However, this was based upon the 
rise of >20 ppm above the baseline whereas some authors accept a rise of 5–10 ppm as 
normal.136, 137 If we imply this definition in our study, only 23 patients (14%) had 
delayed OCTT although 148 (90%) suffered from symptoms suggestive of constipation 
or decreased bowel frequency. It is, however, important to know that 2 suspected slow 
OCTT patients (1 with scleroderma and 1 with long-standing cystic fibrosis) had slow 
OCTT. There was a wide range of results (Figure 2-12)Figure 2-12, (Table 2-6) which 
limit generalisation of this test.  
 
Other studies and review articles have encountered these problems.133, 136, 138 Low 
specificity and sensitivity have been reported for lactulose breath tests in literature. This 
may be because of many factors. Lactulose is not a physiological test meal and may 
alter the motility of the GI tract and result in false positive results. On the other hand, if 
part of it is absorbed by the small intestine it may show an early rise on small intestinal 
absorption followed by a delayed rise when reaching the caecum. This is also described 
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by Simre´n M et al.133 Similarly, there are far more controversies in terms of implication 
of the test in malabsorption and small bowel bacterial overgrowth.133, 136, 139 
 
About one third of the population suffer from symptoms of gastroparesis, irritable 
bowel syndrome, constipation and bloating etc. This results in significant utilisation of 
NHS time and resources. It is, however, well recognised that there is no single test to 
investigate motility disorders of the stomach, intestine and colon. In the first part of this 
chapter, the role of CE is described in detail. American and European 
neurogastroenterology guidelines about different techniques to assess GI motility were 
published in 2010.136 According to these guidelines, a rise in 5–10 ppm is considered as 
a positive test. They also demonstrated a wide range of results in the normal population 
(OCTT 53–208 minutes). In addition, high variations (14%–39%) were observed when 
the tests were implied in subjects on two occasions. OCTT using hydrogen breath test in 
another study was found to be faster than the other two methods (one with blue food 
colour and the other with radio opaque markers).140 Another limitation of this test is the 
inability to measure the solid phase OCTT as the test meal used is liquid. 
 
There are, however, certain advantages of this test as well. These include that the test is 
validated and uniform across the centres of the world. It is easy to perform and well 
tolerated by patients. It does not require radiation as used in scintigraphy; nor is there a 
test meal required as some patients may not like that or may develop a reaction to 
certain food particles. In addition, it is less expensive than the other methods.  
 
Limitations: This was a retrospective single centre study. In addition the implications of 
the test on patient’s management could not be study. It is a liquid phase transit test 
which is not a true reflection of food transit in GUT.  As there is no standardization of 
its interpretation in relation to other more accurate methods, more studies are required to 
validate this test. 
  
Conclusion: It is concluded that the hydrogen breath test is inexpensive, easy to perform 
and can be used when other precise methods are not available. It may also be used in 
younger patients and in pregnancy because there is no risk of radiation. However, care 
must be taken during interpretation, and patients with a strong suspicion of GI transit 
problems should be considered for scintigraphy or CE.
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3 Resolution of type 2 diabetes following RYGB  
 
 
Excerpts of this chapter have been modified and presented in ASGBI by way of an oral 
presentation. 
 
Ullah S, Meden L, Jain PK, Sedman P. Resolution of type 2 diabetes following 
Roux-en-Y gastric bypass. Is this mediated by changes in gut hormones? (Oral  
Presentation in Moynihan’s prize session. ASGBI 2011). 
 
Excerpts of this chapter have been modified and presented in ASGBI as a poster. 
Ullah S, Arsalai-Zadeh R, Sedman P, G. Avery G, MacFie J. Role of gstrointestinal 
transit and pouch emptying in resolution of type 2 diabetes following Roux-en-Y 
gastric bypass. (Poster ASGBI 2011). 
 
 
3.1 Introduction 
 
Obesity is one of the leading preventable causes of death worldwide and with rates of 
adult and childhood obesity increasing authorities now view it as one of most serious 
public health problems of the 21st century. Not surprisingly, this epidemic has resulted 
in an exponential increase in the number of patients seeking bariatric surgery (surgical 
weight loss procedures). There is increasing evidence to suggest that Roux-en-Y gastric 
bypass (RYGB) is the operation of choice. It is associated with minimal morbidity and 
significant weight loss.141,142 
  
Insulin resistance is a very common feature of morbid obesity which leads to 
hyperinsulinemia, impaired glucose tolerance and type 2 diabetes. Weight loss surgery 
results in 50–70% loss of excess body weight and cures diabetes in up to 77% of 
patients. What is most curious, however, is that resolution of diabetes frequently occurs 
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within seven to ten days of bariatric surgery. Clearly, therefore, weight loss alone 
cannot account for the improvement in glucose metabolism.142 
 
Recent evidence suggests that the dramatic improvement in diabetes may be mediated 
by modulation of insulin secretion by glucagon-like peptide-1 (GLP-1) from the distal 
ileum. This mechanism is explained in detail in Chapter 1. A brief description of GLP-1 
in relation to DM is given here. 
 
This hormone possesses two important functions: 
 
1. Insulinotropic effect: GLP-1 is secreted from the distal small intestine in response to 
glucose. It results in the suppression of glucagon and the increased secretion of insulin. 
2. Ileal brake hormone: GLP-1 is called brake hormone because on stimulation it 
reduces GE and modulates IT to reduce food entry into the small intestine.8, 143 There is 
evidence suggesting that these effects are impaired in patients with obesity and 
improved after obesity surgery.8, 26, 143 
 
Ghrelin is another important recently identified GI hormone secreted from the empty 
stomach and proximal small intestine. This hormone has also been explained in detail in 
Chapter 1. It is a powerful appetite stimulant and levels are increased before and 
decreased after food intake.142 It may also decrease insulin secretion and affect other 
hormones, resulting in hyperglycaemia.142 The possible mechanism on appetite and 
satiety is mediated by the autonomic nervous system (the vagus and sympathetic chain) 
and controlled by the medulla and the hypothalamus.142, 144 Decreased plasma levels 
were recorded after RYGB,142 which may result in improved insulin secretion. Also, 
there are conflicting reports of increased, decreased and unchanged ghrelin levels after 
bariatric surgery.142 
 
The action mechanism of gastrointestinal hormones and altered anatomy influence food 
intake and its delivery to the intestine are not fully understood. It is thought that the 
bypassed stomach and decreased ghrelin (appetite hormone) may result in early satiety. 
Early exposure of food to the distal small intestine may result in the stimulation of GLP-
1, resulting in increased insulin secretion and the resolution of diabetes.142,143 It would 
seem, therefore, that the nature, amount and frequency of food ingestion may influence 
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these gut peptide activities. In this regard, it is interesting to note that most bariatric 
surgical procedures will have a significant impact on both GE and intestinal motility. 
Many studies have investigated GE of patients with morbid obesity, some studies 
finding increased GE, others no change and others decreased GE.53, 54, 58-61, 63-65, 145 The 
lack of consistency in results may relate to the methods employed or to a lack of 
standardisation of patients. There are few studies available which have specifically 
addressed the issue of intestinal motility, although it is interesting to note that  RYGB 
will inevitably increase gastric motility as much of the upper gut is bypassed.  
 
The aim of this study was to investigate changes in GLP-1 and ghrelin that occur in 
patients following bariatric surgery and attempt to determine whether these changes are 
primarily mediated by food intake (amount and volume) or changes in intestinal 
motility. In addition, the results of these investigations will be critically appraised in 
conjunction with any changes in insulin sensitivity or diabetic status. 
The following two hypotheses were proposed and tested in this study: 
1. Foregut hypothesis 
2. Hindgut hypothesis 
3.1.1 Foregut hypothesis 
Following surgery (RYGB), foregut may play an important role in the resolution of type 
2 DM because  
1. The bypassed stomach may produce lower levels of ghrelin. 
2. The small gastric pouch and hormones may influence (induce) satiety.  
3. Food may reach the distal small intestine quicker (fast GE/pouch emptying), 
causing early release of incretins. 
4. All these changes may improve glucose levels and insulin resistance (IR) 
following surgery. 
 
Foregut
  
↓ Ghrelin––––––– ↓ Time taken by food to enter the small intestine and reach the distal 
ileum, ↑Satiety, improved IR, ↓Glucose 
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3.1.2 Hindgut hypothesis 
The second hypothesis to be tested in this study was as follows: 
1. Possible early delivery of food to the small intestine and distal ileum (fast IT). 
2. There may be early and/or exaggerated GLP-1 release. 
3. The above may induce hypoglycaemia and decreased IR. 
Hindgut
  
↑GLP-1––––––––– ↓ Time taken by food to enter the small intestine and reach the distal 
ileum, ↑Satiety, improved IR, ↓Glucose 
 
 
3.2 AIM 
 
The primary aim of this study was to assess IR and diabetic status in patients with 
morbid obesity before and after bariatric surgery, and attempt to determine whether or 
not this is influenced by changes in GE, intestinal motility and gut peptides.  
 
Study design  
This was a prospective observational study conducted in Hull & East Yorkshire 
Hospitals NHS Trust. 
 
3.2.1 Ethical approval and ARSAC approval 
This study was reviewed and approved by South Humber Research Ethical Committee 
in May 2009. 09/H1305/33 
 
ARSAC approval was obtained for this study by Dr G Avery, Consultant Radiologist, 
Castle Hill Hospital, Cottingham (email: ged.avery@hey.nhs.uk). 
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3.2.2 Informed consent 
Patients with type 2 DM were identified by the clinical team. A brief discussion 
regarding the study was given and an information leaflet was provided containing the 
information set out in Appendix 1. 
3.2.3 Inclusion and exclusion criteria 
Table 3-1: Inclusion and exclusion criteria 
INCLUSION CRITERIA 
 
EXCLUSION CRITERIA 
Patients with BMI >40, or >35 with 
comorbidities (NICE guidelines), 
undergoing surgery for morbid obesity 
(includes patients with type 1 and type 2 
diabetes) 
1. Patients requiring insulin after a 
6-hour fast. 
2. Hypoglycaemia requiring glucose 
before or during the course of 
study procedures. 
3. Hyperglycaemia requiring insulin 
or oral hypoglycaemic agents  
during the course of study 
procedures.  
Age >18 years Age <18 years  
Either sex Allergies to radioactive material 
Patients fit for surgery Failure to obtain written and verbal 
informed consent 
 Too disabled to have scintigraphy 
 Inability to understand English  
 Possible pregnancy 
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3.3 Methodology 
3.3.1 IR and diabetic status 
 
Effects of hormones and GI motility on insulin secretion, IR and the resolution of 
diabetes were assessed. GI motility and hormone response were also plotted on 
computer-generated graphs. Pre- and post-operative findings were compared with 
appropriate statistical tests. 
 
Homeostatic model assessment126 is a method of assessment of the B cell function and 
diabetic status of patients. This was first described in 1985 and this method can be 
implied to assess diabetic status and IR by using basal glucose, insulin levels/or C 
peptide levels. The basis of diabetic status is IR and the ability to measure it enables us 
to understand the diabetic status and the effect of treatment used for DM. IR is an 
important factor to determine the risk of ischemic heart disease, DM, hyperlipidemia, 
hypertension and obesity. The pathophysiology of DM in obesity demonstrates that 
there is higher than normal insulin secretion in type 2 DM but that it remains ineffective 
because of IR. There is physiological as well as pathological IR which is beyond the 
domain of this thesis; however, they are well described in a paper published by Wallace 
TM et al.146 
 
The Homeostasis Model of Assessment (HOMA) is a method of assessment of IR. It is 
robust and requires glucose and insulin/or C peptide levels in a fasting state. Other 
methods include continuous infusion of glucose with model assessment (CIGMA), 
frequently sampled intravenous glucose tolerance test (FSIGTT), Hyperglycaemic 
clamp (HC) and Euglycaemic clamp (EC). All these methods require either glucose 
infusion and or insulin which will interfere with/influence the response of other 
hormones including insulin, GLP and ghrelin in our study. Therefore, HOMA-IR 
method was adopted in this study and other methods were deemed not to be suitable in 
this study. IR using HOMA-IR is calculated as follows: 
 
Insulin resistance = fasting insulin (mIU/L) x fasting glucose (mmol/L) / 22.5 
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Glucose levels in this study were also checked by a glucometer (standardised and 
calibrated) available in radiology department. Plasma samples were taken to assess 
insulin, ghrelin and GLP-1 levels. These samples were stored at -70°C and transported 
in batches of 40 samples to the Department of Biochemistry, University of Hull, for 
Enzyme-linked immunosorbent assay (ELISA) analysis.  
 
3.3.2 GI motility (scintigraphy) 
 
Scintigraphy is a gold standard investigation for GE. Patients are fasted overnight and 
given a meal containing isotope 99m Tc (radioactive material). Dynamic acquisitions 
are taken for 100 minutes followed by static acquisitions at fixed time points such as 
120, 180, 240, 360 and 480 minutes after the meal. The % of activity in stomach and % 
of activity in the intestine is recorded. Similarly, gastric half-emptying time (T50) is 
also calculated and activity is drawn on a computer-generated plot and compared with 
the local reference values.147 
 
Scintigraphy is the only reliable method to assess both regional and total IT.148,149,150 
Small bowel transit is measured as the percentage of the delivered radioactivity entering 
the colon by a specified time (colonic filling), for example  at 6 hours.150 The technique 
is similar to above and in the Mayo method  accelerated small bowel transit is defined 
as colonic filling of >70% at 6 hours and delayed small bowel transit is defined as 
colonic filling of <11% at 6 hours.151 GI transit studies are regularly conducted in the 
Nuclear Medicine Department and results are interpreted in relation to the normal 
values calculated by departmental studies conducted on healthy volunteers in the past. 
 
A very small dose of radioactive material (0.3mSv 99m Tc) was used for this study. We 
are all exposed to background radiation of 2.3mSv/year from the environment during 
day-to-day activities. In relation to background radiation, this amount is 7.5 times less 
than what we are exposed to in a year. It is equivalent to 45 days of background 
radiation and if compared with radiation exposure from a CT scan of the abdomen, it is 
23–33 times less than that. The radiation dose is 10 times less than standard small bowel 
barium studies.152  
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3.3.2.1 Setup 
 
This study was conducted in Castle Hill Hospital, Cottingham, and the University of 
Hull. Castle Hill Hospital is a tertiary hospital which provides bariatric surgery services. 
Patients with morbid obesity and refractory to non-operative treatments are referred to 
the bariatric surgery unit by their general practitioner or primary care trust (PCT). They 
are reviewed by one of the two bariatric surgeons in the outpatient department. They are 
also assessed by a dedicated bariatric nutritionist and psychologists. Initial assessments 
include anthropometric measurements, maintenance of food diary records, level of 
activity/exercise advice and medical and social history. A further six-week plan is made, 
including the tasks to modify food and nutrition and improvement in activity. In 
addition, initial information about the surgery, procedures, indications, potential 
complications and short- and long-term side effects are also explained. Patients who 
were listed for RYGB were considered for discussions to participate in this research 
project. 
 
They were identified by the clinical team at this stage. They received a brief explanation 
about the study and an information leaflet was provided. Details of the patients 
interested in this project were passed on to the researcher and subsequently seen by him 
in further routine bariatric clinic follow-up. The aims of the study were explained 
together with the methods, the subject’s involvement (i.e. overnight fast, fasting blood 
sample, test meal in the morning, followed by further blood test and GI scintigraphy). 
Subjects were advised to continue as per routine and continue regular medications until 
the night before the tests. They were advised not to take antidiabetic medicines in the 
morning and to attend the Nuclear Medicine Department at Castle Hill Hospital, 
Cottingham. On arrival the baseline data (age, gender, weight, height), other 
comorbidities and medication history were recorded. 
 
Laboratory preparations: As the sample techniques were different for each hormone 
assay, the blood collection bottles were prepared in the morning before conducting the 
study. Each hormone assay required specific preparation for blood sampling.  
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A. Ghrelin samples: The instruction notes recommended by the assay kits were 
followed. We used Millipore Elisa Kits cat number EZGRT-89K for human ghrelin 
measurements. As ghrelin is considered an extremely unstable hormone and requires 
rigorous protection, the Vacutainer tubes were treated (added) with Pefabloc to a 
concentration of 1mg/ml. 
B. GLP-1 samples: Ice-cooled Vacutanors were used. DPP-IV inhibitor (10 Ul/ml of 
blood) was added in vaccinators before blood sampling.  
C. For glucose and insulin: No additives used. 
 
A venflon was inserted and the first blood sample withdrawn using a syringe. Blood 
samples were then transferred into the vacutainers. Blood glucose levels were checked 
with a departmental glucometer. This glucometer is routinely calibrated by the 
Pathology/Biochemistry Department of the Hospital. The venflon was flushed with 1 ml 
normal saline (0.9%) and used again for further samples later on. Before the next blood 
sample, 3 ml blood was drawn and discarded to avoid any dilution secondary to the 
previous saline flush. The samples were immediately transferred into the laboratory and 
processed for centrifuge and storage. Centrifuge settings at 3,000 rev for 15 minutes at 
temperature 4 +/- 2 were used. Ghrelin samples were acidified by HCL to a final 
concentration of 0.5N. All samples were stored at -70°C and analysed on a later date in 
batches. 
 
3.3.2.2 Test meal 
 
The test meal in this study consisted of 1 scrambled egg with 1 slice of white toast and 
100 ml orange juice. The approximated calories of the meal size were as follows. 
1 slice of white toast = 80 calories  
1 scrambled egg = 100 calories 
150 ml orange juice = 70 calories 
Total = 250 calories. 
 
A small amount of radioactive material (0.3mSv 99m Tc) was used for this study. We 
are all exposed to background radiation of 2.3mSv/year from the environment during 
day-to-day activities. In relation to the background radiation, this amount is 7.5 times 
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less than what we are exposed to in a year. It is equivalent to 45 days of background 
radiation and if compared with radiation exposure from a CT scan of abdomen, it is 23–
33 times less than that. The radiation dose is 10 times less than standard small bowel 
barium studies. Patients were explained about the amount and mode of this radiation. 
Radioactive Tc was added in the scrambled egg and patients were advised to consume 
the meal within 5–10 minutes.  
 
The meal size was very carefully chosen based upon our departmental experience as 
these patients cannot consume normal-sized or large meals after RYGB. Two weeks 
after surgery only one fasting blood sample was taken. Six months after surgery 
(RYGB), the tests and test meal were repeated in accordance with the guidelines as 
explained for per operative studies. 
 
ARSAC approval: In addition to ethical approval, an ARSAC approval was also 
obtained for this project as it involved radiation exposure to patients. 
3.3.2.3 Image processing and measurement of GE 
 
The Nuclear Medicine Department in Castle Hill Hospital is equipped with two gamma 
cameras which are used routinely for clinical purposes (Figure 1-11). The images of 
these cameras are sent to a central system and then processed for results. Multiple 
computers with the necessary software are installed in the Department. The researcher 
and consultant radiologist had access to a camera, the computers and the data of this 
study.  
 
A total of 100 (1 image/minute) anterior and posterior images were recorded for each 
patient to measure GE (Figure 3-1, Figure 3-2, Figure 3-3). This data was recorded as 
dynamic acquisitions; however, it can also be used as static images. Radioactivity in the 
stomach represents food in the stomach. In gastric scintigraphy (GS) (pictures below), 
the food passing through the pylorus can be seen clearly. An area of interest (AOI) 
(Figure 3-4, Figure 3-5) was drawn around the stomach in both anterior and posterior 
images. Images were realigned to fit in the AOI to get an accurate count. This required 
images to move up, down, left, right or rotate as shown in Figure 3-5. In this picture, the 
patient during the 5th minute of the study may have moved towards the head end of the 
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camera. This resulted in the image falling outside the AOI, which required readjustment 
into the AOI for further calculations. All the images (100 anterior and 100 posterior) for 
each patient were readjusted according to the movement and then a geometric mean was 
calculated using software. T50 and % emptying at different time points were calculated, 
and computer-generated time vs. activity graphs were generated (Figure 3-6, Figure 
3-7). 
 
 
Figure 3-1: GE on anterior images 
Image of stomach with radioactivity representing food in it.  
Note: GE can clearly be demonstrated by passage of food/bolus through the pylorus. 
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Figure 3-2: GE and intestinal appearance of radioactivity 
Anterior acquisitions (images) taken every minute showing the radioactivity in the 
stomach and small intestine. 
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Figure 3-3: Marking the AOI around the stomach and intestine 
Area around the stomach is marked on anterior images and posterior images.  
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Figure 3-4: Marking AOI 
Image processing for GE. AOI marked around the stomach in both anterior and 
posterior images. 
 
 
 
Figure 3-5: Image realignment for GE 
This figure represents the patient movement which resulted in the image being partially 
or completely outside the AOI. Images were readjusted for alignment manually using 
the software as shown above.  
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Figure 3-6: Time vs. radioactivity curve 
Time vs. activity graph. X axis representing time (minutes) and Y axis representing the 
counts/sec radioactivity in the AOI. A geometric mean was calculated from anterior and 
posterior acquisitions. 
Green line represents absolute data. 
Dotted white line represents linear fit on absolute data. 
Blue line marks the half-emptying time in this patient (T50 = 59.6 minutes) 
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Figure 3-7: % GE at 10-minute intervals 
Time vs. radioactivity and % emptying at 10-minute intervals. 
Linear fit T50 (half-emptying) of this patient=59.6 minutes. 
 
Post-operatively the stomach was bypassed, therefore food (containing radioactivity) 
could only be seen in the gastric pouch, and gastric pouch emptying was calculated 
using the same method as implied for GE measurement (Figure 3-8, Figure 3-9, Figure 
3-10).  
 
As most of the stomachs were bypassed, the gastric pouch was small compared to the 
stomach size, and food entry into the small intestine was seen during the procedure. 
However, we noticed that at a later stage it was difficult to identify the pouch (after 
emptying); therefore, a skin marker (on the right side and next to the pouch) was 
applied to keep a reference point during the time of IT calculation (Figure 3-8 and 
Figure 3-9). 
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Figure 3-8: Post-operative gastric pouch AOI 
Post-operative (RYGB) gastric pouch in one patient (posterior and anterior views on GI 
scintigraphy. AOI is marked around the pouch. A small marker was placed next to the 
pouch to keep a reference point during the study as at a later stage (IT) pouch 
identification was difficult after emptying of food. Times vs. radioactivity computer-
generated graphs were made for each patient on the same lines as GE (Figure 3-10). 
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Figure 3-9: Pouch identification and marker 
This figure demonstrates the gastric pouch emptying (anterior images) during 4 
consecutive minutes. Pouch is marked with red arrow. Small dot next (right) to pouch is 
a marker for future pouch site reference during IT time calculation. 
 
Figure 3-10: Measurement of pouch emptying following RYGB 
AOI drawn around the pouch (anterior and posterior images). Time vs. activity graphs 
were computer generated. In this patient, pouch half-emptying time was 22.2 minutes. 
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3.3.2.4 Measurement of IT 
GI scintigraphy was continued after GE studies. A marker (a very small amount of 
radioactivity covered in a double plastic sticker and secured with tape on the skin) was 
placed on the epigastric region next to the stomach for a reference point. (Figure 3-11, 
Figure 3-12, Figure 3-13). This reference point was crucial in calculations of IT at a 
later stage. This is demonstrated in the following figures showing the food entry into the 
small intestine which resulted in an empty/invisible stomach at a later stage. This is also 
demonstrated on another patient’s images in Figure 3-14. 
 
 
Figure 3-11: GS at 100 minutes (anterior view) 
  
 
Figure 3-12: GS at 130 minutes 
Note that the stomach is not visible and there was a negligible amount of 
radioactivity/food left in the stomach. The marker indicates the reference point of the 
stomach for calculation. 
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Figure 3-13: GE at 160 minutes 
GI motility of the same patient at 160 minutes. No food is left in the stomach and most 
is visible in the intestine. 
 
Figure 3-14: Intestinal radioactivity in reference to the skin marker 
GE resulting in the disappearance of the stomach image on anterior acquisition. The 
marker (on the right side of the stomach) is used as a reference point for calculations. 
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Both anterior and posterior acquisitions were continued at approximately 30-minute 
time intervals. The process was continued until the food was visible in the terminal 
ilium/caecum. This was confirmed by the consultant radiologist with a special interest 
in GI motility. All the images were realigned with AOIs around the stomach. The 
intestines were marked in both anterior and posterior images (Figure 3-14, Figure 3-15 
and Figure 3-16). To calculate accurate radioactivity count, the markers were excluded 
for the count calculations on both anterior and posterior images. AOIs were drawn 
around the stomach and rest of the abdomen. This was performed on both anterior and 
posterior acquisitions. Radioactivity counts for each area (gastric and intestinal) were 
calculated as follows: 
 
Geometric mean = square root of (AOI on anterior acquisition X AOI on posterior 
acquisitions) 
The % emptying of the stomach and IT were thereafter calculated. In last images when 
the caecum was identified, the AOI around the caecum and or the large intestine was 
also drawn and the radioactivity was counted in the same way as in the stomach and 
small intestine (Figure 3-17, Figure 3-18, Figure 3-19). 
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Figure 3-15: AOI around the stomach and intestine (anterior views) 
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Figure 3-16: AOI around the stomach and intestine (posterior views) 
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Figure 3-17: AOI around the stomach, small intestine and large intestine 
(Anterior acquisitions) 
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Figure 3-18: AOI around the caecum/ascending colon 
This figure demonstrates the AOI around the caecum/ascending colon, small intestine 
and stomach. Note the gradual caecal filling from time 160 minutes to time 280 
minutes. Simultaneously, the food in the small intestine and GE is also elaborated. 
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Figure 3-19: The caecum and terminal ileum 
 (Anterior and posterior acquisitions). 
 
Post-operatively, IT was very fast. As the pouch was very small in size, the food 
quickly entered into the small intestine. The marker was placed at 0 minutes (before 
start of scintigraphy) as the pouch size was small and we proposed that this may result 
in quick pouch emptying. The rest of the procedure was as described above. Figure 
3-21, Figure 3-20 and Figure 3-22 demonstrates IT following RYGB. 
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Figure 3-20: Gastric pouch emptying measurement 
The AOI around the gastric pouch (anterior and posterior acquisitions) and a marker 
next (right) to the gastric pouch. The AOI around the intestine is also marked. 
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Figure 3-21: AOI around the gastric pouch, small intestine and caecum 
The AOI around the caecum, intestine and gastric pouch. There is a change in GI transit 
as there is more radioactivity in the caecum and ascending colon in the last part of this 
image. 
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Figure 3-22: Ascending colon and transverse colon radioactivity 
AOI around ascending and transverse colon. The count in the rest of the intestine (small 
intestine) is also elaborated. 
 
3.3.3 Hormones  
 
The following hormones were measured before and after bariatric surgery. Post-op 
samples were taken at 2 and 6 weeks after surgery (Figure 3-25).  
1. Ghrelin (foregut hormone).  
2. GLP-1 (distal small intestine hormone). 
3. Insulin (pancreatic hormone). 
 126
4. Glucose.  
 
Glucose levels were checked by a glucometer (standardised and calibrated) available in 
the Radiology Department during the time of the study. Plasma samples were taken as 
per the kit instructions and assessed for insulin, ghrelin, GLP-1 and glucose levels in the 
Biochemistry Lab in the University of Hull. These samples were stored at -70°C and 
then transported in batches of 40 samples to the Department of Biochemistry, 
University of Hull, for analysis. Hormone assays using ELISA kits are in practice and 
have been used in previous studies153,154,155 (see Figure 3-25). 
3.3.3.1 Ghrelin 
This hormone has been described in detail in Chapter 1, Table 1-1. A brief description is 
as follows:6, 142, 156, 157 
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Figure 3-23: Overview of ghrelin 
Source – gastric fundus 
Target – hypothalamus 
Actions: Stimulates appetite, levels ↑ before meal and ↓ after meal intake (30 minutes). 
Acts as meal initiator. 
It is proposed to increase glucagon level and decrease insulin levels. 
It was proposed that post-RYGB food bypasses ghrelin-producing cells, which may 
result in decreased ghrelin levels. 
 
3.3.3.2 GLP-1 
GLP-1 has been described in detail in Chapter 1, Table 1-1. Here is a brief description 
based upon the published literature:19, 20, 143, 158, 159 
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Figure 3-24: Overview of GLP-1 
GLP-1 is produced by L cells in the distal ileum in response to food. 
On stimulation – ↑ insulin level, ↓glucagon (Incretin Effect). 
It appears to function ↓GE (Ilealbreak hormone). 
Levels are considered to be ↓ in obesity  
It is proposed that the levels increase after gastric bypass resulting in better glycaemic 
control and decreased IR. 
We proposed that the increased levels may be observed after the RYGB which may 
influence the diabetic status of patients after surgery. 
3.3.3.3 Insulin 
 
Introduction: Insulin was discovered in the 1860s. It is produced by the pancreas and is 
the central regulator for carbohydrate and fat metabolism. It is produced in the beta cells 
of the islets of the pancreas. It is produced in proinsulin form and later the removal of C 
peptide results in its activated form insulin.1, 3 
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Typical normal insulin levels are 8–11 μIU/ml (57–79 pmol/L) after a meal. 
Physiology:  
1. Insulin controls the glucose intake in muscle and adipose cells. Lack of this 
function results in impaired glucose tolerance, DM. 
2. Integral part of proteins, DNA and enzymes synthesis. 
3. Glycogen synthesis, which is stored in the liver, is converted to glucose when 
required. 
4. Lipids under the influence of insulin are converted to triglycerides. 
5. Decreases gluconeogenesis (the production of glucose from non-carbohydrate 
sources). 
6. K homeostasis (acts on cells to uptake the K – failure of this action results in 
hyperkaleamia). 
7. Acts as an arterial muscle relaxant which helps in the secretion of 
hydrochloric acid (HCL) from stomach. 
 
In our study, insulin levels were assessed in plasma levels before and after RYGB. We 
also assessed the meal-related response to insulin and IR after surgery (RYGB). 
3.3.3.4 Glucose 
Glucose levels were assessed with a glucometer at fasting, 30 minutes and 60 minutes 
after meal intake. The last blood glucose levels were checked when the food reached 
into the caecum. 
2 weeks post-op fasting levels were checked. 
6 weeks after surgery the levels were repeated as per the pre-operative protocol.  
Furthermore, glucose levels were also assessed in patches in the Biochemistry Lab, 
University of Hull. 
3.3.4 Schedule of investigations (Figure 3-25) 
3.3.4.1 Pre-operative investigations  
 
1. GI hormone studies 
2. GI motility studies 
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The tests involved the subjects fasting overnight and attending the Nuclear Medicine 
Department, Castle Hill Hospital, in the morning. A Research fellow conducting all 
investigations helped the Nuclear Medicine Department. IV cannulas were sited and 
pre-procedure blood samples were taken. Cannulas were flushed with heplok 
(heparinised saline) to prevent clotting between blood samples. 
 
A standard meal containing isotope 99m Tc (radioactive material) was given at this 
stage. Dynamic acquisitions were taken at 100 minutes followed by static acquisitions at 
fixed time points such as 120, 180, 240, 360 and 480 minutes after the meal. 
Simultaneously, three more blood samples were withdrawn from the cannula. The first 
two blood samples were taken at fixed time points of 30 and 60 minutes, and the last 
blood sample was taken at the time when food was seen in the distal ileum/iliocaecal 
region. All blood samples were centrifuged; serum and plasma were stored at -70°C 
immediately after being withdrawn. For further details, see (Figure 3-25). 
 
3.3.4.2 Post-operative investigations  
 
3.3.4.2.1 Two-week post-operative investigations  
First follow-ups were organised 2 weeks after surgery in the outpatient clinic. Patients 
were requested to attend the clinic in a fasting state, where they were seen by the 
research fellow. Any post-op concerns were liaised with the consultant surgeon and 
fasting blood samples were taken, processed and stored. A two weeks post-operative 
follow-up was performed to investigate the early resolution of diabetes, improvement of 
IR and any alterations in ghrelin and GLP-1 levels. 
3.3.4.2.2 Six-week post-operative investigations  
Second follow-ups were organised 6 weeks after surgery. Patients were requested to re-
attend at the Nuclear Medicine Department with overnight fasting. Investigations 
included: 
 
1. GI hormone studies. 
2. GI motility studies. 
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Investigations were conducted on the same lines as pre-operatively. 
 Also see  the flow chart   
 
 
3.3.5 Hormone assays 
 
Overnight fast 
Patients to attend 
Nuclear Medicine 
Department
Cannula  
1st blood sample, 
Heplok flush  
Standard test meal 
containing isotope  
99m Tc 
Further blood samples after  
30 and 60 minutes and last blood 
sample when food seen in the distal 
ileum/ileocaecal region. 
Dynamic gamma camera 
scintigraphy for 100 minutes 
followed by static acquisitions at 
120, 180, 240, 360 and 480 
minutes. 
 Plasma to be isolated and samples 
stored at -70°C immediately after 
being withdrawn from cannula. 
Plasma isolated and 
stored at -70°C 
 
 Figure 3-25: Flow chart showing the investigations 
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Figure 3-26: Assays 
 
General principles: Every effort was made to protect the hormones/peptides from 
withdrawal from the patients to assays. Preservatives were used as per the kits. The 
samples were stored at –70°C, and transported in an ice-cooled container to the central 
Biochemistry Lab, University of Hull. They were stored until the day of assays in 
duplications. The samples were defrosted immediately before the assays. 
 
Glucose: Cayman’s glucose assay kits, Cat number 1009582 were used for this assay. 
These kits are simple, reproducible and highly sensitive for assaying glucose in plasma, 
serum and urine. 
 133
 
This kit implies Glucose Oxidase-Peroxidase reaction for determination of glucose 
concentration. In this assay, glucose is oxidised to δ-gluconolactone. The reduced form 
of glucose oxidase is regenerated to its oxidised form by molecular oxygen to produce 
hydrogen peroxide. Finally, with horseradish peroxidase as a catalyst, hydrogen 
peroxide reacts with 3,5-dichloro-2-hydroxybenzenesulfonic acid and 4-
aminoantipyrine to generate a pink dye with an optimal absorption at 514 nm. 
 
Plate setup and procedure:  
1. Plate setup used duplicated samples on the plate.  
2. Assay buffers were thawed and equilibrated to 4°C. All samples and reagents 
were equilibrated at 4°C. 
3. The final volume of assay was 150 uL in each well. 
4. The incubation temperature was 37°C. 
5. All samples and standards were assayed in duplication. 
6. Absorbance was monitored at 500–520 nm using a plate reader. 
 
Table 3-2: Glucose standards used in assay 
 
 
 
 
 
 
 
 
 
 
 
Standard preparation: Eight clean 12 x 75 mm glass test tubes were taken and labelled 
A-H. The amount of glucose standard and assay buffer to each tube were added as 
described in the table above. The diluted glucose standards are stable for two hours at 
room temperature. 
 
Tube Glucose Stock(pi) 
(1000 mg/dL) 
Assay Buffer (pi) Glucose Concentration 
(mg/dL) 
A 0 200 0 
B 2 198 12.5 
C 5 195 25 
D 10 190 50 
E 20 180 100 
F 30 170 150 
G 40 160 200 
H 50 150 250 
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Performing the assay:  
1. 5 ul sample or standard was added in labelled tubes. 
2. 500 ul of the enzyme mixture was added to the tube. The tubes were taped and mixed. 
3. The tubes were placed in an incubator for 10 minutes at 37°C. 
4. After that 150 ul was placed in each well (in duplication). 
5. Absorbance was read at 500–520 nm using a plate reader. 
Calculations:  
1. The average absorbance of each standard and sample was calculated. 
2. The absorbance value of the standard A (0 mg/dL) was subtracted  from itself and all 
other values (both standards and samples). This is the corrected absorbance. 
3. Corrected absorbance values of each standard as a function of the concentration of 
glucose were drawn. 
The concentration of glucose for each sample from the standard curve was calculated as 
follows:  
Glucose (mg/dl) = [corrected absorbance – (y-intercept)] 
                                                           Slope 
Assay range 0–250 mg/dl. 
Standard curves: The following standard curves were generated: 
X axis representing glucose concentration (mg/dl) 
Y axis representing absorbance (514 nm) 
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Insulin: 
 
Insulin Elisa tests were performed with INVITROGEN kits, catalogue number 
KAQ1251, on pre-collected plasma samples.  
 
Principle: The assay uses monoclonal antibodies directed against insulin. Samples 
including standards of known insulin content, control specimens and unknowns were 
pipetted into the wells. A detector monoclonal antibody labelled with horseradish 
peroxidase (HRP) was added. After an incubation period, the plate was washed to 
remove unbound enzyme-labelled antibody and the substrate solution was added. This 
was followed by incubation. The reaction was stopped with HCl and the plates read 
spectrophotometrically. The intensity of colour in this method is directly proportional to 
the concentration of insulin in the original specimen. 
 
Procedure:  
1. After defrosting the samples and preparing standards, 50 µl of each standard, 
control or sample were added into the appropriate wells. 
2. 50 µl of Anti-Insulin-HRP conjugate was added into all wells. 
3. The plates were covered with a plate cover and incubated for 30 minutes at room 
temperature. 
4. Fluid from the wells was aspirated and plate wells washed 3 times with wash 
solution. 
5 100 µl of chromogen solution was added into each well. 
6. Plates were incubated for 15 minutes at room temperature in the dark. 
7. 100 µl of stop solution was added into each well. Plates were gently mixed. The 
solution in the wells changed from blue to yellow (see the figure below). 
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8. The absorbance of each well was read at 450 nm. 
9. Standard curves were plotted as below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-27: Insulin standard curve
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10. Concentrations for unknown samples and controls from the standard curve were 
read. 
 
Typical example data for the assay was as follows: 
 
 
Table 3-3: Insulin reference values 
Assay reverence values between 0–250 µIU/ml 
 
 
GLP-1: 
 
GLP-1 assays were performed with ALPCO Elisa kits, cat number 43-GPTHU-E01. 
Pre-collected plasma samples were defrosted immediately before the assays.  
 
Principle: This test is designed for the quantitative measurement of GLP-1. The assay 
is based upon a two-site “sandwich” technique with two selected GLP-1 antibodies. 
Assay standards, controls and test samples are added directly to the wells of a 
microplate that is coated with streptavidin. Subsequently, a mixture of GLP-1 specific 
antibody and a horseradish peroxidate (HRP) conjugated GLP-1 specific antibody is 
added to each well. After the incubation period, a “sandwich” immunocomplex of 
“streptavidin–biotin-antibody–GLP– HRP conjugated antibody” is formed and attaches 
to the walls of the plate. The unbound HRP conjugated antibody is removed in a 
subsequent washing step. For the detection of this immunocomplex, each well is then 
Standard 
Insulin (µIU/ml) 
Optical Density 
(450 nm)
250 2.34 
128 1.31 
44.4 0.51 
13.8 0.13 
5.1 0.07 
0 0.03 
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incubated with a substrate solution in a timed reaction and then measured in a 
spectrophotometric micro plate reader. The enzymatic activity of the immunocomplex 
bound to GLP-1 on the walls of the microtiter wells is directly proportional to the 
amount of GLP-1 in the sample. 
 
Procedure: Antibody mixture was prepared by 1:21 fold dilution of the Tracer 
Antibody and by 1:21 fold dilution of the biotinylated Capture Antibody with the Tracer 
Antibody Diluent. For each strip, a  mix of 1 ml of the Tracer Antibody Diluent (30017) 
with 50µL the Capture Antibody (30361) and 50µL of the Tracer Antibody (30360) 
were added in a clean test tube. 
 
100 µL of standards, controls and test samples were added to the designated micro 
wells. 100 µL of Antibody Mixture was added to each well. The plates were covered 
with plate sealer and incubated at 2–8°C, static for 20–24 hours. The next day (i.e. after 
24 hours) the plate sealer was removed and the contents of the wells were 
aspirated.Wash with wash buffer was performed with an automated micro plate washer. 
200 µL of HRP Substrate was added to each well. The plate was covered with 
aluminum foil to avoid exposure to light. The plates were incubated at room 
temperature for 20 minutes. Aluminum foils were removed and 50 µL of stop solution 
was added to each well. The contents were mixed gently and the plates were read for 
absorbance at wavelength 450 nm/620 nm or 450 nm/650 nm within 10 minutes in a 
micro plate reader. 
 
Interpretation of results:  The average absorbance for each pair of duplicate tests was 
calculated .The standard curves were generated by the average absorbance of all 
standard levels, including the zero standard, on the ordinate against the standard 
concentrations on the abscissa using point-to-point or log-log paper. The GLP-1 
concentrations for the controls and test samples were read directly from the standard 
curve using their respective absorbance.  
Absorbance  
(unknown) 
Value of unknown = Absorbance (unknown) / absorbance (2nd standard) x Value of 
2nd STD) 
Standard curves were as follows: 
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Figure 3-28: Standard curve for GLP 
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Reference values were GLP-1 were 0–54pmol/L using this assay. 
 
 
Ghrelin: 
Ghrelin assays were performed with Millipore HUMAN GHRELIN (TOTAL) ELISA 
KIT, 96-Well Plate (catalogue number EZGRT-89K). 
 
Principles:  
1.  This assay is also a “sandwich” ELISA based on the capture of human 
ghrelin molecules in the sample by anti-human ghrelin IgG and the immobilisation of 
the resulting complex to the wells of a microtiter plate coated by a pre-titered amount of 
anchor antibodies.  
2. In addition, there is simultaneous binding of a second biotinylated antibody 
to ghrelin and then the washing away of unbound materials, followed by conjugation of 
horseradish peroxidase to the immobilised biotinylated antibodies. 
3. The washing away of free enzyme, and quantification of immobilised 
antibody-enzyme conjugates by monitoring horseradish peroxidase activities in the 
presence of the substrate 3,3’,5,5’tetra methylbenzidine.  
4. The enzyme activity is measured spectrophotometrically by the increased 
absorbency at 450 nm. 
 
 
Procedure:  
After the preparation of standards and defrosting the stored samples the following steps 
were followed for the measurement of ghrelin levels in plasma samples: 
1. Wash buffer was mixed in 900 ml distilled water. 
2. Each well was washed with 300 Pl diluted wash buffer.  
3. 20 µL matrix solution was added to blank, standards and quality control wells. 
4. 30 µL assay buffer was added to each of the blank and sample wells. 
5. 10 µL assay buffer added to each of the standard and quality control wells. 
6. 20 µL ghrelin standards was added in duplicate in the order of the ascending 
concentrations to the appropriate wells. 
7. 20 µL QC1 and 20 µL QC2 were added in duplicate to the appropriate wells. 
8. 20 µL of the Plasma samples were added in duplicate to the remaining wells. 
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9. 50 µL Antibody Solution Mixture (1:1 mixture of capture and detection 
antibody) was added to each well. 
10. The plates were covered with plate sealer and incubated at room temperature for 
2 hours on an orbital microtiter plate shaker set to rotate at moderate speed 
(about 400–500 rpm). 
11. The plate sealer was removed and decanted solutions were removed from the 
plates.They were tapped as before to remove residual solutions in the wells. 
12. The wells were washed 3 times with diluted Wash Buffer, 300 µL per well per 
wash. 
13. There was decanting and tapping after each wash to remove residual buffer. 
 
Calculations: Graph of reference curve was generated by plotting the absorbance unit of 
450 nm, less unit at 590 nm, on the Y axis against the concentrations of ghrelin standard 
on the X axis. The dose–response curve of this assay fits best to a sigmoidal 4- or 5-
parameter logistic equation. The results of plasma samples were calculated with any 
computer programme having a 4- or 5-parameter logistic function. 
 
The theoretical minimal detecting concentration of this assay is 100 pg/ml.  
Standard curves were as follows: 
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Figure 3-29: Standard curve for ghrelin 
y = ‐1284.5x2 + 6114.1x ‐ 1005.7
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The appropriate range of this assay (total ghrelin) is 100 pg/ml–5,000 pg/ml. 
 
Funding and expenditure 
 
Source of funds: Scarborough Combined Gastroenterology Research Fund, 
Scarborough 
The cost of the study was as follows: 
1. Scintigraphy £250 x 2 (studies per patient) x 25 (number of patients) = 
£12,500.00 
2. Hormone assays 40 assay/kit, total number of kits required=19, approximated 
price/kit (£350–370), total cost = £6500 (approximately). 
3. Travel and refreshments for the participants. 
4. Parking charges for participants.  
5. Stationery and postal charges. 
Total cost = approximately £21,500 
6. The cost related to conduct of the study and salary to the research fellow was 
funded by the University of Hull. 
3.3.6 Data storage and research facilities 
All the collected data were anonymised and stored on computers in the Research Office 
in the Academic Surgical Unit at Castle Hill Hospital in a non-identifiable way. These 
are password protected, and part of the hospital IT network system. They are protected 
both by antivirus and firewall software, as with all Trust computers. Only the named 
investigator will have access to patient data. Transfer of electronic data was anonymised 
and only carried out through encrypted and password-protected USB devices provided 
or via www.nhs.net email accounts. Furthermore, hard copies of the forms were also 
filed in the Research Office in Castle Hill Hospital. A coded lock and general hospital 
security services protect these premises.  
3.4 Statistics 
Data was entered in Microsoft Excel 2007 spreadsheets and analysed by Excel 2007 and 
SPSS 19. Data is described as Mean + Standard deviation unless otherwise described. 
Paired and unpaired student t tests were used and p value of less than 0.05 was 
considered to be statistically significant. 
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3.5 Results 
3.5.1 Improvement of weight, BMI and diabetic status following RYGB 
Table 3-4: Change in weight, BMI, Diabetic status, GE after RYGB. 
22 patients (Male 6, Female 16), Weight 1,2,3 = Pre operative, 2 weeks, 6 weeks after surgery respectively.BMI 1, 2, 3 = Pre operative, 2 
weeks, 6 weeks after surgery respectively, DM 1,2 ,3= Fasting glucose levels (pre operative, 2 weeks, 6 weeks after surgery respectively)  
Weight improved from a mean of 130+/-22 to 111+/-18 kg 6 weeks. Fasting glucose levels improved from a mean of 11.0+/-4.3 to 8.0+/- 
2.3 m mol/L. GE was fast after RYGB (pre operative 94+/-74 minutes vs. post operative 21+/-21 minutes). 
 Age 
(years) 
Height 
(cm) 
Weight 1 
(kg) 
Weight 2 
(kg) 
Weight3  
(kg) 
T50  
(pre-op) 
T50  
(post-op) 
BMI1 BMI 2 BMI 3 DM 1 DM 2 DM 3 
N Valid 22 22 22 22 22 22 22 22 22 22 22.00 22.00 22.00 
Missing 0 0 0 0 0 0 0 0 0 0 0.00 0.00 0.00 
Mean 46 166 130.7 117.2 111.5 94 21 21 42.4 40.4 11.08 7.68 8.03 
Median 46 164 127.0 113.0 107.5 69 18 18 42.2 40.3 11.01 7.75 7.41 
Std. Deviation 8 9 22.5 20.8 18.8 74 21 21 5.6 5.2 4.31 2.60 2.83 
Range 29 30 85.0 78.2 78.0 288 85 85 22.3 21.3 4.70 3.11 4.18 
Minimum 29 152 93.0 80.8 76.0 32 1 1 34.1 32.0 19.74 11.81 16.40 
Maximum 58 182 178.0 159.0 154.0 320 86 86 56.4 53.3 7.66 5.68 5.63 
Percentiles 25 43 159 115.0 101.8 98.8 52 4 41.9 38.0 41.9 11.01 7.75 7.41 
50 46 164 127.0 113.0 107.5 69 18 46.4 42.2 46.4 13.19 9.96 10.02 
75 52 175 145.0 134.0 123.0 95 30 52.9 46.0 52.9 22.00 22.00 22.00 
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3.5.2 Change in GE following RYGB 
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Figure 3-30: GE before surgery 
Total number of patients = 22. X axis = GE emptying at (0 to 100 minutes after food intake). Y axis = food/radioactivity in gastric pouch. 
A mean of 83% radioactivity (food) was seen in stomach at 0 minutes and it reduced to 32 % at 100 minutes. 
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Table 3-5: GE (time vs. radioactivity) for each patient 
The first image was taken immediately after the food intake. Thereafter images were taken continuously for 100 minutes. 
Data of images after every 10 minutes is presented for each patient. 
X axis = patient number, Y axis = GE.  
Over 80% radioactivity was seen in the stomach in 17 patients at the start of the test. Less than 40% left in the stomach in 15 patients at the 
end of the test (100 minutes). 
 
 
time 
(minutes) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
0 61.02 74.92 81.11 85.29 88.09 82.23 86.57 72.65 82.77 88.72 84.03 84.21 75.24 84.87 82.49 83.79 83.12 81.14 82.21 88.18 85.46 86.49 
10 58.99 69.16 80.93 84.45 85.62 82.19 82.81 71.03 74.46 87.41 68.16 80.35 66.61 83.79 81.95 81.98 84.33 78.64 80.42 87.48 84.76 86.24 
20 45.32 60.83 74.94 79.50 77.27 81.32 78.91 71.66 64.06 86.77 58.80 79.61 56.52 81.17 78.18 78.09 82.32 73.49 77.27 86.17 84.07 85.53 
30 41.40 53.94 66.48 70.72 68.58 80.12 71.97 68.48 46.93 85.07 55.26 68.16 46.80 65.61 71.39 74.83 74.21 67.27 72.25 82.28 77.92 85.45 
40 32.56 44.10 63.39 58.30 61.87 75.76 69.01 67.60 25.97 85.42 50.36 53.75 37.47 55.20 60.95 68.38 57.84 65.42 67.87 79.97 66.97 84.71 
50 26.64 39.95 62.51 44.49 56.56 73.03 60.82 66.91 15.12 83.71 42.93 43.03 30.02 45.72 52.61 61.04 45.73 65.45 58.02 74.95 61.77 84.57 
60 26.29 36.17 60.35 30.82 47.00 65.53 59.19 64.80 12.64 83.71 40.66 37.82 26.67 34.86 47.62 59.21 36.73 61.45 50.58 68.75 55.01 83.28 
70 25.05 30.96 51.21 22.42 38.97 59.94 55.00 62.06 10.67 83.69 36.29 27.11 23.38 31.31 42.92 53.63 32.12 57.46 45.21 66.12 49.51 79.65 
80 21.39 31.19 49.03 13.50 34.15 58.19 46.49 60.91 9.28 83.49 31.20 19.83 18.21 24.19 39.99 49.57 26.36 54.84 40.00 59.62 41.56 78.51 
90 18.12 27.69 44.53 6.67 26.25 56.25 43.44 56.97 8.95 82.14 27.02 18.87 13.16 20.13 36.01 41.33 23.10 47.10 34.57 53.22 36.46 78.32 
100 17.61 27.04 31.75 4.67 22.04 52.75 39.58 54.66 7.74 80.72 23.80 15.28 8.62 8.81 35.78 31.46 18.80 41.09 25.96 51.09 31.13 72.70 
 148 
 
 
 
Table 3-6: GE before surgery (mean). 
Mean and Std Deviations of radioactivity at each data point (10 minute intervals). 82+/-6 % radioactivity at the start of the test, 54+/-17 % 
after 50 minutes and 32+/-20% at 100 minutes.  
 
Time  
 
0 10 20 30 40 50 60 70 80 90 
 
100 
N Valid 22.00 22.00 22.00 22.00 22.00 22.00 22.00 22.00 22.00 22.00 22.00 
Missing 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Mean 82.03 79.17 74.63 67.96 60.59 54.34 49.51 44.76 40.52 36.38 31.96 
Std. Deviation 6.29 7.73 10.89 12.25 15.58 17.82 18.52 19.01 20.07 20.39 20.47 
Range 27.70 28.49 41.45 44.05 59.45 69.45 71.07 73.02 74.21 75.47 76.05 
Minimum 61.02 58.99 45.32 41.40 25.97 15.12 12.64 10.67 9.28 6.67 4.67 
Maximum 88.72 87.48 86.77 85.45 85.42 84.57 83.71 83.69 83.49 82.14 80.72 
Percentiles 25 81.13 73.60 69.76 63.02 52.90 43.01 35.84 30.00 23.49 19.82 17.03 
50 83.46 81.97 78.14 69.65 62.63 57.29 49.10 44.07 40.00 35.29 29.09 
75 85.72 84.53 81.57 75.60 68.54 65.82 62.29 58.08 55.68 48.63 43.59 
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Figure 3-31: Box plot representing GE before RYGB 
Y axis = % GE, X axis = Time  
Mean GE + St Deviation presented in box plot. 82+/-6 % radioactivity at the start of the test, 54+/-17 % after 50 minutes and 32+/-20% at 
100 minutes. 
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Post-Operative Pouch Emptying 
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Figure 3-32: Post-operative GE (pouch emptying) 
Total number of patients = 22 
X axis = pouch emptying at (0 to 100 minutes after food intake).Y axis = food/radioactivity in gastric pouch. 
Patient number 9 and 17 had over 60% radioactivity in the pouch at the start of the test compared to patient number 5, 6,13,16,22 with less 
than 5% radioactivity in the pouch 
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Table 3-7: Pouch emptying for individual patients 
Time (Y Axis) vs. Radioactivity (X Axis) in gastric pouch following RYGB. Wide variation in pouch retention and pouch emptying noted. 
Patient number 9 and 17 had maximum (over 60%) radioactivity in the pouch at the start of the test compared to patient number 5, 
6,13,16,22 with less than 5% radioactivity in the pouch. 
Time  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
0 11.25 31.79 33.64 28.24 4.78 3.31 44.91 18.76 66.21 22.91 9.25 41.95 4.31 7.86 14.08 2.77 64.56 28.75 22.29 16.34 26.03 2.48 
10 12.25 13.52 3.73 2.58 2.94 3.12 2.15 12.79 45.65 1.44 6.75 12.66 1.60 3.95 13.96 1.82 61.19 3.34 1.56 9.22 14.60 1.26 
20 11.61 5.63 3.16 1.03 1.11 3.74 2.04 9.04 35.90 1.08 3.72 10.36 0.92 2.19 13.55 1.66 56.12 2.99 1.43 4.93 6.54 1.34 
30 7.07 6.05 3.13 0.86 1.02 2.99 1.76 5.22 27.73 1.10 4.66 5.68 1.03 1.93 13.43 1.34 45.09 3.16 1.35 4.00 4.36 1.48 
40 3.75 3.40 3.29 0.80 0.99 2.96 1.90 4.10 2.51 0.79 2.59 4.71 0.41 1.83 12.66 0.84 34.95 3.32 1.44 2.42 1.54 1.43 
50 3.85 3.56 3.22 0.64 0.56 2.66 1.14 3.54 2.48 0.96 2.31 3.66 0.45 1.56 11.65 0.70 30.42 2.91 1.30 1.25 1.10 1.23 
60 4.30 3.43 3.05 0.68 0.59 1.74 0.58 3.46 2.09 0.77 2.21 4.05 0.45 1.64 9.42 0.56 21.44 3.12 1.06 1.65 1.06 1.31 
70 4.32 3.54 2.56 0.60 0.52 1.81 0.51 3.02 2.08 0.79 2.53 4.07 0.36 1.55 5.63 0.56 16.80 2.72 1.24 1.50 1.00 1.36 
80 2.64 2.94 2.77 0.42 0.48 1.58 0.43 3.02 2.02 0.62 2.60 4.17 0.44 1.58 5.52 0.54 13.00 2.80 1.29 1.60 1.14 0.93 
90 2.95 1.32 2.78 0.37 0.46 1.49 0.44 3.09 2.00 0.46 2.41 3.56 0.37 1.59 5.14 0.51 9.07 2.68 1.02 1.28 0.85 1.10 
100 2.85 1.26 2.29 0.50 0.49 1.28 0.43 3.17 1.16 0.42 1.72 3.91 0.27 1.24 4.72 0.50 4.85 2.55 1.47 1.27 0.80 1.14 
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Table 3-8: Post-RYGB pouch emptying (mean) 
77% of food/radioactivity had left the pouch and were seen in the small intestine immediately after food intake. A mean of 23+/-18% 
radioactivity was noticed in gastric pouch at the start of the test and it reduced to 1.7+/-1.3% at 100 minutes. 
 0 
minute 
10 
minute 
20 
minute 
30 
minute 
40 
minute 
50 
minute 
60 
minute 
70 
minute 
80 
minute 
90 
minute 
100 
minute 
N Valid 22.00 22.00 22.00 22.00 22.00 22.00 22.00 22.00 22.00 22.00 22.00 
Missing 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Mean 23.02 10.55 8.19 6.57 4.21 3.69 3.12 2.69 2.39 2.04 1.74 
Std. Deviation 18.63 14.89 13.16 10.43 7.31 6.42 4.56 3.46 2.72 2.01 1.39 
Range 63.73 59.93 55.20 44.23 34.53 29.97 20.99 16.44 12.57 8.70 4.58 
Minimum 2.48 1.26 0.92 0.86 0.41 0.45 0.45 0.36 0.42 0.37 0.27 
Maximum 66.21 61.19 56.12 45.09 34.95 30.42 21.44 16.80 13.00 9.07 4.85 
Percentiles 25 7.09 2.07 1.41 1.35 1.32 1.06 0.75 0.74 0.60 0.50 0.50 
50 20.52 3.84 3.44 3.15 2.46 1.93 1.69 1.68 1.59 1.41 1.26 
75 32.25 12.97 9.37 5.77 3.49 3.54 3.44 3.15 2.84 2.82 2.62 
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Figure 3-33: Box plot representing pouch emptying 
X axis = time, Y axis = radioactivity. Small amount of radioactivity (23%) noted at the start of the test and it reduced to 1.7% at 100 
minutes. 
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Figure 3-34: Change in GE following RYGB 
X axis = Comparison of T50 (pre and post RYGB). Y axis = time. The graph above 
shows that all patients had fast pouch emptying compared to their pre-operative GE.  
 
 
 
 
X axis = Pre and post operative GE, Y axis = GE time. Box plot representing GE before 
surgery and gastric pouch emptying after RYGB. There was significantly fast pouch 
emptying when compared with pre-operative GE (p < 0.01).  
Figure 3-35: Box plot representation of pre- and post-op GE 
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A total of 25 patients were recruited. Three patients were excluded due to the 
following reasons: 
1. Post-operative complications and the patient not being able to complete the research. 
2. Failing to comply pre-operatively with the nutritional instructions and being 
withdrawn from the operative waiting list. 
3. Funding for the procedure being refused by the PCT for one patient and not operated 
on for RYGB and consequently dropped from the study. 
 
The final data of the 22 patients is included in this study (Table 3-4). This included 6 
male and 16 female diabetic patients with morbid obesity. GE was assessed in a total of 
22 patients. The basic demographic data is presented in Table 3-4. The mean age was 46 
± 8 years (range 29–58). The mean height was 166 ± 9 cm, pre-operative weight 130 ± 
22.5 kg (range 178–93) and corresponding BMI was 47.3 ± 6.3. Post-operatively, all 
patients lost weight and their weight and BMI decreased and the corresponding values 
were as follows:  
 
2 weeks after surgery = mean weight 117 ± 20, BMI 42.4 ± 5.6 
6 weeks after surgery = mean weight 111 ± 8, BMI 40.4 ± 5.2 
 
GE before surgery was calculated continuously for 100 minutes and individual patient 
data is presented above (32 % at 100 minutes. 
 
Table 3-5, Table 3-6, Figure 3-30, Figure 3-31). The half-emptying time (T50) of the 
stomach before surgery was 94 minutes. A mean 82 ± 6% of food was seen in the 
stomach after meal intake (Table 3-4, 32 % at 100 minutes. 
 
Table 3-5, Figure 3-31). The rest of the food was already seen in the intestine. 
 
Post-operatively, most (approximately 90–95%) of the stomach was bypassed. A small 
pouch size (approximately 50 ml) and stoma (approximately 1cm diameter) were 
created during surgery. A post-operative pouch emptying is described in Figure 3-
33Figure 3-33, Figure 3-34Figure 3-34, Table 3-7Table 3-7 and Table 3-8.  A total of 
23 ± 18% of food was retained in the pouch at the end of the meal intake. The 
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remainder had already entered into the jejunum. This further emptied quickly to a mean 
10 ± 14% left in the pouch after 10 minutes and continued emptying quickly. Pouch 
half-emptying time was significantly short (p<0.01) compared to pre-operative GE 
(Figure 3-35, Figure 3-34). 
 
 
3.5.3 Change in IT following RYGB 
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Figure 3-36: Pre-operative caecal filling time 
X axis = Time, Y axis = % radioactivity. Serial calculations were performed for each 
patient at 30 minute intervals until Caecum was confidently identified for each patient. 
Each patient represented with a series of the same colour readings. 
 
 
 
Table 3-9: Pre-operative IT time 
Mean 40.21% 270 minutes
Median 41% 265 minutes
St dev 16% 39 Minutes
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Pre-operative Mean intestinal transit time was 270 minutes for 40% radioactivity 
calculated in the caecum. 
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Figure 3-37: Post-operative IT time 
X axis = Time, Y axis = % radioactivity. Serial calculations were performed for each 
patient at 30 minute intervals until Caecum was confidently identified for each patient. 
Each patient represented with a series of the same colour readings. 
 
 
 
Table 3-10: Post-RYGB IT time 
Mean   39% 212 Minutes
Median 40% 220 Minutes
St dev 20% 44 Minutes
Post RYGB Mean intestinal transit time was 212 minutes for 39% radioactivity 
calculated in the caecum 
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Table 3-11: Pre- and post-RYGB IT time vs. radioactivity (%) 
Comparison of data of 22 patients. Pre-operative IT reduced from 271 minutes to 212 
minutes for the same amount of radioactivity 40% (pre-operative) vs. 39% (post 
RYGB). 
 
 IT 1 (%) IT 2 (%) 
Time 1 
(minutes) 
Time 2 
(minutes) 
N Valid 22 22 22 22
Missing 0 0 0 0
Mean 40 39 271 212
Median 42 40 265 220
Std. Deviation 16 20 39 44
Minimum 0 9 170 100
Maximum 67 71 360 300
Percentiles 25 33 22 250 188
50 42 40 265 220
75 49 56 290 240
 
 
 
 
Table 3-12: comparison of IT following RYGB 
Paired t test showing significantly short IT (271 minutes vs. 212 minutes p < 0.05) for 
the same amount of radioactivity (40% vs. 39% P > 0.05) after RYGB. 
 
Paired Differences 
t df 
Sig. (2-
tailed) Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 1 % - % -1.59 24.36 5.19 -12.39 9.21 -.306 21 .762
Pair 2 minutes 
- 
minutes 
-58.64 52.22 11.13 -81.79 -35.48 -5.267 21 .000
 
 
 159
 
Figure 3-38: Box plot comparison of pre- and post-RYGB radioactivity in the 
caecum vs. filling time 
Significantly (P < 0.01) improved IT (271 minutes vs. 212 minutes) for the same 
amount of radioactivity (40% vs. 39% P > 0.05) calculated in caesium after RYGB 
 
IT time is described in Figure 3-36, Figure 3-38, Table 3-9, Table 3-10, and Table 3-12. 
Pre-operative mean IT time was 270±39 minutes for 40.2±16 % radioactivity/food 
recorded in the iliocaecal region. Post-operatively, fast IT time was recorded of 212±44 
minutes for 39±20 radioactivity/food in iliocaecal region. There was no significant 
difference (p 0.76) for the amount of radioactivity/food noticed in the iliocaecal region 
on the last scan; however, the IT time was significantly decreased after RYGB (p 
<0.01), as shown in Table 3-12. 
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3.5.4 Change in gut hormones (ghrelin & GLP-1) following RYGB 
 
1. Diabetic status before and after RYGB 
a. Fasting glucose levels  
Glucose levels described in m mol/L 
 
 
 
Table 3-13: Fasting glucose levels before and after RYGB 
Pre-operative fasting glucose levels 11.08+/-4.31 reduced to 7.68+/-2.60 at 2 weeks 
follow up and 8.03+/-2.83 at 6 weeks follow up after RYGB. 
 Pre-op Two weeks Six weeks 
N Valid 22.00 22.00 22.00 
Missing 0.00 0.00 0.00 
Mean 11.08 7.68 8.03 
Median 11.01 7.75 7.41 
Std. Deviation 4.31 2.60 2.83 
Minimum 4.70 3.11 4.18 
Maximum 19.74 11.81 16.40 
Percentiles 25 7.66 5.68 5.63 
50 11.01 7.75 7.41 
75 13.19 9.96 10.02 
 
 
Fasting glucose levels before and after RYGB: Post-operative low glucose levels were 
recorded. One patient adopted a different pattern of eating behaviour following RYGB 
as this patient was not able to take the similar amount of solid meal. However, the 
patient developed a habit of taking lots of fluids (milk, juice, sugary drinks), resulting in 
high glucose levels.  
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Table 3-14: Change in fasting glucose after RYGB 
A significant improvement in fasting glucose levels was observed after surgery 
when compared with the corresponding pre-operative levels (p 0.001 and 0.01). 
  
Paired Differences 
t df 
Sig. (2-
tailed) 
Mea
n 
Std. 
Deviati
on 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 
1 
Pre-op two 
weeks 
3.40 4.43 0.94 1.44 5.36 3.60 21.00 0.00
Pair 
2 
Pre-op six 
weeks 
3.05 4.69 1.00 0.97 5.13 3.05 21.00 0.01
Pair 
3 
Two_weeks  
Six weeks 
-
0.35 
3.45 0.74 -1.88 1.18 -
0.48 
21.00 0.64
 
 
 
 
Improvement in fasting glucose levels ( Y axis) was observed after surgery (2 weeks, 6 
weeks in X axis) when compared with the corresponding pre-operative levels (p 0.001 
and 0.01). 
 
Figure 3-39: Box plot representing fasting glucose levels pre- and post-RYGB 
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Table 3-15: Pre-operative meal-related glucose response 
This included fasting samples. Further samples were taken at 30 minutes and 60 
minutes after food intake. The last sample was taken when food reached the iliocaecal 
region. Meal intake resulted in an increase in mean glucose level from fasting levels 
11.0+/-4.3 to 12.6+/-4.4 at 30 minutes, 12.6+/-4.5 at 60 minutes and then reduced to 
10.2+/-4.1 when food reached in caecum. 
 Pre-op fasting 30 60 caecum 
N Valid 22 22 22 22
Missing 0 0 0 0
Mean 11.08 12.69 12.68 10.24
Median 11.01 12.05 12.01 9.11
Std. Deviation 4.31 4.48 4.54 4.13
Range 15.04 17.43 16.96 14.49
Minimum 4.70 7.25 5.72 5.54
Maximum 19.74 24.68 22.68 20.03
Percentiles 25 7.66 9.01 8.64 7.17
50 11.01 12.05 12.01 9.11
75 13.19 14.77 14.99 12.32
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Figure 3-40: Serial pre-operative meal-related response in individual patients 
Graphic representation of serial glucose tests and results on 22 paterients before 
surgery. 
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Figure 3-41: Box plot representing pre-operative meal-related glucose response 
Y axis = glucose levels, X axis = time since food intake. Meal intake resulted in an 
increase in mean glucose level from fasting levels 11.0+/-4.3 to 12.6+/-4.4 at 30 
minutes, 12.6+/-4.5 at 60 minutes and then reduced to 10.2+/-4.1 when food reached in 
caecum. 
 
Table 3-16: Post-RYGB meal-related response 
Improved fasting glucose levels 8.0+/-2.8 mmol/l compared to pre operative fasting 
levels. Meal intake resulted in an increase to 11.1+/-3.2, 10.7+/-3.7 at 30 and 60 
minutes respectively. 
 
Fasting post-
op 30. 60 caecum 
N Valid 22 22 22 22
Missing 0 0 0 0
Mean 8.03 11.14 10.70 8.43
Median 7.41 11.64 10.48 8.07
Std. Deviation 2.83 3.27 3.75 3.13
Range 12.22 13.75 14.95 12.14
Minimum 4.18 6.25 5.05 4.46
Maximum 16.40 20.00 20.00 16.60
Percentiles 25 5.63 8.41 8.26 5.74
50 7.41 11.64 10.48 8.07
75 10.02 12.86 12.98 11.08
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Figure 3-42: Meal-related glucose response in individual patients. 
Graphic representation of serial glucose tests after meal intake in 22 patients at 6 weeks 
following RYGB. Increase at 30 and 60 minutes demonstratd. 
 
 
Figure 3-43: Box plot representing post-RYGB meal-related response 
Improved fasting glucose levels 8.0+/-2.8 mmol/l compared to pre operative fasting 
levels. Meal intake resulted in an increase to 11.1+/-3.2, 10.7+/-3.7 at 30 and 60 
minutes respectively. 
 
 165
 
 
 
Change in glucose levels after RYGB 
 
Table 3-17: Comparison of pre-RYGB and 6 weeks post-RYGB meal-related 
glucose response 
Fasting glucose levels significantly decreased after surgery (p = 0.01). No significant 
change in meal related response after RYGB (glucose levels at 30 minutes, 60 minutes 
and food in caecum). 
  
Paired Differences 
t df 
Sig. (2–
tailed) Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 1 fasting 
pre-op 
fasting 
post-op 
3.05 4.69 1.00 0.97 5.13 3.05 21.00 0.01
Pair 2 30 – 30 1.55 5.13 1.09 -0.73 3.82 1.42 21.00 0.17
Pair 3 60 – 60 1.98 5.44 1.16 -0.43 4.39 1.71 21.00 0.10
Pair 4 caecum 
- 
caecum 
1.82 4.45 0.95 -0.16 3.79 1.92 21.00 0.07
 
Glucose levels were converted to mmol/L. Fasting glucose levels reduced from 
11.0±4.3 to 7.6±2.6 at 2 weeks after surgery and at the 6-week follow-up to 8.0±2.8. 
This change was significant p 0.01 at 2 and 6 weeks respectively after surgery (Table 3-
13, Table 3-14, Figure 3-39). The standard meal resulted in an increase in glucose from 
11.0±4.3 to 12.6±4.4 at 30 minutes, sustained at 12.6±4.5 at 60 minutes and reduced to 
10.2±4.1 when food reached into the caecum (Table 3-15). 
 
Following RYGB, the fasting levels 8.0±2.8 increased to 11.1±3.2 at 30 minutes, and 
continued to decrease thereafter to 10.7±3.7 at 60 minutes after food intake and to 
8.4±3.1 when the food reached into the caecum (Table 3-17). Although decreases over 
all postprandial responses were seen after RYGB, it was statistically significant in the 
fasting state only. 
 166
 
2. Change in insulin and IR before and after RYGB 
2a. Change in insulin levels 
Insulin levels described in mIU/L. 
Table 3-18: Fasting insulin levels before and after RYGB 
A constant decrease in fasting insulin levels after surgery was recorded. Pre operative 
60.7+/- 64.4, 2 weeks after RYGB 48.0+/-54.4, 6 weeks after surgery 41.6+/-55.8 
 
pre-op fasting 
2 weeks post-op 
fasting 
6 weeks post-op 
fasting 
N Valid 22 22 22
Missing 0 0 0
Mean 60.71 48.01 41.67
Median 33.44 27.00 16.46
Std. Deviation 64.47 54.41 55.88
Range 220.24 179.21 182.24
Minimum 15.52 5.24 6.10
Maximum 235.76 184.45 188.34
Percentiles 25 23.81 11.21 11.68
50 33.44 27.00 16.46
75 65.17 43.83 35.00
 
 
Figure 3-44: Box plot representing fasting insulin levels before and after RYGB 
X axis = Time of measurement, Y axis = levels. Continuous decline noticed as pre 
operative 60.7+/- 64.4, 2 weeks after RYGB 48.0+/-54.4, 6 weeks after surgery 41.6+/-
55.8. 
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Table 3-19: Comparison of fasting insulin levels 
Significant improvement in fasting insulin level at 6 weeks follow-up compared with 
pre-operativefasting insulin level (p= < 0.01). 
 
Paired Differences 
t df 
Sig. (2-
tailed) Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 1 pre-op 
fasting 
– 2 
weeks 
fasting 
12.70 32.53 6.94 -1.72 27.13 1.83 21.00 0.08
Pair 2 pre-op 
fasting 
– 6 
weeks 
fasting 
19.04 20.85 4.45 9.79 28.28 4.28 21.00 0.00
Pair 3 2 
weeks 
fasting 
– 6 
weeks 
fasting 
6.33 26.88 5.73 -5.59 18.25 1.10 21.00 0.28
 
Table 3-20: Pre-operative meal-related insulin response 
Following meal intake insulin levels increased to 86.3+/-75.8 at 30 minutes and 95.3+/-
75.7 at 60 minutes. Levels decreased to 63.4+/-75.4 when food reached in the caecum 
 
pre-op 
fasting 30 60 caecum 
N Valid 22 22 22 22 
Missing 0 0 0 0 
Mean 60.71 86.38 95.31 63.48 
Median 33.44 63.51 67.72 35.69 
Std. Deviation 64.47 75.85 75.70 75.48 
Range 220.24 329.30 305.08 334.62 
Minimum 15.52 8.95 15.49 7.02 
Maximum 235.76 338.25 320.57 341.64 
Percentiles 25 23.81 45.43 48.81 18.23 
50 33.44 63.51 67.72 35.69 
75 65.17 91.84 115.42 92.84 
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Figure 3-45: Box plot representing pre-operative meal-related response 
X axis = time since food intake, Y axis = Insulin levels. Following meal intake insulin 
levels increased to 86.3+/-75.8 at 30 minutes and 95.3+/-75.7 at 60 minutes. Levels 
decreased to 63.4+/-75.4 when food reached in the caecum 
      
 
Table 3-21: Post-operative meal-related insulin response 
Lower fasting levels, exaggerated post postprandial response noted after RYGB. 
Levels (fasting 41.6+/-55.8, 30 minutes 110.2+/-67.5, 72.3+/-52.7 at 60 minutes, 
38.4+/-47.8 when food in caecum) 
 
6 weeks 
fasting 30 60 caecum 
N Valid 22 22 22 22
Missing 0 0 0 0
Mean 41.67 110.24 72.36 38.45
Median 16.46 97.85 62.62 22.02
Std. Deviation 55.88 67.52 52.70 47.88
Range 182.24 254.95 219.93 197.75
Minimum 6.10 21.08 13.70 0.00
Maximum 188.34 276.03 233.63 197.75
Percentiles 25 11.68 52.45 33.76 14.94
50 16.46 97.85 62.62 22.02
75 35.00 150.32 88.48 33.87
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X axis = time since food intake, Y axis = Insulin levels. Exaggerated and early response 
of insulin after RYGB. Levels (fasting 41.6+/-55.8, 30 minutes 110.2+/-67.5, 72.3+/-
52.7 at 60 minutes, 38.4+/-47.8 when food in caecum) 
 
 
 
Table 3-22: Comparison of pre- vs. post-RYGB meal-related response 
Post-operative meal-related insulin response was significantly higher compared to pre-
operative meal-related response (all p values < than 0.05). 
 
Paired Differences 
t df 
Sig. (2-
tailed) Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 1 pre-op 
fasting – 6 
weeks 
fasting 
19.04 20.85 4.45 9.79 28.28 4.28 21.00 0.00
Pair 2 30 – 30 -23.85 44.62 9.51 -43.64 -4.07 -2.51 21.00 0.02
Pair 3 60 – 60 22.95 44.31 9.45 3.30 42.60 2.43 21.00 0.02
Pair 4 caecum - 
caecum 
25.04 36.59 7.80 8.81 41.26 3.21 21.00 0.00
Figure 3-46: Post-operative meal-related insulin response 
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2b. Change in insulin resistance following RYGB 
Insulin resistance was calculated with HOMA-IR method = fasting insulin (mIU/L) x 
fasting glucose (mmol/L) / 22.5 
 
Table 3-23: IR before and after RYGB 
Decreased IR after RYGB. IR1= fasting IR before surgery, IR2= fasting IR 2 weeks 
after surgery, IR3= fasting IR 6 weeks after surgery. Fasting values (pre-operative 
fasting 30.0, at 2 weeks post RYGB 17.5, 6 weeks post RYGB 15.8). 
 IR1 IR2 IR3 
N Valid 22 22 22
Missing 0 0 0
Mean 30.07 17.51 15.82
Median 18.95 7.42 6.76
Std. Deviation 34.95 22.53 24.78
Range 133.89 83.15 85.05
Minimum 3.35 0.85 2.54
Maximum 137.24 84.01 87.59
Percentiles 25 10.09 4.65 3.10
50 18.95 7.42 6.76
75 30.78 19.28 12.18
 
 
 
Table 3-24: Comparison of pre- vs. post-RYGB IR 
Significant improvement in IR after surgery at 2 weeks after surgery and 6 weeks after 
surgery compared with pre-op IR (p 0.03, < 0.01 respectively). 
 
Paired Differences 
t df 
Sig. (2-
tailed) Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 1 IR1 - IR2 12.56 25.53 5.44 1.24 23.87 2.31 21.00 0.03
Pair 2 IR1 - IR3 14.25 17.12 3.65 6.66 21.83 3.90 21.00 0.00
Pair 3 IR2 - IR3 1.69 18.71 3.99 -6.60 9.98 0.42 21.00 0.68
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Figure 3-47: Box plot representing fasting IR before and after RYGB 
X axis = Timing (IR1=pre operative, IR2=2 weeks, IR3= 6 weeks after RYGB). Y Axis  
= Levels. Significant improvement in IR after surgery at 2 weeks after surgery and 6  
Weeks after surgery compared with pre-op IR (p 0.03, < 0.01 respectively). 
 
 
 
3. Change in ghrelin after RYGB 
 
pre-op 
fasting 30 60 caecum 
N Valid 22 22 22 22 
Missing 0 0 0 0 
Mean 789.19 801.98 716.73 777.28 
Median 665.51 684.88 650.67 773.03 
Std. Deviation 493.09 483.24 405.96 495.51 
Range 2014.61 1639.01 1761.47 2054.10 
Minimum 308.40 289.73 189.41 96.23 
Maximum 2323.01 1928.74 1950.89 2150.33 
Percentiles 25 434.17 417.83 456.02 383.96 
50 665.51 684.88 650.67 773.03 
75 944.46 974.55 824.64 953.45 
Table 3-25: Pre-operative meal-related ghrelin response 
Pre operative Meal related Ghrelin levels (fasting 789+/-493, 30 minutes post prandial 
801+/-483, 60 minutes post prandial 716+/-405, food in caecum 777+/-495.  
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Figure 3-48: Box plot representing pre-operative meal-related ghrelin response 
X axis= Timing in relation to food, Y axis = levels. Meal related response was blunted 
before surgery (p > 0.05) 
 
 
Table 3-25: Fasting ghrelin levels before and after RYGB 
A continuous decrease in fasting gherkin levels noticed at 2 weeks and 6 weeks after 
surgery. (Levels 789 vs. 599, 532 at 2 weeks and 6 weeks respectively) 
 pre-op fasting 2 weeks fasting 6 weeks fasting 
N Valid 22 22 22 
Missing 0 0 0 
Mean 789.19 599.99 532.17 
Median 665.51 640.82 521.72 
Std. Deviation 493.09 275.52 261.12 
Range 2014.61 966.70 1271.86 
Minimum 308.40 127.17 147.64 
Maximum 2323.01 1093.88 1419.50 
Percentiles 25 434.17 347.21 339.45 
50 665.51 640.82 521.72 
75 944.46 818.45 599.55 
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Figure 3-49: Box plot representing fasting ghrelin levels before and after RYGB 
X axis = Timing in relation to food, Y axis = levels. A continuous decrease in fasting 
ghrelin levels noticed at 2 weeks and 6 weeks after surgery. (Levels 789 vs. 599, 532 at 
2 weeks and 6 weeks respectively) 
 
 
Table 3-26: Comparison of fasting ghrelin levels before and after RYGB 
Significant decrease in fasting plasma ghrelin levels after surgery at 2 weeks and 6 
weeks after surgery (p 0.05, 0.01 respectively). 
 
Paired Differences 
t df 
Sig. (2-
tailed) Mean 
Std. 
Deviation 
Std. Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 1 pre-op 
fasting – 2 
weeks 
fasting 
189.21 434.11 92.55 -3.27 381.68 2.04 21.00 0.05
Pair 2 pre-op 
fasting – 6 
weeks 
fasting 
257.02 424.71 90.55 68.72 445.33 2.84 21.00 0.01
Pair 3 2 weeks 
fasting – 6 
weeks 
fasting 
67.82 214.83 45.80 -27.44 163.07 1.48 21.00 0.15
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Table 3-27: Post-RYGB meal-related ghrelin response 
No significant change noticed on meal related response after surgery (fasting 523+/-
261, 30 minutes 518+/-277, at 60 minutes 558+/-407, food in caecum 544+/-284).  
 
6 weeks 
fasting 30 60 caecum 
N Valid 22 22 22 22
Missing 0 0 0 0
Mean 532.17 518.77 558.40 544.65
Median 521.72 466.13 431.66 485.45
Std. Deviation 261.12 277.37 407.35 284.22
Range 1271.86 1186.64 1905.67 1313.25
Minimum 147.64 138.76 147.64 244.15
Maximum 1419.50 1325.40 2053.31 1557.40
Percentiles 25 339.45 315.05 313.94 328.46
50 521.72 466.13 431.66 485.45
75 599.55 710.08 637.91 678.17
 
   
 
 
 
Figure 3-50: Post-RYGB meal-related ghrelin response 
X axis = Timing in relation to food, Y axis = levels. Meal-related ghrelin response 
remained blunted after the surgery (p > 0.05) 
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Table 3-28: Comparison of pre- and post-RYGB meal-related response 
Significantly lower levels of ghrelin at fasting, 30 minutes after meal intake and when 
food reached into the caecum were observed after RYGB. 
 
Paired Differences 
t df 
Sig. (2-
tailed) Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 1 pre-op 
fasting 
– 6 
weeks 
fasting 
257.02 424.71 90.55 68.72 445.33 2.84 21.00 0.01
Pair 2 30 – 30 283.21 401.80 85.66 105.06 461.35 3.31 21.00 0.00
Pair 3 60 – 60 158.33 431.22 91.94 -32.86 349.52 1.72 21.00 0.10
Pair 4 caecum 
– 
caecum 
232.63 400.42 85.37 55.10 410.17 2.73 21.00 0.01
 
 
 
4. Change in GLP-1 following RYGB 
Table 3-29: Pre-operative meal- related GLP-1 response 
Highest levels of GLP were noticed at 60 minutes and decreased when food reached in 
the caecum. 
 pre-op fasting 30 60 caecum 
N Valid 22 22 22 22
Missing 0 0 0 0
Mean 4.96 4.56 5.74 5.05
Median 2.95 3.25 3.10 3.24
Std. Deviation 6.50 4.53 9.65 5.60
Range 29.77 19.62 46.24 25.32
Minimum 1.21 1.24 1.15 1.71
Maximum 30.98 20.86 47.39 27.03
Percentiles 25 1.75 2.54 2.40 2.57
50 2.95 3.25 3.10 3.24
75 5.52 4.14 4.67 5.53
 
 176
  
Figure 3-51: Box plot representing ppre-operative meal-related GLP-1 response 
X axis= Timing in relation to food, Y axis = levels. Highest levels of GLP were noticed 
at 60 minutes (5.7+/-9.6) and decreased when food reached in the caecum. 
 
 
 
Table 3-30: Fasting GLP-1 levels before and after RYGB 
Fating GLP-1 levels continued to decrease following RYGB (mean values 4.96+/- 6.50 
vs. 3.29+/-3.02, 3.03+/-4.76). 
 pre-op fasting 2 weeks fasting 6 weeks fasting 
N Valid 22 22 22
Missing 0 0 0
Mean 4.96 3.29 3.03
Median 2.95 2.52 1.94
Std. Deviation 6.50 3.02 4.76
Range 29.77 14.58 23.34
Minimum 1.21 0.82 0.42
Maximum 30.98 15.40 23.76
Percentiles 25 1.75 1.64 0.94
50 2.95 2.52 1.94
75 5.52 4.24 3.19
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Table 3-31: Comparison of fasting GLP-1 levels before and after RYGB 
Significantly lower GLP levels at 6 weeks when compared with pre-operative fasting 
levels (p = 0.01). 
 
Paired Differences 
t df 
Sig. (2-
tailed) Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 1 pre-op 
fasting – 2 
weeks 
fasting 
1.67 4.36 0.93 -0.26 3.60 1.8
0 
21.00 0.09
Pair 2 pre-op 
fasting – 6 
weeks 
fasting 
1.92 3.14 0.67 0.53 3.32 2.8
7 
21.00 0.01
Pair 3 2 weeks 
fasting – 6 
weeks 
fasting 
0.26 2.21 0.47 -0.72 1.23 0.5
4 
21.00 0.59
 
 
Figure 3-52: Box plot representing fasting GLP-1 levels before and after RYGB 
X axis= Timing in relation to food, Y axis = levels. Fating GLP-1 levels continued to 
decrease following RYGB (mean values 4.96+/- 6.50 vs. 3.29+/-3.02, 3.03+/-4.76). 
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Table 3-32: Meal-related GLP-1 response after RYGB 
Highest levels of GLP-1 noticed at 30 minutes after surgery (3.03+/-4.76, 13.53+/-7.90, 
10.41+/-7.56, and 6.11 +/- 10.52). 
 
6 weeks 
fasting 30  60 caecum 
N Valid 22 22 22 22
Missing 0 0 0 0
Mean 3.03 13.53 10.41 6.11
Median 1.94 10.80 7.78 4.04
Std. Deviation 4.76 7.90 7.56 10.52
Range 23.34 29.40 26.67 51.23
Minimum 0.42 1.54 1.57 1.19
Maximum 23.76 30.95 28.25 52.41
Percentiles 25 0.94 8.09 4.17 2.40
50 1.94 10.80 7.78 4.04
75 3.19 19.11 15.64 6.05
 
 
 
Figure 3-53: Box plot representing post-RYGB meal-related GLP-1 levels 
X axis= Timing in relation to food, Y axis = levels. An early and exaggerated post 
prandial response after RYGB. Highest levels of GLP-1 noticed at 30 minutes after 
surgery (3.03+/-4.76, 13.53+/-7.90, 10.41+/-7.56, and 6.11 +/- 10.52). 
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Table 3-33: Comparison of pre- and post-RYGB meal-related GLP-1 levels. 
Post-operative meal-related response was significantly early and exaggerated after 
RYGB (P values fasting 0.01, 30 minutes after meal intake <0.01, 60 minutes after meal 
intake 0.01).  
 
Paired Differences 
t df 
Sig. (2-
tailed) Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 1 pre-op 
fasting – 
6 weeks 
fasting 
1.92 3.14 0.67 0.53 3.32 2.87 21.00 0.01
Pair 2 30 – 30  -8.98 6.31 1.35 -11.78 -6.18 -6.67 21.00 0.00
Pair 3 60 – 60 -4.67 8.22 1.75 -8.31 -1.02 -2.66 21.00 0.01
Pair 4 caecum 
- 
caecum 
-1.06 5.83 1.24 -3.65 1.52 -0.85 21.00 0.40
 
 
 
3.6 Discussion 
3.6.1 Implications of change in GI motility on resolution of DM 
 
It is suggested that GI motility and GE are closely related to obesity. This is based upon 
the fact that GI motility and GE deliver the nutrients into the small bowel. Altered GI 
motility in obesity is also speculated; however, in our systematic review of literature 
(Chapter 1, section 1.3) we have demonstrated mixed results in favour of altered 
(increase/decrease) or normal GE in obesity. A well-designed, controlled study is 
required to clarify this issue.  
In our study the gastric half-emptying (T50) in 22 morbidly obese type 2 diabetic 
patients before surgery was 94 minutes. This is comparable with our departmental 
reference value for T50 = 99 minutes (based upon a study conducted upon 27 healthy 
normal weight, non-diabetic subjects).147  
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It is, however, important to note the post-operative (post-RYGB) findings of our study. 
A small-size gastric pouch was created during the surgery (size 50 ml). Although this 
restricted the food to be accommodated in the pouch, the pouch filled and emptied 
quickly (T50 = 21 minutes). It is also important to note that although the stoma of the 
pouch size was kept very small (1 cm), this did not entirely restrict the food from 
emptying into the jejunum. The possible explanations of quick pouch emptying are as 
follows:  
1. Loss of pyloric control may result in pouch emptying under the influence of 
gravity. 
2. The cylindrical narrow passage of the pouch may exhibit more tension on pouch 
wall compared to the wide pouch (like the original stomach), resulting in a 
quicker contraction to empty. 
 
IT in obesity was not investigated in the past. Our study is a rare one of its kind to focus 
on IT in obesity and the first one to demonstrate the change in IT following RYGB. 
This is an important part of this study as we wanted to assess the hormonal response 
(ghrelin, insulin and GLP-1) along with the GE and IT. IT was normal in obesity (IT 
time 270 minutes). IT time was, however, quicker following RYGB (IT time 212 
minutes); however, it has previously been demonstrated that there could be a very wide 
range of IT time and only extremes of the slow transit time should be considered 
significant.160 The possible explanations of slightly fast post-operative IT may be as 
follows: 
1. Bypassed stomach and loss of pyloric control resulted in early food entering into 
the intestine. 
2. A small part of the small intestine was bypassed, which may have contributed to 
a relatively short intestinal segment for food to reach into the caecum. 
3. It may have been influenced by enteric hormones influencing GI transit. 
 
Early entry of food into the intestine may have several implications in the regulation of 
metabolism and the secretion of GI hormones. On the one hand, this may have resulted 
in early excitation of some of the foregut hormones; however, on the other hand, RYGB 
results in bypassing the metabolically active duodenum, and secretions from the 
pancreas, liver and bile. This may result in an overall decreased CCK, GIP and other 
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foregut hormones and, on the other hand, may have an excitatory effect on intestinal 
mucosa to secrete hormones necessary to absorb the nutrients.  
 
The vagus nerve is the main afferent nerve supply from the GI tract to the brain; 
however, the role of this nerve in processing the nutritional information from the GI 
tract mucosa to the brain is not understood. It is therefore assumed that the vagus nerve 
has a very small role in processing this information and hormones like GIP and CCK 
are considered as the most potent hormones to detect glucose, lipids in the intestine and 
the regulation of nutritional capacity and absorption in the proximal small intestine. 
Bypassing the stomach and the metabolically active proximal small intestine, along with 
quick eating of food into more distal parts of the small intestine, will result in less 
exposure of food to the hormones. Glucose is, however, sensed by GIP-secreting cells 
and a quick response is generated in the form of exaggerated insulin release. GIP 
function is not effected by vagotomy and vagus stimulation;144 therefore, glucose 
haemostatic function remains preserved following RYGB. It is possible that this 
function is enhanced because sudden glucose entry into the small intestine may result in 
an exaggerated proximal small intestinal hormone response compared to a pulsatile 
release after a controlled GE before RYGB.  
 
3.6.2 Implications of change in gut hormones 
 
The food is detected in the stomach by the muscle wall by stretch receptors and these 
signals are transmitted to the brain (the medulla, hypothalamus and cerebral cortex). 
These afferent fibres also innervate the mucosa of the stomach and the food in the 
stomach stimulates the gastric hormones like leptin and ghrelin. Ghrelin is considered as 
an appetite regulatory hormone, and a previous study by Le Roux et al161 demonstrated 
that, in patients with post-vagotomy, the food intake was not stimulated by ghrelin. 
Food behaviour is an important factor in obesity and it plays an important role in 
obesity treatment. It is, however, interesting to note that the stomach can only detect the 
volume of the food, and the calorimetric analysis of the food is performed by the small 
intestine. With the findings that ghrelin possibly plays an important role in food and 
appetite regulation along with the twist that the stomach only regulates the volumetric 
aspects of food intake, bariatric surgery (RYGB) may show some interesting findings 
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when the stomach is bypassed along with, presumably, ghrelin-producing cells. Our 
study looked into these aspects as we investigated the change in fasting ghrelin levels 
along with the change in the meal-related response following RYGB. 
 
GLP-1 was also the focus of our attention as it is considered as an incretin hormone. In 
addition, its role in ileal brake activity and its release is considered to be mediated by 
not only the direct contact of food with the L cells but also by neural reflux in the GI 
tract.162, 163 The insulinotropic effect of GLP-1 has been studied in the past;22, 159, 164, 165 
however, there is very little data in support of its secretion in conjunction with GI 
motility. Similarly, ileal brake activity has not been studied completely. We looked into 
these aspects as we investigated the change in fasting GLP-1 levels along with the 
change in meal-related response in GLP-1 levels following RYGB. Ileal brake activity 
was studied indirectly as the last plasma samples for GLP-1 were taken when food was 
seen in the iliocaecal region directly observed by GI scintigraphy. 
 
Results of our study were, however, very interesting as we also noticed a constant 
decline in ghrelin levels of 789.19 (fasting pre-op), 599.99 (fasting at 2 weeks after 
RYGB) and 532.17 (fasting at 6 weeks after RYGB) consistent with some previous 
studies;98, 166, 167 however, the expected higher fasting levels in obesity (presumed 
satiety hormone) were not seen in our study as described by Cummings et al in their 
papers.13, 142 The decrease in fasting ghrelin levels were statistically significant (p value 
0.05, 0.01); however, these finding were contrary to the fact that most (90% or more) of 
the stomach was bypassed and the decline in ghrelin levels only reached a fraction of 
the expected (90% or more) decline. The possible explanations of these findings are that 
ghrelin may not be produced solely by the stomach and other parts of the GI tract or 
body may continue to produce ghrelin. Other possible reasons include hyperstimulation 
of the gastric pouch and/or bypassed stomach, which may still produce ghrelin as it may 
not be totally denervated (vagotmised) by RYGB. More work is required to prove or 
reject these hypotheses. 
 
Pre-operative meal-related response of 789.19 (fasting), 801.98 (30 minutes following 
food intake), 716.73 (60 minutes following food intake) and 777.28 (food seen in the 
iliocaecal region) was blunted before surgery as none of these changes reaches a 
statistical significance. This finding is also contrary to the previous papers suggesting 
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higher fasting plasma ghrelin levels and proposed decrease levels after surgery 
suggesting the role of this hormone in satiety.7, 13, 142, 168 In addition, we did not observe 
the higher expected fasting levels as we presumed that ghrelin levels would be high in a 
fasting state to demonstrate its role of being a satiety hormone. This may demonstrate 
that ghrelin is not a sole satiety signal but an important component of satiety 
mechanism. On the other hand, the lack of significant change following food intake 
could not be explained. Following surgery and a significant weight loss, improved IR 
and diabetic status were observed. At 6 weeks follow-up, meal-related ghrelin levels 
were as follows: 532.17 (fasting), 518.77 (30 minutes following food intake), 558.40 
(60 minutes following food intake), 544.65 (food in the iliocaecal region). These 
findings were also consistent with the pre-operative findings, as the expected higher 
fasting levels were not observed and a blunted meal-related response was observed. 
This justifies more research in this field before including or excluding the role of 
ghrelin in obesity and the management of obesity. There was, however, a limitation of 
our research as we focused on the meal-related response of ghrelin and exogenous 
administration was not intended.  
 
GLP-1 response, however, is very closely related to insulin, elaborating the incretin 
effect as reported in the previous studies.9, 19, 26, 142, 159, 164, 169 There was a continuous 
decline in fasting GLP-1 levels noticed following RYGB as mean values decreased 
from 4.96 (pre-operative fasting levels) to 3.29 (2 weeks after RYGB fasting levels) and 
3.03 (6 weeks after RYGB fasting levels). These changes were statistically significant 
(p < 0.05). Meal-related response before RYGB revealed the highest concentration 
when most of the food was in the small intestine (t 60 minutes after food intake). This 
response was, however, exaggerated and an earlier response (peak values) was observed 
after RYGB. This was in conjunction with early food entry into the small intestine 
observed with GI scintigraphy (GE and IT) as the gastric pouch emptied quickly. This is 
possibly mediated by the gut-brain-peripheral axis and considered to act as a paracrine 
hormone as short half-life may not make it possible to reach the beta cell receptors in 
the pancreas to secrete insulin. We noticed a very close relation/response of GLP-1 to 
insulin levels (before and after RYGB) as others have also reported the similar 
response; however, the use of GLP-1/GLP-1 analogue as a treatment option remains a 
question to be answered. This is because of its short half-life, easy degradability, 
availability in only injectable form and the dilemma of who will respond to this 
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treatment. NICE has therefore recommended to use GLP-1 analogues only as a second-
line treatment option and to closely monitor HbA1c. If patients do not respond after 6 
months, it is advised to withdraw this treatment. In a recent review by Burcelin et al,169 
the current evidence of GLP-1 in its therapeutic strategies was evaluated. It was 
concluded that more pharmacological evidence is required to validate GLP-1 as 
cardioprotective, beta cell-regenerative and anti-apoptotic functions.169 
3.6.3 Role of GLP-1 as intestinal brake hormone 
 
The inhibitory effect of food in the terminal ileum resulting in modulation of GE by 
pyloric control, gastric acid and other enteric peptides is called ileal brake. It is believed 
that GLP-1 acts as a potent mediator to enhance the ileal brake activity, which may play 
an important role in weight loss following bariatric surgery.170 There is, however, no 
study to prove this theory that GLP-1 potentiates this important enteric reflex.170 This is, 
in fact, based upon the studies showing the endocrine suppression by food in the 
ileum.19, 171 It is also demonstrated that GLP-1 can completely eliminate the acid 
production in the stomach by vagus nerve stimulation.19, 172 Schirra et al used GLP-1 
receptor antagonist exendin and demonstrated that it markedly stimulated the pyloric 
contractility, suggesting that GLP-1 has an inhibitory effect on antroduodenal motility 
in addition to its insulinotropic effect.32  
 
In our study, the last blood samples were taken when the food was seen in the terminal 
ileum/ileocaecal region. We wanted to assess the change in GLP-1 levels in conjunction 
with GI motility and food in iliocaecal region. Similarly we also wanted to assess the 
change in GLP-1 levels in conjunction to food in the iliocaecal region following RYGB. 
A continuous decline in GLP-1 was observed when the food was seen in the terminal 
ileum/ileocaecal region. This was not associated with any change in GE or intestinal 
motility before RYGB (Figure 3-30,Figure 3-31, Figure 3-36,Table 3-6) and post-
operative early and exaggerated GLP-1 was not correlated to pouch emptying or IT 
(Figure 3-32,Figure 3-32Figure 3-36),(Table 3-8, Table 3-51, Figure 3-53)  
 
3.7 Conclusions 
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1. GE may be normal in obesity, contrary to previous data suggesting impaired 
GE in obesity. 
2. Post-operatively, the gastric pouch empties quickly, resulting in an early 
nutrient supply to the gut which potentiates the important incretin hormone 
GLP-1. 
3. Although lower levels of ghrelin were observed following RYGB, they could 
not be causally related to the change in their production as opposed to gastric 
size and change in diabetic status. 
4. This study has established the average IT time in morbid obesity (270 +/- 39 
minutes) and that the IT time does not significantly change subject to the short 
segment of the small intestine bypassed during RYGB (post-RYGB IT transit 
time is 212 +/- 44 minutes). 
5. Early and uncontrolled (lack of pyloric control) food delivery to the intestine 
results in an exaggerated GLP-1 response which potentiates the insulin-
contributing resolution of diabetes following RYGB.  
 
Limitations: It is, however, important to note the limitation of this study as we did not 
intend to use GLP-1/analogue or ghrelin analogue to see the pharmacological effect of 
these hormones on GI motility and change in diabetic status. In addition, we did not 
focus on the metabolic role of liver, muscles and fat (change in protein, fat and glucose 
metabolism); however, we feel that it is important to assess these functions at cellular 
levels as well as at hormonal levels to establish the improvement in diabetic status 
following RYGB. Furthermore, the important part of food restriction and the exclusion 
of the metabolically active duodenum (along with a change in other upper GI hormones) 
play an important role in the improvement of diabetic status. The impact of these 
changes on the hypothalamus and other food and satiety centres in the brain also needs 
to be explored. 
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4 Gastroparesis and modulation of gastric function 
 
Excerpts of this chapter have been modified and published as:  
Ullah S, Arsalai-Zadeh R, Sedman P, Avery G,  MacFie J Temporary gastric 
neuromodulation for intractable nausea and vomiting. Ann R Coll Surg Engl. 
2011 Nov; 93(8): 624-8. PMID: 22041240. 
 
 
Excerpts of this chapter have been modified and presented in ASGBI, ESSR 
Ullah S, Arsalai-Zadeh, P. Sedman, G. Avery, J. MacFie. Temporary gastric 
neuromodulation for intractable nausea and vomiting. British Journal of Surgery 
2011; 98 (S2):46 (ASGBI). 
Akbar MJ, Ullah S, Mehmood S, MacFie J. Gastric neuromodulation for drug 
refractory gastroparesis, and persistent nausea and vomiting. (ESSR).  
 
 
4.1 Definition 
 
Gastroparesis is a chronic motility disorder of the stomach, defined by delayed GE of a 
solid meal in the absence of mechanical obstruction.  
 
Although the epidemiology of the disorder is not well known, the majority of patients 
presenting with its symptoms are young and middle-aged women.43 Gastroparesis in 
these patients interferes with oral drug absorption and impairs blood glucose levels, 
leading to further complications as a result of problems with ineffective blood sugar 
control. 
 
Gastroparesis is a debilitating condition, which can reduce a functional individual to an 
existence tied to hospitals and emergency rooms. Gastroparetic patients have no good 
long-terms solutions and death can result from interventions and life-threatening 
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complications, such as electrolyte imbalance, dehydration and malnutrition. Soykan et 
al, in their analysis of 146 patients seen over 6 years in 2 centres,173,2 indicate that 10% 
of patients died during the follow-up period. They describe gastroparesis as “far from 
being a benign disorder”. 
4.2 Background and disease prevalence 
 
The true prevalence of gastroparesis is not known; however, it has been estimated that 
up to 4% of the population experiences symptomatic manifestations of this condition.174 
Prevalence of gastroparesis is increased in diabetic patients and may occur in 30–50% 
of patients with diabetes mellitus (DM).175,176 
 
The most frequently reported symptoms of gastroparesis include nausea, vomiting, early 
satiety and postprandial fullness. Abdominal discomfort and pain are also reported. 
Weight loss, malnutrition and dehydration may be prominent in severe cases. 
 
In addition to having a highly negative impact on a patient’s quality of life, 
gastroparesis is associated with significant costs both to patients and to healthcare 
services. In addition to the cost of drug therapy, patients with severe symptoms face 
repeated hospitalisations and often rely on expensive supplemental feeding.177,178,179,180, 
181,182  
 
In 2002 Aamir et al reviewed medical charts of 236 patients with symptomatic 
gastroparesis and found that 24.8% of the patients were hospitalised at least once for 
symptoms of gastroparesis and 36.8% of those patients required 4 more hospitalisations. 
The same study reported that 18% of the studied patients stopped working because of 
their symptoms. 
 
Hospitalisation was also highlighted in several clinical trials of Enterra Therapy. Forster 
et al178 reported that gastroparesis patients involved in their study were hospitalised an 
average of 6 times in the year before Enterra Therapy treatment. The patients involved 
in McCallum et al’s study were hospitalised for a mean of 31 days (range 0–200 days) 
in the year prior to Enterra Therapy treatment. 
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In addition to hospitalisation, many gastroparesis patients required regular nutritional 
report. The main categories of support are Total Parenteral Nutrition (TPN) or 
Parenteral Nutrition (PN). A few studies examined the cost of nutritional support in the 
UK and the USA from the health service perspective.43 Their results clearly demonstrate 
that nutritional support (even if delivered in a home setting) required very 
significant expenditure. The alternative hospital treatment (TPN) is even more costly. 
 
Finally, severe gastroparesis has a negative impact on the patient’s ability to 
perform regular activities, including work. Revicki et al, in their 2003 study,183 
reported statistically significant positive correlation between patient-reported symptom 
severity (measured by the Gastroparesis Cardinal Symptom Index) and the number of 
disability days and number of days with restricted activity. The lost productivity is an 
additional cost borne both by the patient (lost earnings) and society. Furthermore, 
the majority of patients are young women who, in addition to professional work, would 
likely be responsible for caring for their children/family and who are unable to do so 
due to the disabling symptoms. 
 
There is, therefore, a clear need for cost-effective alternative treatment for these 
severely sick patients who are not responding to current therapies and who could only 
be managed with nutritional support (which is expensive and carries a high risk of 
infection) or irreversible surgery. 
 
Gastric electrical stimulation is a safe, reversible and cost-effective treatment alternative 
for patients suffering from chronic, drug-refractory nausea and vomiting secondary to 
gastroparesis. It has been shown to significantly: 
• Reduce nausea and vomiting and improve quality of life.184,178,179,182, 185,186,187, 
188,189,90 
• Improve glucose control in diabetic patients.189,185,179 
• Reduce the use of nutritional support and health care costs needed for 
hospitalisations.184,178,179,180,182,186 
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4.3 Types of gastroparesis 
 
Gastroparesis can result from several causes. The three most common aetiologies are: 
DM, gastric surgery involving vagotomy and idiopathic (no identified cause).173 
 
Diabetic gastroparesis: Gasatroparesis in diabetic patients has been well documented. 
Most often it affects patients with long-term diabetes. This may result in poor glycaemic 
control, persistent nausea and vomiting, which may lead to poor overall nutritional 
status and worsening of DM.185 
 
Post-surgical gastroparesis:  
Post-surgical delayed GE is another problem which clinicians face in day-to-day 
practice. Treatment is based on medical therapy including prokinetics and antiemetics. 
Some of them require long-term enteral or total parenteral feeding. Drug-refractory 
post-surgical gastroparesis can be treated with gastric electric stimulation 
(GES).190,191,192 
 
Post-surgical gastroparesis has been treated successfully in some centres in the world. In 
one study,191 six post-RYGB patients developed gastroparesis. They were treated 
successfully with GES and it resulted in improved symptoms of nausea and vomiting. 
Furthermore, improved GE was also recorded.191 
 
In another study,190 gastric electric stimulators were implanted in patients with 
gastroparesis after gastric surgery for various reasons. This study revealed improved 
nausea, vomiting, quality of life and GE after a long-term follow-up. 
 
Post-esophagectomy delayed GE was treated with GES in two patients.192 Improved 
symptoms (including nausea, vomiting and total symptom score) were recorded after 
GES. 
 
In such drug-refractory post-surgical gastroparesis, the only other option is completion 
gastrectomy, which carries significant morbidity and mortality,190 and it is suggested 
that GES should be considered in such patients.190, 192 
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Idiopathic gastroparesis: Idiopathic gastroparesis is diagnosed in patients with no cause 
of gastroparesis identified on extensive investigations.193, 194 The role of gastric 
neuromodulation in such patients has been described in published literature.43, 189, 195 
 
4.4 Nutritional and economic implications of gastroparesis 
 
In up to 40% of the patients with gastroparesis, however, drugs are ineffective or 
intolerable.173,184 Treatment options for these drug-refractory patients include nutritional 
support (feeding tube and total parenteral nutrition (TPN), which poses a high financial 
burden), or gastrectomy as final resort. Soykan et al173 showed that 22% of their patients 
required short- or long-term parenteral feeding via laparoscopic placement of a 
jejunostomy tube for nutritional support at some point during the study. The systematic 
review of surgical therapy for gastroparesis from Jones et al196 shows that in some 
reported publications, 55% of patients undergoing gastrectomy  needed admissions and 
subsequent surgeries. They also report a paper showing 23 complications requiring 
hospitalisation among 14 of 26 diabetic patients treated with surgical jejunostomy. The 
main categories are support (TPN and delivery of nutrients directly to the bloodstream). 
A few studies examined the cost of nutritional support in the UK and the USA from the 
health service perspective.43 Their results clearly demonstrate that nutritional support 
(even if delivered in a home setting) required very significant expenditure. The 
alternative hospital treatment (TPN) is even more costly. 
4.5 Current treatment options  
4.5.1 Medical 
There is currently no cure for gasteoparesis. The primary goals of existing treatments 
are symptom relief, and restoration and maintenance of adequate nutrition. Current 
treatment options include dietary modifications and the use of drugs (prokinetics and 
antiemetic). In up to 40% of the patients, however, drugs are ineffective or 
intolerable.173, 184 
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4.5.2 Nutritional  
Treatment options for these drug-refractory patients include nutritional support (feeding 
tube and total parenteral nutrition (TPN), which poses a high financial burden), or 
gastrectomy as final resort. Soykan et al173 showed that 22% of their patients required 
short- or long-term parenteral feeding via laparoscopic placement of a jejunostomy tube 
for nutritional support at some point during the study. The systematic review of surgical 
therapy for gastroparesis from Jones et al196 shows that in some reported publications, 
55% of patients undergoing gastrectomy needed admissions and subsequent surgeries. 
They also report a paper showing 23 complications requiring hospitalisation among 14 
of 26 diabetic patients treated with surgical jejunostomy. 
4.5.3 Gastric neuromodulation 
GES is achieved by delivering low-energy, high-frequency electrical stimulation (about 
4 times that of the stomach basal rate) to the lower part of the stomach via an 
implantable system. Although the exact mechanism of the action is unknown, the 
possible explanation for efficacy of GES is the following:197 
• Increase in GE. 
• Enhancement of fundic relaxation (accommodation). 
• Decrease in gastric sensitivity. 
• Enhancement of postprandial gastric slow-wave amplitude and velocity. 
• Activation of afferent sensory pathways to central mechanisms for 
nausea/vomiting control. 
• Alteration of cholinergic/sympathetic pathways. 
 
The first report of cholinergic gastric pacing (high-energy, low-frequency stimulation) 
was published in the 1960s. GES with Enterra Therapy has been available in Europe 
since 2002. 
 
Indication: GES is indicated for patients with severe symptoms who do not respond to 
conventional therapy for gastroparesis. It has been proven to be both safe and effective 
in long-term studies.158, 186, 188, 190 
 
Procedure: The Enterra GES system (the only such commercially available product) 
consists of implantable components (two intramuscular electrodes and a battery-
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powered neurostimulator, called an IPG or (Implantable Pulse Generator) and a non-
implantable physician programmer (see pictures below showing an IPG and electrode). 
 
 
Figure 4-1: IPG and electrode 
Implantable IPG, elcrode wire (one end to be attached to IPG and other end in 
submucosa). 
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The system can be implanted using by way of laparotomy or laparoscopy – the decision 
depends on the physician’s choice and the patient’s medical history and status. The 
implantation is performed under general anaesthesia and should take around one hour. 
The two electrodes are fixed to the muscle layer of the great curvature of the gastric 
antrum approximately 10 cm above the pylorus and 1 cm away from each other. They 
are connected to the IPG, which is placed in a subcutaneous pocket in the abdominal 
wall (typically the upper right quadrant). Following the implantation and patient’s 
recovery, the system is switched on. The rate and amplitude of the current can be non-
invasively adjusted to optimise treatment for each patient. 
 
Clinical benefits: Several clinical studies have demonstrated that GES therapy is a safe 
and effective treatment for chronic refractory nausea and vomiting associated with 
gastroparesis. 
 
• The therapy significantly improves symptoms of gastroparesis (chronic 
nausea and vomiting) and patients’ quality of life (QOL) and these benefits are 
sustained in the long term (up to 10 years).178-180, 182, 184, 187 
•  GES therapy reduces the use of drugs (prokinetices and antiemetic) and the 
need for hospitalisations.178, 180-182 
• GES therapy is superior to drugs in improving GI symptoms, healthcare 
resources and long-term healthcare benefits.182 
• GES therapy produces significant improvement in patients’ nutritional 
status (increased body weight and BMI) and reduces the need for nutritional support. 
This benefit is also sustained in the long term (up to 5 years).178, 179, 185, 186, 198 
 
Long-term GES therapy is a safe treatment option with a low rate of complications. This 
is particularly impressive given that patients suffering from severe gastroparesis are at 
high risk of infection due to malnutrition, skin contamination from enteral tube and 
ostomies, and the systemic effect of DM. 
 
GES with Enterra therapy is completely reversible – if the device is unavoidable, it can 
be safely explanted. 
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Symptom relief: Reported symptom improvement following GES therapy (reduction in 
nausea, vomiting or total symptom score) is greater than 50% in almost 80% of 
patients.184,178, 179, 186, 187, 189 In some studies, the improvement was as high as 90%.184 
 
It has been reported that GES therapy could be an effective therapy for treating chronic 
severe vomiting and nausea whether GE is delayed or not as there seems to be no 
correlation between symptom improvement and improved GE.180, 184-187  
 
Reduction in hospitalisation: In a study of 37 patients, Lin et al181 showed that 
hospitalisation days decreased from 31 days to 14 days at one year post-implantation 
with 29% of patients requiring no admission, and further decreased to 6 days at 3 years 
with 69% of patients requiring no admission. The major reasons for hospitalisation prior 
to the implant surgery were complications of gastroparesis. After surgery for GES 
therapy, the admissions were explained by complications of diabetes (poor glucose 
control, ketoacidosis and infection), some recurrence of nausea and vomiting, feeding 
tube complications or infection or injury at the pulse generator site. 
 
In a study of 18 patients (9 patients on drug therapy and 9 patients on GES therapy),  
Cutts et al showed that GES did significantly reduce hospital days, with a decrease from 
a baseline means of 36.4 to 2.76 days per year at the end of 36 months 182 
 
In a study of 16 patients, McCallum et al90 showed that hospitalisation for gastroparesis 
symptoms decreased from 31 for the year before receiving GES therapy to 6 during the 
first year of GES. 8 patients (50%) required no hospital admissions. 
 
In a study of 55 patients, Forster et al178, 179 showed that days spent on hospital 
admissions were significantly decreased. For the year prior to placement of the GES, the 
average for days spent hospitalised was 57 and this fell to 17 the next year. This 
reduction alone could explain much of the patient’s improvement in their QOL. 
 
Reduction in nutritional support and weight gain: Lin et al180, 181 showed that the need 
for nutritional support decreased from 15 patients (out of 37) at the baseline to 8 
patients at one year after implant and to 5 patients at 3 years after implant. Moreover, no 
patient was receiving TNP after receiving GES. Compared to the baseline, the median 
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body weight significantly increased at 12 months and was maintained beyond 3 years of 
GES. 
 
McCallum et al 90 showed that at implantation, 7 out of 16 patients required nutritional 
support in the form of a feeding jejunostomy tube but that of these 7 patients, 4 were 
able to discontinue the jejunal feeding at 2, 4, 6  and 11 months after GES, and 3 still 
required supplemental feeding at 12 months. They also showed that average body 
weight increased by more than 3 kg at 6 months and continued at 12 months. 
 
Forster et al 178, 179 showed that BMI and body weight increased significantly. In terms 
of nutritional parameters, the patients’ average body weight increased by almost a 
kilogram and the BMI by 0.4 units. The majority of patients had their jejunal feeding 
tubes removed by one year and no one was receiving TPN. Of the 25 patients who had a 
jejunal feeding tube (1 had a gastrojejunostomy) after placement of the GES, only 8 
(32%) required this feeding approach at 12 months.  
 
Reduction in the use of drugs: Lin et al185,180 showed that the need for medication 
decreased. 29 patients (out of 35) were at least one prokinetic at baseline and 14 of these 
29 patients were off prokinetic after 3 years of GES. Similarly, 25 of these 35 patients 
requiring at least one antiemetic (10 patients on two antiemetic and two on three) at 
baseline decreased to 19 (one on three antiemetics). 
 
Current practice: Is the technology currently being used? 
The technology has been used both in the NHS and private hospitals and currently the 
following UK centres are offering this therapy: Broomfield Hospital, Broomfield; 
Chelmsford/Royal Free Hospital, London; Aberdeen Royal Infirmary, Aberdeen; 
Glasgow Royal Infirmary, Glasgow; BMI Ross Hall Hospital Glasgow, Glasgow; and 
Cork University Hospital, Wilton. 
 
GES is not a national priority. However, improved glucose control in patients with 
diabetic gastroparesis (one of the clinical benefits of the GES therapy) is a key priority 
of many diabetes programmes, such as the Diabetes National Service Framework. 
Moreover, reduction in healthcare expenditure by reducing patients’ need for 
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hospitalisation, nutritional support and drug use is a priority for all European healthcare 
systems. 
 
NICE Guidelines: NICE issued the Interventional Procedure Guidance (IPG103) in 
December 2004. It stated the following: 
1 – “Current evidence on the safety and efficacy of gastroelectrical stimulation for 
gastroparesis does not appear adequate to support the use of this procedure without 
special arrangement for consent and for audit or research”. 
 
There have been many publications since the NICE guidance issue of 2004. Long-term 
safety and efficacy of Enterra therapy has been reported in several publications.182-184, 
188, 190 At the time of the NICE guidance publication, only one major publication was 
available.186 
 
1. “The procedure should only be performed in specialist gastroenterology unit with 
expertise in gastrointestinal motility disorder”. 
2. “This therapy is indeed only performed in specialized centres”. 
3 “Current evidence on efficacy of the procedure relates mainly to relief from nausea 
and vomiting and that there was little evidence that the procedure improves gastric 
emptying”. 
 
GES therapy is indeed indicated for the relief of the symptoms of gastroparesis (mainly 
nausea and vomiting) and literature did demonstrate that symptom improvement does 
occur even if GE remains delayed.178, 179, 184, 185, 187 There is no correlation between 
improved GE and symptom improvement. Symptom improvement is what drives 
improved quality of life in these patients and is what reduces healthcare costs. 
 
A recent publication stated that Enterra therapy could be an effective treatment for the 
debilitating symptoms of chronic severe nausea and vomiting whether GE is delayed or 
not and even advocates the use of this therapy for non-gastroparetic patients with these 
debilitating symptoms.197 
 
Finally, the significant benefit to diabetic patients has already been discussed previously 
in this document (improvement in symptoms and better glucose control,179, 182, 185, 187 
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and the possibility to even undergo transplant surgery195, 199). In their recent publication, 
Anand et al188 showed that the survival rate was lower for diabetic patients not 
implanted with a GES device than the survival rate of diabetic patients implanted with a 
GES device.  
 
GES therapy is the only available treatment to patients suffering from chronic nausea 
and vomiting (secondary to gastroparesis) for whom conservative therapy has failed and 
who do not want to undergo the irreversible gastrectomy. Given that gastrectomy is 
associated with very high morbidity and mortality, an increasing number of specialists 
agree that it should no longer be considered as a viable treatment option. Therefore, 
GES therapy ranks high as a treatment option for this debilitating and expensive 
condition. 
 
4.6 Setting up new service and approvals 
 
The provision of the GES service was not available in Castle Hill Hospital, Cottingham. 
Therefore the study proposal was prepared on the basis of background studies and 
published data as explained in the earlier parts of this chapter. 
 
The proposal was submitted to a new appliances committee, trust finance committee, 
and medical director. It was approved based on principles that the funding will be 
applied to a PCT on exceptional treatment panel circumstances and procedure will be 
conducted in patients subject to the availability of funds. 
 
Proposal for consideration: We would propose to use GES therapy in the treatment of 
patients with chronic intractable nausea and vomiting secondary to gastroparesis. GES 
would be offered to patients who failed or could not tolerate pharmacologic therapy 
before the irreversible surgery (gastrectomy). Moreover, due to the high risks of 
infection and the costs associated with supplemental feeding (enteral and parenteral 
nutrition), GES therapy should be considered before those treatments are offered. 
 
Staffing or service implications (for new and developing centres): Appropriate surgeons 
underwent training in the technique of implantation and relevant staff underwent 
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training in the subsequent follow-up of implanted patients. The temporary GES 
facilities were set up in the endoscopy department with access to a double lumen 
endoscope and the permanent procedure would be conducted in an operating theatre 
under general anaesthesia. The nursing staff were also provided with necessary training 
and familiarised with the equipment. This training was provided by Medtronic and the 
surgical team. 
 
Cost estimate for GES therapy: The price for a complete Enterra system is £8,250 (1 
implantable pulse generator costing £4,500 + intramuscular leads kit costing £3,750). 
This is exclusive of VAT (20%) and carriage. 
Surgical and hospital costs were added on top of this.  
 
How does the treatment compare with those (of the general type) from other clinical 
areas? 
 
GES therapy is indicated for severely sick patients with no good long-term solutions. 
Therefore, the treatment should be seen as comparable to other life-saving interventions 
offered to patients with chronic diseases. As stated by Soykan et al,173 gastroparesis is 
“far from being a benign disorder” as 10% of their patients thought during the follow-up 
period. It is an extremely debilitating disorder that greatly impacts patients’ QOL and 
carries a high risk of mortality, which can result from interventions and life-threatening 
complications, such as electrolyte imbalances, dehydration and malnutrition. 
Gastroparesis is also associated with significant financial burden, both for patients and 
taxpayers.  
 
Based upon this information, the first 6 patients underwent temporary GES and their 
data was collected prospectively over a period of 7 days. After confirmation of the 
beneficial effects of GES, the funding applications were prepared and sent to the 
corresponding PCTs for approval.  
 
4.7 Methodology 
Six patients, (M:F=4:2, mean age 49, range 44–57 years) underwent the procedure. 
Three patients had confirmed slow GI transit. Aetiology included previous gastric 
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surgery in two, DM in one and idiopathic nausea and vomiting in three patients. Gastric 
neuromodulation (GNM) pacing wires were placed endoscopically and left in situ for 7 
days. Patients underwent GS before and 24 hours after the commencement of GNM. 
Total gastroparesis symptom score (TSS), vomiting frequency score/week (VFS), 
health-related quality of life (QOL) using SF12 questionnaire, GE, nutritional status and 
weight were compared before and after GNM. 
4.7.1 Patient selection and assessment 
Patients with refractory nausea and/or vomiting who failed to respond to medical 
treatment and who were not found to have any correctable pathology were selected for 
consideration of GNM (Table 4-1). At least one of the two symptoms had to be severe 
and associated with nutritional or QOL impairment to be included for the procedure. 
The patients were investigated to exclude mechanical gastric outlet and bowel 
obstruction by endoscopy and radiological investigations including plain abdominal 
radiograph, CT scan and/or contrast studies. All patients had an initial trial of antiemetic 
and or prokinetic drugs for at least six months. After a failure with medical treatment, 
they were considered for a trial of temporary GNM. Baseline data such as TSS, VFS, 
QOL using SF12 and nutritional status were assessed in the selected patients. TSS is the 
sum of 5 four-point categorical scales (0 for absent up to 4 for extremely frequent and 
extremely severe) for symptoms such as vomiting, nausea, early satiety, bloating and 
abdominal pain. In addition, all the patients underwent a standard gastric scintigraphy 
before GNM. 
 
Detailed descriptions of the clinical problems of these patients are as follows: 
 
Patient 1: This 57-year-old gentleman underwent surgery (gastrojejunostomy) for an 
annular pancreas in 1998. Later on he had persistent symptoms necessitating surgeries 
including gastrectomy and RYGB in 2001 and refashioning in 2004. He had multiple 
inpatient admissions and outpatient follow-ups for nausea, vomiting, bloating, tiredness 
and early satiety. He required nutritional support and yet struggled to put on/maintain 
his weight. He was investigated and confirmed not to have mechanical obstruction on 
numerous occasions. He required prokinetics and antiemetics and was unable to eat and 
drink properly. Pre-operative investigations confirmed delayed gastric half-emptying 
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with a time of 514 minutes (Figure 4-2). A detailed description of gastric symptom 
severity score (GSS) is described below (Table 4-2, Table 4-8). 
 
 
Figure 4-2: Patient 1, pre-GNM GE 
Half-emptying time very prolonged (514 minutes). 
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Figure 4-3: Patient 1, post-GNM GE 
No change observed after GNM. 
 
Patient 2: A 40-year-old gentleman with long-standing gastrointestinal dysmotility. He 
underwent an ileostomy in 2005 for intractable slow transit. Ileostomy output reduced 
over the period and was working only 2–3 times a week. He suffered from nausea, 
vomiting (20–40 times a week), bloating, early satiety and abdominal pain. He took 
Domperidone, an antiemetic and a very large dose of Movicol.  
 
His work and social life was significantly limited. He had six admissions to the hospital 
in one year and was extensively investigated. There was no mechanical obstruction 
found on CT scan and other contrast studies. Subsequent GE studies revealed prolonged 
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GE, half-emptying time 104 minutes, (Figure 4-4) and he was considered suitable for 
GNM. Pre-operative GE and GSS symptoms are explained below in Table 4-3 and 
Table 4-8. 
 
 
Figure 4-4: Patient 2, pre-GNM GE 
GE half emptying (T50) time 104 minutes. 
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Figure 4-5: Patient 2, post-GNM GE 
Post-GNM T50=53 minutes. 
 
Patient 3: This 44-year-old gentleman presented with a long-standing history of nausea, 
vomiting and weight loss. He had lost 18 kg in weight and vomiting frequency was at 
least 20 times a week over the last four years. This had significantly limited his work 
and social life. He was on regular antiemetics and prokinetics without much success. He 
was extensively investigated under an upper GI surgeon. He had a CT scan, small bowel 
studies, oesophageal manometry and GE studies. All the investigations were 
inconclusive and based upon the nuclear scan and barium studies he was diagnosed with 
slow GI transit (gastroparesis). He was therefore considered suitable for GNM. His GE 
(Figure 4-6Figure 4-6: Patient 3, pre-GNM GE) and GSS score are described below 
(Table 4-4, Table 4-8) below. 
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Figure 4-6: Patient 3, pre-GNM GE 
GE was normal T50 = 29 minutes before GNM. 
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Figure 4-7: Patient 3, post-GNM GE 
GNM did not result in any significant change in GNM (GE T50 = 23 minutes). 
 
Patient 4: This 57-year-old lady was referred with severe nausea, vomiting, bloating, 
abdominal discomfort and early satiety for the last few years. She had lost weight (4 
stone) and appetite and continued to vomit 3–4 times a week. Her past medical history 
included long-standing DM (15 years), arthritis and depression. Her medications 
included Metformin, Movicol, Dulcolax, Morphine and antidepressants. She was 
investigated and confirmed not to have mechanical bowel obstruction. Pre-operative 
investigations confirmed delayed gastric half-emptying (time 98 minutes). GE and GSS 
reports are described in Figure 4-8, Table 4-5 and Table 4-8.  
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Figure 4-8: Patient 4, post-GNM GE 
GE improved from 98 minutes to 41 minutes after GNM in this patient.  
 
Patient 5: This 54-year-old lady was referred with delayed orocaecal transit secondary 
to gut motility failure. She suffered from intractable nausea, severe bloating, abdominal 
pain and early satiety since the last few years. Her past medical history included long-
standing backache and hypercholesterolemia. Her medications included Tramadol, 
Simvastatin, Movicol and Paracetamol. She was investigated and confirmed not to have 
mechanical bowel obstruction on CT scan. Pre-operative investigations revealed gastric 
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half-emptying time of 37 minutes. GE and GSS are described in Figure 4-9,Table 4-6 
and Table 4-8 respectively.  
 
 
Figure 4-9: Patient 5, pre-GNM GE 
Pre –GNM T50 = 37 minutes.  
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Figure 4-10: Patient 5, post-GNM GE 
T50 increased but remained within normal limits of our reference value (T50=71 
minutes). 
  
Patient 6: This 44-year-old gentleman suffered from long-standing severe symptoms of 
nausea, eructation, bloating, abdominal pain and early satiety. He had been under the 
care of upper GI consultants for the last three years. He underwent a Nissen’s 
fundoplication in Sheffield in 2006 which resulted in worsening of his symptoms and he 
had a reversal of this procedure in 2008. As he remained symptomatic despite being on 
regular metoclopramide and PPI, he was considered an appropriate candidate for GNM. 
He also suffered from depression and was on venlafaxine. Pre-GNM gastric half-
emptying time was 65 minutes (Figure 4-11) and details of GSS are described in Table 
4-7 and Table 4-8. 
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Figure 4-11 Patient 6, pre-GNM GE 
Patient suffered from severe symptoms despite normal GE time (T50 = 65 minutes). 
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Figure 4-12: Patient 6, post-GNM GE 
Improved after GNM (T50=48 minutes). 
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4.7.2 Patients 
Table 4-1: Aetiology and patient selection 
  
Gend
er 
 
 
Age 
Duration of 
Symptoms 
(yrs) 
 
Aetiology  
1 M 57 12 
 
 
Annular pancreas treated with subtotal (4/5th) gastrectomy, RYGB, 
refashioning of RYGB. 
2 M 40 6 Slow pan enteric GI transit treated with iliostomy. Recurrence of symptoms. 
 
3 M 44 3 Idiopathic nausea and vomiting.. Weight loss 15 kg. 
 
4 F 57 3 Long-standing DM (15 years). 
 
5 F 54 3 Idiopathic severe nausea, bloating and abdominal pain. 
 
6 M 44 
4 
Long-standing nausea, acid reflux and bloating. Treated with Nissen 
fundoplication. Symptoms deteriorated necessitating the reversal of Nissen 
fundoplication. 
 
4.7.3 Scintigraphy 
Scintigraphy was used as a gold standard for measurement of GE before and after the 
GNM. After an overnight fast, subjects were given a test meal containing a small dose 
99m Tc (0.3mSv). The meal was prepared just before the beginning of the test and 
consumed within 10 minutes. With the subjects lying supine, dynamic acquisitions were 
taken for 100 minutes and each image comprised anterior and posterior acquisitions. 
The areas of interest (AOI) were drawn on anterior and posterior images. Geometric 
means of radioactivity were calculated and computer-generated time activity curves 
were generated. Gastric half-emptying time (T50) was calculated and compared with 
our reference values (99 ± 26 minutes) based upon a study in healthy volunteers.147 
 
4.7.4 Follow-up 
After the application of GNM, the patients were admitted to the ward for observation 
for 24 hours. A repeat gastric scintigraphy (GS) was performed on the first day after 
GNM. Patients were then sent home and requested to keep diaries of symptoms, 
medication and food intake for the next seven days. The patients were reviewed in the 
 212
outpatient department for the removal of the wires seven days after the procedure. 
Repeat QOL, weight and nutritional assessments were recorded. 
4.8 Analysis / statistics 
Pre- and post-GNM data including TSS, VFS, QOL and gastric half-emptying time 
were entered into an Excel spreadsheet. Comparison between pre- and post-GNM was 
performed using SPSS version 17.0. The Wilcoxon test was used to determine the 
differences between medians. 
4.9 Results 
The GNM procedure was performed in all six patients without any complications. All 
six patients tolerated the wire for a week with no spontaneous dislodgement of the wire. 
Alterations in GE, clinical symptoms and QOL following GNM were as follows (Table 
4-8, Table 4-9): 
4.9.1 GE 
Gastric half-emptying time improved in 4 patients and increased in 1 patient (Table 4-
8). One patient with a previous history of gastrectomy and RYGB had a very prolonged 
GE time but there was no evidence of obstruction on endoscopic and radiological 
investigations. GNM did not have any effect on GE in this patient (Table 4-8, Figure 
4-2, Figure 4-3). 
Table 4-2: Patient 1 GSS score 
  Pre-GES Post-GES 
Total Gastroparesis Symptom Score 
(a–e) 
17 13 
                   a– Nausea 2 2 
                   b– Vomiting 4 0 
                   c– Bloating 4 4 
                   d– Early satiety 4 4 
                   e– Abdominal pain 3 3 
Vomiting/week 30 0 
Weight (kg) 58 59 
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Table 4-3: Patient 2 GSS score 
  Pre-GES Post-GES 
Total Gastroparesis Symptom Score 
(a–e) 
16 0 
                   a– Nausea 3 0 
                   b– Vomiting 2 0 
                   c– Bloating 4 0 
                   d– Early satiety 4 0 
                   e– Abdominal pain 3 0 
Vomiting/week              20              0 
Weight (kg) 87.1 89.5 
 
 
 
Table 4-4: Patient 3 GSS score 
  Pre-GES Post-GES 
Total Gastroparesis Symptom Score
(a–e) 
13 4 
                   a– Nausea 4 2 
                   b– Vomiting 4 1 
                   c– Bloating 1 0 
                   d– Early satiety 3 0 
                   e– Abdominal pain 1 1 
Vomiting/week             20              3 
Weight (kg) 64 65 
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Table 4-5: Patient 4 GSS score 
  Pre-GES Post-GES 
Total Gastroparesis Symptom Score 
(a–e) 
11 13 
                   a– Nausea 2 1 
                   b– Vomiting 2 1 
                   c– Bloating 3 1 
                   d– Early satiety 4 1 
                   e– Abdominal pain 0 0 
Vomiting/week 3 3 
Weight (kg) 85.5 85.9 
 
 
Table 4-6: Patient 5 GSS score 
  Pre-GES Post-GES 
Total Gastroparesis Symptom Score
(a–e) 
13 6 
                   a– Nausea 2 1 
                   b– Vomiting 0 0 
                   c– Bloating 4 2 
                   d– Early satiety 3 1 
                   e– Abdominal pain 4 2 
Vomiting/week 0 0 
Weight (kg) 69 69.9 
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Table 4-7: Patient 6 GSS score 
  Pre-GES Post-GES 
Total Gastroparesis Symptom Score
(a–e) 
14 3 
                   a– Nausea 3 0 
                   b– Vomiting 0 0 
                   c– Bloating 4 0 
                   d– Early satiety 3 1 
                   e– Abdominal pain 4 2 
Vomiting/week 0 0 
Weight (kg) 83.5 84 
 
 
4.9.2 Nutritional status 
Results are expressed as median (inter-quartile range). The overall TSS improved after 
GNM in comparison with the baseline [13.5(12.5–16.25) vs. 3.5(2.25–7.75)]. VFS 
improved in 3 of the 4 symptomatic patients. All patients reported an improvement in 
oral intake and a mean weight gain of 1.02 kg (range 0.3–2.4 kg) was observed over the 
7-day test period (Table 4-8). 
 
4.9.3 Quality of life (QOL) 
Health-related QOL was assessed by SF12 questionnaire. Physical Composite Score 
improved in 4 patients [27.5(23.3–33.9) vs. 34.3(21.6–52.8)] and Mental Composite 
Score improved in 5 patients [34.9(22.5–42.5) vs. 35.9(21.6–49.4)]  (Table 4-9). 
 
Table 4-8: TSS, VFS, weight and GE before and after GNM 
TSS (total symptom score =  sum of nausea, vomiting, bloating, early satiety and 
abdominal pain scores) 
VFS (vomiting frequency/week score). 
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 Patient  
number 
  
TSS VFS 
 
Weight Gain 
(Kg) 
GE (t 1/2) 
Pre Post Pre Pre 
 
 
Pre Post 
1 17 13* 30 0* 
 
1 
 
515 600 
2 16 0* 20 0* 
 
2.4 
 
104 42** 
3 13 3* 20 3* 
 
1 
 
29 23 
4 11 4* 3 3 
 
0.3 
 
98 41** 
5 13 6* 0 0 
 
0.9 
 
37 71 
6 14 3* 0 0 
 
0.5 
 
65 48** 
Median (IQR) 
13.5(12.5–
16.25) 
3.5(2.25–
7.75) 
11.5(0–22.5) 0(0–3) 
  
1.02 
(mean) 
 
– – 
P (mean) 0.02 0.10 
 
– 
 
– 
 
*Subjects with significant improvement in symptom scores and **GE after GNM. 
Score are expressed as median (IQR) unless otherwise explained. 
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Table 4-9: QOL before and after GNM 
 
Patient 
Number 
Physical Composite score 
 
Pre-op                  Post-op 
Mental Composite score 
 
Pre-op                            Post-op  
 
1 
 
22.8 21.7 39.1 42.6* 
 
2 
 
38.8 52.4* 52.5 62.1* 
 
3 
 
27.2 40.5* 36.7 45.2* 
 
4 
 
27.9 28.1* 24.3 29.2* 
 
5 
 
23.4 21.1 17.1 22.8* 
 
6 
 
32.3 53.9* 33                        18.2 
 
Median 
(IQR) 
 
27.5(23.3–33.9) 34.3(21.6–52.8) 
34.9(22.5–
42.5) 
35.9(21.6–49.4) 
 
P 
 
                          0.24 0.34 
 
QOL before and after GNM; *Subjects with improved physical composite score (n = 4), 
mental composite score (n = 5). 
 
4.10    Discussion 
This small experience with temporary GNM demonstrates that GNM is safe and 
effective in improving both the clinical symptoms of gastroparesis and the objective 
measurements of GE.  
 
Multiple case series have previously been published in support of the efficacy of GNM 
in gastroparesis and intractable nauseas and vomiting.6–16 The larger part of the treated 
patients suffered from diabetics and idiopathic gastroparesis, followed by patients with 
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post-surgical and post-transplant gastroparesis. Recently, a systematic review of case 
series has been published elaborating the outcome of the procedure in different centres 
across the world.200 The review demonstrated the significant benefits for high-frequency 
GNM in the treatment of refractory gastroparesis. Reduction in nausea and vomiting, 
nutritional support and an improvement in GE were also emphasised.200 In addition to 
diabetic and idiopathic gastroparesis, previous studies have demonstrated promising 
results in post-gastric surgery gastroparesis refractory to medical treatment treated with 
GNM.11,18 There are, however, only a few studies focusing on the objective changes in 
GE following GNM.90, 185, 186, 200 The data is inconclusive in terms of the effect of GNM 
on GE. In one study, GNM in 16 post-surgical patients improved GI symptoms but did 
not change the GE after 12 months.90 In another study, both liquid GE (after temporary 
GNM) and solid GE (after permanent GNM) improved in patients with gastroparesis 
secondary to diabetes, post-surgical and idiopathic cases.201 Others have also reported 
improvement of GE after 6 months and 1 year.186 
 
Temporary GNM electrodes can be placed using endoscopic approach where the 
electrode (wire) is brought out of the nose, whereas the other method involves the 
transperitoneal intramuscular (muscularis properia) placement using percutaneous 
endoscopic or laparoscopic technique.201 The wire is then attached to an implantable 
pulse generator (IPG) and programmed to deliver low-energy, high-frequency GNM as 
described in the previous section of this paper. Endoscopic placement of temporary 
GNM has become a more widely established method, although both endoscopic and 
percutaneous methods for placement of temporary wires are safe and effective.201 In 
successful cases, temporary GNM is replaced by a permanent device. In some cases 
permanent devices were placed without an initial trial of temporary GNM.188 Placement 
of a permanent electrode is more invasive and requires open or laparoscopic abdominal 
surgery.186, 202 Electrodes are attached to the IPG and after programming, the IPG is 
implanted in a subcutaneous pocket (generally the left hypochondrium). Permanent 
GNM has potential complications such as infection, device erosion, pain at the 
implantation site, perforation of the stomach/intestine, device migration and volvulus 
secondary to wires.179, 188, 200 An overall complication rate of 8.3% has been reported in 
the previous literature.200 
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Our case series is of small numbers and consisted of patients with severe symptoms of 
mixed aetiology. We applied temporary GNM for a short period (7 days). Each subject 
included in this trial was selected very carefully after multiple clinical assessments and 
extensive investigations. In one patient (Patient 1) we recorded exceptionally prolonged 
GE (Table 4-8, Figure 4-2). This was also confirmed on endoscopic evaluations on 
multiple occasions as food was present in the gastric pouch several hours after the 
ingestion. Endoscopic assessment also revealed that the pouch tissue had become 
fibrotic, very friable and associated with multiple ulcers. This may be secondary to 
prolonged stasis of food and multiple surgeries. The possible mechanisms of extremely 
prolonged GE may be a vagotomy, loss of normal tissue and fibrotic conversion 
resulting in no or abnormal gastric slow waves. GE time did not improve in this patient 
after GNM (Figure 4-3). Slow GE following GNM, an unusual finding, was recorded in 
one patient and we were unable to identify any explanation for this peculiar change as 
GE improved in the remaining 3 patients. TSS improved in all of our patients after a 
GNM trial, whereas VFS did not change in one of our patients with low pre-operative 
VFS. The mixed response of GE in our patients may be because of the diverse and 
complex aetiologies. Change in GE may have been more consistent in patients with 
uniform aetiologies and less complex surgical history. The improvement in QOL was 
very subjective as the mental composite score improved in 4 patients and physical 
composite scores improved in 5 patients. All patients were able to eat and tolerate more 
food and fluids after GNM. This was confirmed with the objective evidence of 
increased weight after the test period.  
The prompt and marked response in our patients with gastroparesis, intractable nausea 
and vomiting clearly suggests that permanent GNM is a potential long-term solution. 
The overall cost of one procedure is approximately £10,000–£15,000. Therefore, the 
case selection for a permanent device should be a careful process, based upon not only 
the subjective and objective improvements after temporary GNM, but after 
consideration of the overall cost and potential complications. Patient response to a 
temporary device can guide selection for insertion of a permanent device. Further 
research is justified in this field focusing on the mechanisms of GNM and long-term 
outcomes of the procedure.  
 
Limitations: The mechanism underlying the clinical benefits of GNM is not fully 
understood. It is believed that the beneficial effects are mediated by local 
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neurostimulation and possibly involves the central nervous system. Other proposed 
mechanisms include gastric fundus relaxation and contribution of GI motility 
hormones.203 Most of the studies, however, observed minimal acceleration in GE, 
suggesting that improved nausea and vomiting may not be due to an improvement in 
GE.21,23 We observed that in only one case the clinical improvement was not associated 
with objective improvement in GE. However, improvement in GE time in three patients 
within 24 hours of GNM reflects that it enhanced the GI motility. Due to unclear 
mechanism of action, potential placebo effect more research is required. We propose 
that a study looking into the impact of placebo effect by switch off and on under close 
observation and blinding the patients and researcher over a period of few days may help 
to clear this issue. In addition the hormonal changes (Gherkin, GLP, Gastric, and CCK) 
in relation to switch on and off may also give valuable information. 
 
Conclusion  
Temporary GNM improved upper GI symptoms, QOL and nutritional status in patients 
with intractable nausea and vomiting. It does affect GE in this chronically debilitated 
group of patients. More research is required to determine the indications for this 
procedure and to understand the mechanism of action. 
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5 Change in energy expenditure following bariatric 
surgery. Implications of food intake in GI motility. 
 
 
Excerpts of this chapter have been modified and published. 
Ullah S Arsalani-Zadeh R, MacFie John. Accuracy of prediction equations for 
calculating resting energy expenditure in morbidly obese patients. Ann R Coll Surg 
Engl. 2012 Mar; 94(2): 129–32. PMID: 22391385. 
 
Excerpts of this chapter have been modified and presented in ASGBI as posters. 
Ullah S, Arsalani-Zadeh R, Jain P, Sedman P, MacFie J. Changes in resting energy 
expenditure following Roux-en-Y gastric bypass. 
Ullah S, Kirkwood B, Jain P, Sedman P, MacFie J. Accuracy of prediction 
equations for estimating resting energy expenditure in morbidly obese patients.  
 
5.1 Background 
Obesity is a major health issue and the prevalence of obesity and related complications 
is increasing worldwide.204 According to department of health projected figures show 
that 60% of men, 50% of women and 25% of children will be obese by 2050. Currently 
obesity causes significant cost to the NHS. The direct costs caused by obesity are 
estimated to be £4.2 billion per year which includes the cost to treat the co-morbidities, 
health service expenditure, prescriptions, hospital costs and drugs. In addition the 
indirect costs include disability, unemployment, early retirement and 18 million sick 
days, 40 000 lost years working life. Over all the obese patients die 9 years early than 
non obese. There are Intangible additional losses including loss of self esteem, 
relationships, pain, depression etc.Therefore it is high in NHS agenda to control obesity 
and prevent related complications. 
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Weight management programmes are based upon estimation of energy intake and 
expenditure, together with appraisals of behaviour therapy and lifestyle modification. 
The most common way in which this is done is the use of standardised predictive 
equations which permit an estimate of the resting metabolic rate. The most commonly 
used equations by dieticians are Schofield’s equation, Harris and Benedict equation. 
These equations are based upon age, sex, and body weight with additional factors for 
stress, growth and dietary-induced thermogenesis.  
 
Harris and Benedict equation (HB): This equation was published by James Harris and 
Francis Benedict in 1918-1919. The baisics of this equation are as follows. 
For Men: BMR = 66.4 + (13.7 x weight in kg) + (5.0 x height in cm) – 6.75 x age in 
years). 
For Women:  BMR = 65.5 + (9.5 x weight in kg) + (1.84.0 x height in cm) – 4.6 x age 
in years). 
And enegy intake using this equation is as follows. 
Little or no exercise: Daily Kilo Calories = BMR x 1.2 
Little exercise (1-3 days per week): Daily Kilo Calories = BMR x 1.37 
Moderate exercise (3-5 days per week): Daily Kilo Calories = BMR x 1.55 
Heavey exercise (6-7 days per week): Daily Kilo Calories = BMR x 1.72 
Very Heavy exercise: Daily Kilo Calories = BMR x 1.9 
 
 Schofield Equations: Schofield’s equations (SC) were published in 1985. The basis of 
this equstion included 50% BMR calculations on healthy army subjects in Italy.The 
equation is explaind as follows. 
Females (kcal/day) Males (kcal/day) 
10–17 years 
18–29 years 
30–59 years 
13.4W + 692 
14.8W + 487 
8.3W + 846  
10–17 years 
18–29 years 
30–59 years 
17.7W + 657 
15.1W + 692 
11.5W + 873 
Females over 60 years (kcal/day)  Males over 60 years (kcal/day) 
60–74 years 
75 years + 
9.2W + 687 
9.8W + 624 
60–74 years 
75 years + 
11.9W + 700 
8.3W + 820 
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In addition factor for activity and diet-induced thermogenesis is added as below. 
Bed-bound immobile  +10% 
Bed-bound mobile/sitting +15–20% 
Mobile on the ward  +25% 
The main criticism on these equations is as follows 
1. The Equations are mainly based for healthy subjects. 
2. They are based upon weight, height, activitivity whereas they do not take the 
real time acitivity, BMR, REE into account. 
3. The equations were developed long time age (especially HB Equation) whereas 
now a days many accurate methods (Direct and indirect calorimetry) to assess 
the BMR and REE are available. 
4. BMR is extremely difficult to measure as it requires a person in fasting for at 
least 12 hours, immediately after they wake up and should ideally be calculated 
in a dark room, without any stress, and subject in their bed. Therefore REE is 
more practicle and accurate method of calcutaing energy expenditure and should 
be used for estimation/calculation of energy intake. 
 
In management of obesity most of the weight management programmes are based upon 
low-fat, low-calorie diets with a fixed amount of calories (i.e. 1000–1200 kcal for 
women and 1200–1600 kcal for men). Ideally, weight management programmes should 
be based upon individual requirements and therefore accurate assessment of energy 
expenditure is desirable.205 
 
Prediction equations for estimating resting energy expenditure (REE) are based upon 
demographic information such as age, weight, height and gender.206, 207 Previous studies 
have suggested they may be inaccurate in obese patients.205, 208-210 This may result in 
overfeeding or underfeeding of this group of patients. The aim of this study was to 
compare the measured REE using a bedside indirect calorimetry (IC) device with 
commonly used formulae, i.e. Schofield (SC) and Harris-Benedict (HB).211 
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5.2 Methods 
5.2.1 Subjects 
The outpatient dietetic assessment included the measurement of energy expenditure (IC, 
HB, Schofield). This was performed pre-operatively, and 6 weeks and 3 months 
following surgery. A total of 31 morbidly obese patients undergoing RYGB surgery 
were assessed during the period January 2009 to March 2010.  
 
5.2.2 Measurement of REE 
REE was measured using a bedside IC device (Fitmate COSMED®). Fitmate is a small 
(20 x 24 cm), portable metabolic analyser designed to measure oxygen consumption and 
energy expenditure (Figure 5-1, Figure 5-2). This device can be used to measure REE in 
a resting state as well as during exercise. It contains a turbine flow meter for measuring 
ventilation and a galvanic fuel cell oxygen sensor for analysing the fraction of oxygen in 
the expired gases, and incorporates an innovative sampling technology. The device has 
been validated with the Douglas bag system for non-obese and obese subjects and was 
found to calculate REE accurately (r=0.97, P=0.579) and the results were 
reproducible.212 This device also conducts a self-calibration in 20 seconds before each 
calorimetry.212 Subjects were assessed in a calm place, in supine position and after 30 
minutes of initial rest period. Subjects were encouraged to keep silent and breathe 
normally for 15 minutes during calorimetry. REE was also calculated with Schofield  
and HB formulae using actual body weight, gender, height and age. 
 
Figure 5-1:Fitmate COSMED® calorimeter 
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Figure 5-2: Indirect calorimetry using Fitmate device 
Device, screen view and print out of the result after calorimetry. 
 
5.3 Statistics 
 
Data was entered into an Excel datasheet and statistical analysis was performed using 
SPSS 17. Values are expressed as mean +/– standard deviation (SD) unless otherwise 
stated. Significance of difference was calculated using two-tailed paired or unpaired 
student t test. The Fisher exact test was used for categorical data. P value of   < 0.05 
was considered statistically significant. Pearson correlation R was also calculated. 
 
5.4 Results 
 
The pre-operative demographic data, REE, measured by indirect calorimetry and 
predicted equations are shown in Table 5-1. Comorbidities included hypertension in six 
patients, diabetes in nine, asthma in three, obstructive sleep apnoea in three, epilepsy in 
one and polycystic ovaries in one. 
 
Three patients failed to attend the first follow-up at 6 weeks. Another 6 patients 
did not attend the 3-month follow-up. Follow-up data of 22 patients (15 female, 7 
male) was available for the pre- and post-operative analysis ( 
 
Table 5-2).  
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The mean age of the patients was 47 ± 7 years (10 male, 21 female). The mean value of 
BMI was (46 ± 8.6) and REE measured using indirect calorimetry was 1980 ± 558 
kcal/day). Estimated REE using Schofield and HB formulae was 2129 ± 449 kcal/day 
and 2195 ± 505 kcal/day respectively. Predicted equations overestimated the REE by 
7% and 10% respectively. There was a significant correlation between measured and 
estimated values of REE (r=0.63, P<0.001) (Figure 5-3, Figure 5-4). 
 
Post-operative body weight reduced from a pre-operative value of 132 ± 28 kg (mean 
±SD) to 122 ± 27 kg at 6 weeks and 114 ±27 kg at 3 months after surgery < P 0.001). 
Corresponding values for BMI were 46±8, 42±8 and 39±8 < P 0.001).  There was no 
significant change in measured REE over the three-month period (2039±448, 2122 ±498 
and 1987±517, P 0.36, P 0.56) using indirect calorimetry (Figure5-5). In 22 patients 
who completed the follow-ups, pre-operative REE was overestimated by HB and 
Schofield equations (6.3% and 3.6%). At 6 weeks follow-up HB and Schofield 
equations underestimated the REE by 3.3% and 5.2% respectively. Similarly at 3 
months follow-up predicted equations underestimated the REE (HB 1.2%, SC 2.7%). 
However, none of these differences reached statistical significance (Table 5-2) 
 
 
 
 
Table 5-1: Pre-operative data and REE using IC and prediction equations 
Demographic data and pre-operative REEE measured with prediction equations (HB, 
Schofield) and indirect calorimetry. 
• HB and Schofield over-predicted by 10% and 7% respectively.  
 
Age (years) 47 +/- 7 
Male : Female ratio  10:21 
Height (cm) 168 +/- 11  
Weight (kg) 134 +/- 29 
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BMI (kg/m2) 46.6 +/- 8.6 
REE using HB  
       Male    (10)  
       Female (21) 
 
2195 +/- 505 
2777 +/- 373 
1918 +/- 266   
REE using Schofield  
       Male    (10) 
       Female (21) 
 
2129 +/- 449 
2666 +/–307 
1874 +/–216  
REE using IC 
       Male    (10) 
       Female (21) 
 
1980 +/–558 
2329 +/–600 
1814 +/–464    
Over-prediction by 
        Harris-Benedict  
        Schofield 
 
215 +/- 458* 
149 +/- 439* 
 
 
Table 5-2: Change in weight, BMI, REE (IC, HB and Schofield) after surgery 
Total of 22 patients (15 female, 7 male). 
* Difference in REE measurements (IC vs. HB). 
**Difference in REE measurements (IC vs. Schofield) 
(N 22) Weight 
(kg) 
BMI REE-IC 
(kcal/day) 
REE-HB 
(kcal/day) 
REE-
Schofield 
(kcal/day) 
 P value* 
(IC vs. 
HB) 
P value** 
(IC vs. 
Schofield) 
Baseline 132+/-28 46+/-8 2039+/-
448 
2170+/-
497 
2114+449 0.116  0.31 
6 weeks 122+/-27 42+/-8 2122+/-
498 
2049+/-
466 
2010+/-425 0.24  0.06 
3 months 114+/-27 39+/-8 1987+/-
517 
1961+/-
450 
1932+/-417 0.63  0.339 
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Figure 5-3: Pre-operative IC vs. HB 
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Figure 5-4: Pre-operative IC vs. Schofield 
Correlation (R) of pre-operative indirect calorimetry with HB and Schofield equations. 
There was no strong linear correlation between IC and predicted equations (Schofield 
and HB); R= 0.63, p < 0.001. Similar correlation values in figures suggestive of 
resemblance in resting energy measurements using both predicted equations.  
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Figure 5-5: Change in REE (IC) after RYGB 
Change in REE following RYGB using IC. No significant change in REE following 
RYGB at 6-week and 3-month follow-ups (p=0.36, p=0.56). 
 
5.5 Discussion 
Adequate nutritional assessment is important in patients with obesity. The mainstay of 
weight management is to reduce the energy intake and increase expenditure in an 
attempt to achieve a net weight reduction. Numerous prediction equations are currently 
used to assess REE and total energy expenditure. Amongst them HB and Schofield 
equations are widely used.206, 207 These equations are based upon weight, height, age 
and gender. They are currently in practice for normal, overweight, obese and morbidly 
obese subjects. Schofield equations use body weight as the main determinant for REE 
measurement and have been reported to overestimate at low REE and underestimate at 
high REE.213 The HB equation was derived in 1919. It has been reported that HB 
equation also overestimates the REE by 5–15%.214, 215 Similarly, there are studies 
Difference in resting energy expenditure  
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describing the inaccuracy of predicted equations in the obese population.208,216,217 This 
is probably because the actual body weight is used in these formulae. Mifflin et al 
suggested that fat-free mass is the single best predictor to calculate the REE in healthy 
population.214 Lean body mass was found to be the single predictor of basal metabolic 
rate in 60 lean and obese subjects.218 Similarly, other studies also found overestimation 
of REE by prediction equations and suggested the use of actual measurements.219, 220 A 
recently published paper looked into the variance of 27 predicted equations with IC and 
found the HB equation to be 69% accurate.221 Pre-operative REE was overestimated by 
prediction equations in our study. The Schofield and HB equations overestimated by 7% 
and 10% respectively. These results are comparable with other studies as they reported 
5–15% overestimation of REE using prediction equations.214-216 There was strong linear 
correlation when predicted REE was analysed against measured REE (Figure 5-3, 
Figure 5-4).  
 
RYGB was effective in weight reduction and improvement in BMI and related 
comorbidities. Post-operatively, despite the constant weight reduction, we noticed no 
significant change in REE (measured with IC) at 6-week and 3-month follow-ups 
(Figure5-5, Table 5-2).). Others have reported similar findings following 
gastroplasty.222, 223 The explanation for this paradox is probably related to the fact that 
the bulk of tissue loss after bariatric procedures is comprised primarily of body fat 
rather than lean tissue (muscle). There are marked differences between rates of 
oxidative metabolism between fat and muscle and consequently the loss of fat has 
proportionally lesser impact on total REE than a corresponding loss of muscle.224 After 
surgery, the estimated REE was within 1–3% of measured values, suggesting that 
prediction equations are more accurate in non-obese subjects.  
 
Post-RYGB, a reduced body weight may be explained by a decreased food intake which 
is contributed by restricted food entry and early satiety. This may also be contributed by 
altered GE and increased energy expenditure through activation of the sympathetic 
control and breakdown of adipose tissue. The stomach, therefore, is a major regulatory 
factor in energy homeostasis after surgery and accurate measurements of REE and total 
energy expenditure are necessary for a better post-operative outcome. 
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5.5.1 Limitations  
This study has some limitations. The sample size is relatively small but we do not 
consider this has adversely affected our findings as the variability of our data between 
patients was small. We measured REE, not basal requirements because this reflects the 
more usual situation. Estimation of basal requirement necessitates 24 hours of starvation 
and precise standardisation of conditions of measurement. However, we did ensure that 
patients were at rest and established a steady state before commencement of readings. 
Finally, we have assumed the nature of tissue loss. Ideally, future studies would need to 
confirm this.  
5.5.2 Conclusion 
Prediction equations tend to overestimate the REE. IC should preferably be used in 
morbidly obese patients for accurate energy calculation. Change in energy expenditure 
following bariatric surgery is independent of the weight loss. This might reflect losses 
of body fat as opposed to lean tissue. GE plays a very important role in energy intake 
and energy homeostasis following RYGB. 
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6 Assessment of energy expenditure using indirect 
calorimetry (IC) in patients receiving total parenteral 
nutrition (TPN) 
 
 
Excerpts of this chapter were presented as an oral presentation in ASGBI. 
 
Owais A, Ullah S, Bumby R, Coppack A. Permissive underfeeding in patients 
requiring parenteral nutrition. (Oral Presentation in Moynihan’s prize session 
ASGBI 2011). 
 
6.1 Introduction 
 
The importance of artificial nutrition in selected patients groups is well established and 
could be life-saving. However, it is also well known that artificial nutrition may be 
associated with significant complications, such as hyperglycaemia, hyperlipidaemia and 
fluid retention. These, and other complications, are usually associated with overfeeding 
which is now recognised as the most frequent cause of morbidity in these patients. The 
question arises as to why is overfeeding so common? 
One possible explanation is that the prediction equations which are commonly used to 
estimate requirements are inaccurate for use in this patient group, and frequently 
overestimate requirements.  
The estimation of energy requirements of patients receiving artificial nutritional support 
is paramount for calculating their nutritional intakes, thereby avoiding significant 
overfeeding or underfeeding. The most common way in which this is done is the use of 
standardised predictive equations which permit an estimate of the resting metabolic rate. 
The most commonly used equations by dieticians is Schofield’s equations which are 
based upon age, sex, and body weight with additional factors for stress, growth and 
dietary-induced thermogenesis.206 Hereby this equation is briefly explained.  
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Schofield Equations: Schofield’s equations (SC) were published in 1985. The basis of 
this equstion included 50% BMR calculations on healthy army subjects in Italy.The 
equation is explaind as follows. 
 
Females (kcal/day) Males (kcal/day) 
10–17 years 
18–29 years 
30–59 years 
13.4W + 692 
14.8W + 487 
8.3W + 846  
10–17 years 
18–29 years 
30–59 years 
17.7W + 657 
15.1W + 692 
11.5W + 873 
Females over 60 years (kcal/day)  Males over 60 years (kcal/day) 
60–74 years 
75 years + 
9.2W + 687 
9.8W + 624 
60–74 years 
75 years + 
11.9W + 700 
8.3W + 820 
 
In addition factor for activity and diet-induced thermogenesis is added as below. 
Bed-bound immobile  +10% 
Bed-bound mobile/sitting +15–20% 
Mobile on the ward  +25% 
The main criticism on this equation is as follows 
1. The equations are mainly based for healthy subjects and study population 
included 50% healthy army subjects. 
2. They are based upon weight, height, activitivity whereas they do not take the 
real time acitivity, BMR, REE into account. 
3. Now a days many accurate methods (Direct and indirect calorimetry) to assess 
the BMR and REE are available. 
4. BMR is extremely difficult to measure as it requires a person in fasting for at 
least 12 hours, immediately after they wake up and should ideally be calculated 
in a dark room, without any stress, and subject in their bed. Therefore REE is 
more practicle and accurate method of calcutaing energy expenditure and should 
be used for estimation/calculation of energy intake. 
An alternative approach is to measure resting metabolic rate using IC. This is based 
upon the principle that oxygen consumption is an indirect measure of heat production, 
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which is a reflection of all ongoing metabolic processes. Thus, measurement of a 
patient’s oxygen consumption can be used to calculate resting metabolic expenditure 
and hence energy requirements. This method of REE calculculation is explained in 
detail in chapter 6 and a brief description in given in measurements section of this 
chapter. Until recently, measurements of oxygen consumption were only possible in 
dedicated research establishments with sophisticated equipment. In recent years, 
however, technological developments have permitted the development of easy-to-use, 
validated, bedside IC. These have become the gold standard in measuring energy 
requirements for hospitalised patients. However, the use of predictive equations is still 
predominant and indispensable as IC remain expensive, time-consuming and difficult to 
use in certain groups of patients. Therefore, the aim of our audit was to compare energy 
needs estimated using Schofield equations with those measured by IC. 
 
6.2 Methods 
6.2.1 Parameters 
This was a prospective audit of 101 consecutive patients requiring artificial nutritional 
support. This audit was approved by our audit departments. Patients continued to 
receive their nutritional requirements according to the hospital nutrition team guidelines 
(Scarborough and Hull and East Yorkshire Nutrition Guidelines) using Schofield 
equations as illustrated in Appendix 1. Resting metabolic rate was measured using IC. 
The results obtained from IC were not made available to the nutrition teams and did not 
impact on patient care.  
6.2.2 Settings 
The audit was done between March 2008 and March 2010 in two hospitals, 
Scarborough General Hospital, Scarborough, United Kingdom, and Castle Hill Hospital, 
Hull, United Kingdom. 
6.2.3 Sample 
All patients receiving nutritional support (enteral or parenteral) were included. Patients 
who were ventilated or who needed oxygen supply continuously were excluded. 
Indications of feeding are elaborated in the figure below. 
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Figure 6-1: Indications of feeding groups  
Indications of artificial feeding included 25% patients nill by mouth after surgery or 
related complications, 19% prolonged ileus, 31% at risk of aspiration. 
6.2.4 Measurements 
 
Resting metabolic rate was measured using a validated IC (Fitmate, COSMED, Italy). 
Measurements were standardised. All patients were in a fasting state for at least 4 hours. 
Patients were resting for at least 30 minutes, and measurements were taken at a standard 
hospital room temperature. The first 5 minutes of data were discarded to allow a steady 
state to be achieved. Resting metabolic rate was measured from the following 10 
minutes’ oxygen consumption. The device has been validated with a Douglas bag for 
non-obese and obese subjects. It was found to calculate REE accurately (r=0.97, 
p=0.579) and the results were reproducible.212 The device calibrates itself prior to each 
measurement. The device displays quality control messages to enable accurate 
measurement and at the end of the test, results are displayed. Measurement of energy 
expenditure using Schofield equation was based as described in introduction part of this 
chapter. 
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6.3 Results 
This audit comprised 101 consecutive patients requiring artificial nutritional support. 
The median age was 70 (range 21 to 94) and 65% were males. The median duration of 
hospital stay was 25 days (range 4 to 100). Fifty patients were receiving enteral 
nutrition and 51 were receiving parenteral nutrition. The median BMI for the patients 
included in our audit was 24 (range 16–46). 
 
Figure 6-2 shows the distribution for the indication of feeding among patients included 
in this study. 32% of the patients had to be artificially fed as they were at risk of 
aspiration due to either a cerebrovascular accident or aspiration pneumonia. 25% of the 
patients were nil by mouth due to either a medical or a surgical underlying condition. 
Patients who suffered a prolonged ileus following a surgical procedure constituted 19% 
of the patients. 4% of the patients had inadequate oral intake and had to be 
supplemented by artificial feeding. However, in 21% of the patients the indication for 
feeding was not recorded. 
 
The measured energy requirements for those patients using IC were significantly lower 
than the energy requirements estimated by the specialist dietitians using Schofield’s 
equations. The median energy requirements measured by IC was 1359 (range 825–
2668) kcal/day, whilst the median energy requirements estimated by Schofield was 
1758 (range 1256–3048) kcal/day (P value <0.001). This is shown in the scatter plot in 
Figure 6-2 below. 
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Figure 6-2: Scatter plot representing Schofield vs. IC 
The median energy requirements measured by IC was 1359 (range 825–2668) kcal/day, 
whilst the median energy requirements estimated by Schofield was 1758 (range 1256–
3048) kcal/day (P value <0.001). 
6.4 Discussion and conclusion 
 
The results of this audit show that Schofield’s equations overestimate energy 
requirements for hospitalised patients requiring artificial nutritional support. Schofield’s 
equations published in 1985 were a meta-analysis of several studies including over 
4,000 patients.206 These were based upon IC measurements carried out on volunteers of 
whom nearly 50% were healthy military Italian adults. Just over 1% of Schofield’s 
study population were over 60 years old whilst in our study 71% of the patients were 
over 60 years old. This demonstrates that Schofield’s study population is hardly 
representative of the average patient requiring adjuvant nutritional support in a hospital 
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setting. Muller et al213 demonstrated that the Schofield equation overestimated REE at low REE 
values but underestimated REE at high REE values. 
 
Recently, there has been an increasing interest in the concept of “permissive 
underfeeding”. The term “permissive underfeeding” was first used by Zaloga et al in 
1994.225 They described a strategy which was based on the premise that short-term 
dietary restriction (but not elimination) would limit pathological processes while 
minimally impairing organ function. In addition, this may limit the complications 
relating to TPN (hyperglycaemia, hypercholestrolaemia, etc.) and delivery of TPN 
(sepsis). A recent study shows TPN-induced hyperglycaemia.226 In another study, 
patients requiring artificial nutrition after colorectal surgery had a higher risk of 
infection associated with hyperglycaemia.227 Several studies and reviews aimed to 
explain the rationale for permissive underfeeding and why it could confer benefit to 
patients. Most of these studies agreed that a possible explanation is that “permissive 
underfeeding” minimises complications associated with overfeeding, which offset any 
possible disadvantage from failing to achieve the presumed energy requirements for 
patients receiving artificial nutrition.  
 
There is now overwhelming evidence to suggest that the provision of nutrients to 
surgical or septic patients will not reverse the gluconeogenesis that characterises the 
metabolic response to trauma and sepsis. Therefore, the aim of nutritional support, at 
least in this group of patients, is to minimise losses, accepting that these cannot be 
entirely prevented even if a hypercaloric diet is routinely adopted.228, 229  
 
Post-operative prolonged paralytic ileus, sepsis, fistulae, gut motility disorders and 
patients requiring ventilator support are considered for artificial nutrition. Critically ill 
patients are believed to have delayed GE, putting them at risk of aspiration. In addition, 
they remain at risk of feed intolerance and other nutrition-related complications. The 
diagnosis of impaired GE in critically ill patients, sepsis, old age and multi-organ failure 
is important before commencement of artificial feeding.230, 231 We propose that accurate 
feeding regimes should be practiced and that patients should be discussed in nutritional 
multidisciplinary treatment panels (MDTs) and that all these factors should be taken in 
account before commencement of artificial nutrition.  
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We recognise certain limitations to this audit. Firstly, there are relatively fewer patients 
in this study group in comparison to those used by Schofield’s. Despite that, our study 
group is more representative of the actual type of patients encountered by hospital 
dietitians. Secondly, certain patients who were ventilated or required oxygen support 
continuously had to be excluded as the IC used was not validated in this type of 
patients. However, it is unlikely that those patients’ energy requirements are any 
different than the rest of the patients studied here. Thirdly, Schofield’s equations are not 
the only equations used by the dietitians, but certainly it is the most prevalent equation 
used among dietitians in the UK. The use of other equations might reduce the margin of 
error in selected patient groups, but certainly not in this group of patients. Fourthly, and 
most importantly, the data from this audit is limited, and it doesn’t show that patients’ 
outcome could be improved by feeding patients less than their Schofield’s estimated 
requirements. To draw such a conclusion, a prospective randomised trial is required. 
 
Clearly, absolute starvation is harmful. Similarly, the administration of excessive 
calories is detrimental. The optimal level of feeding is still unknown but must be a 
balance between minimising catabolism and avoiding overfeeding-related morbidity. 
The results of our audit suggest that Schofield’s equations overestimate energy 
requirements, which might lead to overfeeding. Dietitians and clinicians should be 
cautious when using prediction equations to avoid any risk of overfeeding. Moreover, 
we suggest that what was termed as “permissive underfeeding” could actually be 
“normocaloric feeding” or “appropriate feeding”. However, the actual benefit to patients 
should be investigated by a randomised trial of “permissive underfeeding”, as defined 
by prediction equation. In addition, the factors like age, GE, risk of aspiration, REE and 
activity should be considered before the commencement of artificial feeding.231 
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7 Conclusions and future research 
 
 
Conclusions  
 
1. GE is not enhanced in morbidly obese diabetic patients. RYGB results in 
rearranged anatomy, resulting in fast pouch emptying and unchanged IT. RYGB 
results in an early and exaggerated GLP-1 response which was very closely 
related to post-operative insulin confirming its role as incretin hormone. Ghrelin 
levels reduced after surgery, but could not be causally related to weight 
reduction or improved diabetic status following RYGB.  
2. The results of our review remain inconclusive in terms of the results and 
mechanism how GES may work in obesity treatment. However, GNM can be 
used effectively to treat gastroparesis. GNM not only improves GSS, VFS, 
weight and QOL; it also results in improved GE in this group of patients.  
3. We elaborate the role of CE and breath test to assess IT. Hydrogen breath test is 
inexpensive, easy to perform and can be used when other precise methods are 
not available.  
4. Change in REE following RYGB is independent of weight loss; therefore, 
accurate measurements of REE and energy intake are required for nutritional 
assessments of this group. Similarly, critical illness, post-operative patients with 
sepsis and multi-organ failure may have delayed GE, at the risk of aspiration and 
re-feeding syndrome. Accurate energy requirements based upon REE along with 
multi-disciplinary meetings may reduce the risks and complications of artificial 
feeding.  
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Future research directions 
 
1. Fat metabolism (adeponectin, leptin), other GI hormones (PYY, GIP) may also 
play an important role in the resolution of DM following surgery (prospective 
study). 
2. Exogenous administration of ghrelin on GI motility and its effect on other GI 
hormones may elaborate its role as a satiety hormone, in resolution of DM and 
weight loss (prospective study). 
3. GLP-1 as an ileal brake hormone is not fully understood. Assessment of GI 
transit after exogenous GLP may elaborate this function (prospective study). 
4. Long-term effects of GNM in the treatment of gastroparesis need to be studied. 
A prospective observational study using permanent GNM and close follow-ups 
may elaborate this function (prospective and retrospective). 
5. The role of GNM in the treatment of achalasia and gastroesophageal reflux 
disease (temporary GNM) (prospective and retrospective). 
6. A prospective study is required to compare the CE and breath test to validate 
them against GI scintigraphy (trial on voluntary subjects). 
7. The role of the MR scan in the assessment of GI motility disorders (prospective 
trial). 
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Appendix 1: INFORMATION FOR PATIENTS 
 
Improvement of glucose metabolism following bariatric surgery: is this mediated 
by alterations in gastrointestinal motility and gut peptides? A prospective 
observational study. 
 
 
 
Date: 06/04/2009 
Version: 2 
 
Appendix 1: INFORMATION FOR PATIENTS 
 
Improvement of glucose metabolism following bariatric surgery: is this mediated 
by alterations in gastrointestinal motility and gut peptides? A prospective 
observational study. 
 
You are invited to take part in a research study. Before you decide, it is important 
for you to understand why the research is being done and what it will involve. 
Please take time to read the following information carefully and discuss it with 
others if you wish. Please ask us if there is anything that is not clear or if you 
would like more information. Take time to decide whether or not you wish to take 
part. 
 
You may withdraw from the study at any stage.  
 
What is the purpose of the study? 
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Gastrointestinal tract hormones and GI transit (emptying of stomach and the time taken 
by food in the intestine) play an important role in food intake, its absorption and further 
processes to be used in energy expenditure. Increased food intake or less energy 
expenditure may result in obesity (increased body weight). Obesity is related to several 
diseases like diabetes, high blood pressure, high cholesterol, etc. It can also lead to 
impaired function of insulin and glucose without diabetes. 
 
It is thought that there is impaired (possibly increased) stomach emptying and IT (the 
time food remains in the intestine) in obesity, which leads to higher amount of calories 
(energy) available to be used. As this function is controlled by hormones (chemicals of 
the gastrointestinal tract), it is thought that their function is also impaired. 
 
Obesity surgery results in improved glucose, insulin levels and also resolves diabetes. It 
is thought that this dramatic effect could be a result of changes in time taken by food to 
reach the last part of the small intestine and changes in hormones (chemicals of the 
gastrointestinal tract). How all these changes have a remarkable effect on glucose, 
insulin and diabetes is not understood. This study is designed and being conducted to 
look into these aspects. 
  
Where is the research being conducted? 
The research is being conducted at Castle Hill Hospital, Cottingham. 
 
Why have I been chosen? 
You are undergoing gastric bypass surgery and, according to your clinical details, you 
are eligible to participate. 
 
What will I be asked to do? 
You will be seen by a research doctor in addition to your consultant. If agreed to 
participate, you will be reassessed and:  
1. You will be requested to sign a consent form. 
2. You will be requested to attend for gastrointestinal motility and hormone tests on a 
separate date before operation. Tests will start at 9am and you will be required to stay 
with us for 6–7 hours.  
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3. You will be requested to attend for hormone tests 2 weeks after surgery. It will take 
5–10 minutes only. 
4. You will be requested to attend for gastrointestinal motility and hormone tests 6 
weeks after operation. Tests will start at 9am and you will be required to stay with us 
for 6–7 hours.  
 
A. Tests before operation 
The tests will involve an overnight fast (not eating and drinking for 6 hours), and 
attending the Nuclear Medicine Department, Castle Hill Hospital, in the morning. A 
research fellow will be conducting all investigations will the help of the Nuclear 
Medicine Department. The researcher will site a cannula and take pre-procedure blood 
samples. The cannula will be reused to take more blood samples as described below. 
Five ml (millilitres) of blood will be drawn each time. 
 
A standard meal containing isotope 99m Tc (radioactive material) will be given at this 
stage. Dynamic acquisition (continuous imaging) will be taken for 100 minutes 
followed by static acquisitions at fixed time points of 120, 180, 240, 360 and 480 
minutes after the meal. Simultaneously, three more blood samples will be withdrawn 
from the cannula, the first at 30 minutes, the second at 60 minutes and last sample at the 
time food is seen in last part of the small intestine. 
 
B. Two weeks after surgery: Tests will only require a 5 ml blood sample (after an 
overnight fast). 
 
C. Six weeks after surgery: Tests will be conducted on the same lines as explained in 
the pre-op section above (A). 
 
Timing  of  
investigations 
Venue Fasting 
investigations
Post-radioisotope  meal 
investigations 
Pre-operative 
 
Nuclear Medicine 
Department, Castle 
Hill Hospital, 
Cottingham 
5 ml blood 
sample  
Gamma camera scintigraphy 
(GI motility studies). 
5 ml blood sample at 30 
minutes 
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5 ml blood sample at 60 
minutes 
5 ml blood sample at the time 
food is seen in the last part of 
the small intestine. 
2 weeks post-
operation 
OPD clinic 5 ml blood 
sample 
 
 
 
6 weeks post-
operation 
Nuclear Medicine 
Department, Castle 
Hill Hospital, 
Cottingham 
5 ml blood 
sample 
Gamma camera scintigraphy 
(GI motility studies).  
5 ml blood sample at 30 
minutes. 
5 ml blood sample at 60 
minutes. 
5 ml blood sample at the time 
food is seen in the last part of 
the small intestine. 
Table of time, venue and investigations 
 
Do I have to take part? 
No, you don’t have to take part. It is entirely voluntary. Your decision whether or not to 
take part will not influence the treatment you receive whatsoever. 
 
Is there any possible benefit to me if I take part? 
There are no benefits as such for taking part in this study. However, if you do take part, 
you will be seen by research doctors as well as your normal team. This will inevitably 
result in extra medical attention. 
 
Are there any risks, disadvantages or costs in taking part? 
There are small risks related to radiation exposure. The amount of radiation used will be 
very small and hereby its comparison with other routine tests is explained.  
1. The dose used in this test is 23–33 times less than a CT scan of the abdomen. 
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2. It is equal to 45 days of background radiation to which we are all exposed on a daily 
basis. 
3. The radiation dose is 10 times less than in standard small bowel barium studies. 
 
You will require a venflon (cannula) on the back of the hand or arm and four blood 
samples will be taken. Each time 5 ml blood samples will be required. These tests will 
be conducted before operation and 6 weeks after operation. 
Another 5 ml blood sample will be required 2 weeks after surgery. 
 
This study will not involve any medicine. 
 
The fee for these tests will be paid by Scarborough Combined Gastroenterology 
Research Fund, Scarborough, and the Academic Surgical Unit, Castle Hill Hospital, 
Cottingham. 
 
Please note: travel, parking and refreshments charges will be paid to you. 
 
Will the information about me be kept confidential? 
Yes, all your information will be kept absolutely confidential. 
 
What will happen to the information about me after the study? 
All the information collated will be analysed and we intend to publish the results of this 
research in peer-reviewed medical journals, reports, conference papers and posters. In 
addition, this study will be a part of an educational qualification, an MD thesis. 
 
Importantly, your identity will be kept confidential at all times.  
 
Can I withdraw from the study? 
Yes, you may withdraw your consent and therefore withdraw from the study at any 
stage without needing to give a reason. This will not affect your legal rights or medical 
treatment in any way.  
 
 
Thank you for taking the time to read this information sheet. 
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Please write down any questions and contact: 
 
Mr. Sana Ullah 
Clinical Research Fellow 
drsanavri@hotmail.com 
sana.ullah@hey.nhs.uk 
Castle Hill Hospital, Cottingham 
Tel: 01482 622285 
 
Mr P Sedman 
Consultant Surgeon 
Castle Hill Hospital, Cottingham, 
Email: Peter.sedman@hey.nhs.uk 
Tel: 01482 623230 
 
Dr G Avery 
Consultant Radiologist 
Castle Hill Hospital, Cottingham 
Email: ged.avery@hey.nhs.uk 
Tel: 01482 623205 
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